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1.1 Introduction 
 
Wound healing is a process to restore tissue integrity after damage or 
injury. This normally beneficial process involves wound contraction to 
reduce the wound surface and finally leaves scar tissue to replace the lost 
tissue. However, clinical problems may arise due to wound contraction 
and the formation of a scar. Examples of problematic scars are 
contractures in burn patients, constrictions, anastomotic strictures after 
surgery or trauma, or growth impairment of the upper jaw after surgery in 
cleft palate repair.
1-11
 Adverse scarring may lead to esthetic problems or 
functional loss of the normal function of the affected region, for example 
if a contracture of a burn wound covers a joint.
3-5
 In patients with severe 
burn wounds, up to 67% of the scars can become hypertrophic.
7
 
Hypertrophic scars are raised and red; they are itching and are frequently 
associated with contractures.
6,7
 For example, hypertrophic scar 
contractures of the lower lip in a burn patient may lead to eversion, which 
can result in drooling.
8
 Burn scars can be treated by flap-plasties, which 
are surgical techniques to release the tension in skin contractures.
3,8
 
Cleft lip and/or palate is a congenital disorder with an incidence of 
about 1/650 in Europe.
12
 Children with orofacial clefts encounter 
functional problems with feeding, hearing, speech, esthetic problems, 
midfacial growth deficiency, orthodontic and dental problems, and 
psychosocial difficulties.
13-16
 Treatment by a multi-disciplinary team can 
continue up to the age of 20 years.
16
 Part of the treatment is the surgical 
closure of the cleft, preferably between six and 12 months of age.
16,17
 
Although different surgical techniques are used, most of them basically 
detach a part of the palatal mucoperiosteum from the palatal bone to 
cover the cleft.
17,18
 After such palatoplasty, the surgical wounds on the 
denuded palatal bone may develop into rigid scars. These scars can 
impair maxillary growth, which may result in orthodontic and esthetic 
problems, including a narrower, shorter maxilla and, relative  to cranial 
base, a displaced maxilla.
5
 Such problems may require additional 
treatment.
16
 These and other related clinical problems are associated with 
wound contraction and scarring. Thus, wound healing can have adverse 
effects and even lead to functional loss of the affected area. 
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Wound contraction and scarring are mainly caused by 
myofibroblasts. These cells can originate from different sources, 
including bone marrow-derived cells (BMDCs). The aim of this study is 
to investigate the contribution of BMDCs to wound healing, with the 
focus on myofibroblasts. If BMDCs are an important source for the 
myofibroblasts in wounds, modulation of BMDC recruitment or their 
differentiation into myofibroblasts may open new therapeutic ways to 
reduce complications after wound healing.  
The next paragraphs will firstly describe myofibroblasts in wound 
healing and their origin. Next, differences in wound healing between 
tissues will be described, focusing on wound contraction and 
myofibroblasts. Subsequently, BMDCs in wound healing will be 
discussed in detail, with the focus on myofibroblasts. Finally, the 
experimental design and specific aims will be described. 
 
 
1.2 Myofibroblasts in wound healing: origin and characteristics 
 
In general, wound healing consists of three consecutive and partly 
overlapping phases of inflammation, tissue formation, and tissue 
remodeling. In the inflammatory phase macrophages clear the wound 
from debris, and produce cytokines that attract cells to the wound bed.
19
 
During the tissue formation phase, a wound is re-epithelialized and 
granulation tissue is formed by invading fibroblasts.
19
 The wounds then 
contract through the action of myofibroblasts, which can reduce the 
wound area up to 70%.
20
 In the tissue formation phase scar formation 
starts, which continues into the tissue remodeling phase that may last up 
to several months.
5
 The size of the cell populations in wound healing is 
controlled by apoptosis, which allows for the elimination of cells without 
an inflammatory response.
21
 Myofibroblasts  are  mainly responsible  for 
wound contraction and scarring. 
In 1971, the myofibroblasts were firstly described as “modified 
fibroblasts” with characteristics of smooth muscle cells in a contracting 
in vivo skin wound model in rats.
22
 Currently, it is thought that 
fibroblasts differentiate into intermediate proto-myofibroblasts, to 
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develop into (mature) myofibroblasts.
23
 Next to the fibroblasts in the 
wound and other local cells, also circulating cells originating from the 
bone marrow have the potential to differentiate into myofibroblast.
24-34
 
These local cells include pericytes, which is shown in patients with 
diffuse cutaneous systemic sclerosis and in mice kidneys.
26,27
 Also 
hepatic stellate cells are able to trans-differentiate into myofibroblasts.
28
  
Circulating BMDCs can differentiate into myofibroblasts.
 29-34
 
Specifically, the subpopulation of the bone marrow-derived (BMD) 
circulating fibrocytes (fibrocytes) have been studied extensively for their 
ability to differentiate into myofibroblasts.
35,36
 Fibrocytes were 
discovered as blood-borne fibroblast-like cells.
37
 It is commonly agreed 
that fibrocytes originate from a CD14
+
/CD16
-
 monocyte subpopulation, 
also called the inflammatory monocytes.
38,39
 In vitro studies showed that 
several cytokines, including TGF-ß1, promote the differentiation of 
BMDCs into fibrocytes.
35,40
 In vivo, an increase in the tissue level of 
activated TGF-ß1 was concomitantly detected with an increase of the 
number of fibrocyte-derived myofibroblasts.
32
 Thus, TGF-ß1 seems to 
play an important role in fibrocyte differentiation.  
Fibrocytes express typical leukocyte-associated markers such as 
CD45 (a common leukocyte antigen) and CD34 (a hematopoietic and 
stem cell antigen), but also express fibroblast-associated markers such as 
the intermediate filament vimentin, and they express collagen types I and 
III, fibronectin, and matrix metalloproteinases (MMP) MMP-2, MMP-7, 
MMP8 and MMP-9.
37,41,42
 MMPs may facilitate the migration of 
fibrocytes into the tissues. 
Fibrocytes are able to differentiate into fibroblasts, myofibroblasts, 
or adipocytes, depending on the cytokines present in the tissue.
29,38
 The 
differentiation of fibrocytes into fibroblasts and myofibroblasts depends 
on TGF-ß1, which inhibits their differentiation into adipocytes.
29,40
 
Fibrocyte-derived fibroblasts can differentiate into myofibroblasts, in 
vitro, when TGF-ß1 or endothelin-1 is added.
35
 Possibly, the fibrocyte-
derived fibroblasts follow the same route of differentiation to 
myofibroblasts as “normal” tissue-derived fibroblasts (see below). It is 
also suggested that fibrocytes also can differentiate into proto-
myofibroblasts, which do not further differentiate.
24
 Upon differentiation 
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into myofibroblasts, fibrocytes decrease their CD45 and CD34 
expression.
32
 Currently, the fibrocytes are the only well-characterized 
bone-marrow derived source for fibroblasts and myofibroblasts. 
However, it cannot be excluded that other BMDCs are able to 
differentiate into fibroblasts or myofibroblasts. As shown above, 
fibrocytes may differentiate directly into myofibroblasts, or they will 
either differentiate into proto-myofibroblasts or firstly in fibroblasts. It 
has been postulated that all myofibroblast precursors follow the same 
differentiation route via an intermediate fibroblast stage.
25
 The detailed 
differentiation of fibroblast to myofibroblast will be described in the next 
paragraphs. 
Fibroblasts differentiation towards proto-myofibroblasts is triggered 
by mechanical tension.
25,43
 Mechanical tension in the granulation tissue is 
generated by the migration of increasing numbers of fibroblasts. 
Migrating fibroblasts apply traction to the ECM which results in 
mechanical tension.
44
 The proto-myofibroblasts start to express stress 
fibers containing ß- and γ-cytoplasmic actins, which allows them to exert 
small contractile forces, and to increase their motility.
45-47
  
Proto-myofibroblasts also start to produce a specific fibronectin 
splice-variant (ED-A fibronectin).
48
 This is stimulated by TGF-ß1,
48
 
which is produced by the proto-myofibroblasts themselves, and by 
macrophages and fibroblasts in the wound.
19,48
 In addition, the fibroblasts 
provide a reservoir of latent TGF-ß1 which can be activated by 
myofibroblasts (see next section).
49,50
 The combination of mechanical 
tension, ED-A fibronectin and TGF-ß1 is crucial for myofibroblast 
differentiation, which is marked by the expression of alpha-smooth 
muscle actin (αSMA).51 Myofibroblasts exert large contractile forces and 
produce abundant ECM components.
48,52,53
  
Contractile forces are generated by the stress fibers of the 
myofibroblasts. They contain fibroblastic ß- and γ-cytoplasmic actins, 
and αSMA.23,37,40 Myofibroblasts are interconnected through gap 
junctions, which suggests that they form multicellular contractile units.
52
 
Blockage of the gap junctions during wound healing reduces the number 
of myofibroblasts and impairs their deposition of ECM components.
54
 
Myofibroblasts further possess supermature focal adhesions ( in vitro) or 
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fibronexi (in vivo).
23,48,51
 Within the focal adhesion, the stress fibers 
connect to integrins, which bind to the ECM.
23
 Using this system, the 
force that is generated by the stress fibers is transmitted to the ECM.  
Reversely, mechanical signals from the ECM can be transduced into 
intracellular signals through this complex.
23
 Myofibroblasts can release 
and activate the latent TGF-ß1 in the ECM, which further stimulates 
myofibroblast differentiation.
49
 Another function of the integrins and the 
contractile forces is that the wounds start to contract to reduce the wound 
area. Myofibroblasts also remodel the ECM, which was deposited by the 
fibroblasts. Collagen type III is degraded during this process by MMPs 
and the myofibroblasts deposit large amounts of collagen type I that will 
later form the scar.
5,55,56
 In dermal wounds, subjected to mechanical 
tension (splinted), the fibroblasts are aligned more parallel to the wound 
surface in the direction of the tension than in unsplinted dermal 
wounds.
45
 Collagen bundles in a scar are more organized than in healthy 
tissue, but they are not thicker and their alignment is  in the direction of 
greatest stretch.
45,57
 
 
 
1.3 Differences in wound healing between tissues 
 
Myofibroblasts appear about 4 days after wounding but the timing may 
vary between tissues. In skin wounds in rats and humans, myofibroblasts 
appear from day 5 and high numbers were detected between about two 
weeks and one month.
58-60
 In palatal wounds in dogs and rats, 
myofibroblasts appear earlier, with a maximum number between day 10 
and 15.
56,61,62
 No human studies could be found regarding timely taken 
samples from palatal wounds to identify myofibroblast populations. 
These differences may relate to the faster healing of oral wounds, the 
reduced wound contraction, and less scar formation compared with skin 
wounds. This might be caused by the moist oral environment and the 
growth factors in saliva, resulting in a diminished inflammatory phase.
63-
65 
Generally, reduced inflammation results in less contraction and 
scarring.
66
 Palatal wound studies in pigs and mice showed that there are 
no significant differences between macrophages in the control and the 
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wounded palate, and that oral wounds showed less inflammation than 
skin wound.
63,67
 The number of myofibroblasts was found to be higher in 
the less inflamed palatal wound. The result in both species was a scarless 
healed palatal wound, in contrast to the skin wounds. Therefore, it was 
suggested that the reduced inflammation phase plays an important role in 
scarless wound healing. These studies suggest that a reduction of 
inflammation reduces scar formation.  
Another possible explanation for the faster healing of oral wounds 
may be the different phenotypes of oral and dermal fibroblasts. Oral 
fibroblasts migrate faster and produce more growth factors than dermal 
fibroblasts.
68,69
 These growth factors include keratinocyte growth factor, 
which stimulate the re-epithelialization.
69
 
It is also suggested that oral wound healing resembles fetal wound 
healing.
63
 Fetal wounds created in the first two trimesters of human fetal 
development heal completely without scarring. A fundamental difference 
between fetal and post-natal wound healing is that fetal wounds typically 
lack the inflammatory phase.
66,70
 This may be partly explained by the 
absence of platelets in early embryos.
71
 Therefore, there is a lack of pro-
inflammatory signals, such as platelet-derived growth factor and TGF-ß, 
which are released by platelets in adults almost immediately after 
wounding by platelets.
66,70,72
  
An environmental difference between adult and fetal tissue is the 
abundantly expressed glycosaminoglycan hyaluronan in the fetal ECM, 
which seems to play a key role in scarless healing.
1
 In fetal wounds, 
hyaluronan expression is up-regulated for a long time, whereas in adult 
wounds it quickly disappears.
73
 Lymphocytes are unable to adhere to 
hyaluronan, which may partly explain the reduced inflammatory phase.
70
 
Hyaluronan further provides a hydrated ECM that facilitates cell motility 
and proliferation and stimulates TGF-ß production, which is an important 
factor for myofibroblast differentiation.
74
 This may explain why 
myofibroblasts quickly appear in fetal wounds.
56,75
 In contrast, the fast 
disappearance of myofibroblasts from fetal wounds remains unclear. 
Alternatively the high levels of MMPs in fetal skin might be responsible 
for the more rapid tissue remodeling.
76
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Myofibroblasts disappear after time by apoptosis in healing 
wounds.
77
 Together with the apoptosis of other cells, a scar with a low 
cell density remains. Scars are more rigid than healthy tissue because of 
the low cell density, the densely packed and aligned collagen type I and 
the absence of elastin.
56,78
 However, if the apoptotic process fails, 
hypertrophic scars may occur. These scars are characterized by a high 
cell density, and typically contain contracting myofibroblasts.
79
 
Hypertrophic often occur in post-burn wounds, which result in 
contractures.
80
 
 
 
1.4 Bone marrow-derived cells in wound healing 
 
To study the contribution of BMDCs to healing wounds in vivo, labeled 
bone marrow cells (BMCs) from a donor can be used to systemically 
replace the recipient bone marrow. Examples to label the BMCs are to 
sex-mismatch donor and recipient, or to use fluorescently labeled cells. In 
a sex-mismatched model, male cells (Y-chromosome positive) can be 
distinguished from female cells (Y-chromosome negative).
81
 
Fluorescently labeled cells can be isolated from transgenic animals and 
subsequently detected in the recipient animal.
82,83
 To label the bone 
marrow, a bone marrow transplantation (BMT) can be used. In a BMT 
model, the BMCs of the recipient animals are ablated by a total body 
irradiation or drugs.
84,85
 To rescue these animals, labeled BMCs are 
injected intravenously. This will create chimera animals, in which the 
cells from the bone marrow and their offspring are detectable.
37,86
 The 
fate of BMDCs in the recipients can be determined by co-staining the 
cells for a cell-type specific marker. By using similar models and 
techniques as described above, the contribution of BMDCs to healing 
wounds can be studied.  
Circulating monocytes, originating from the bone marrow, are 
recruited to a wound.
87,88
 Upon contact with wound fibroblasts, a 
signaling interaction starts which drives monocytes towards macrophage 
differentiation.
89-91
 Fractions of macrophages have been detected in skin 
wounds and burn wounds.
32,86
 Also fractions of about 9-14% of the 
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keratinocytes in healed wounds originate from the bone in mice 
models.
85,92
 The fraction of the BMD keratinocytes seems to be 
independent of the wound type. However, the BMD keratinocyte fraction 
does increase significantly in time from about 1% on day 1 to 9% on day 
21.
85
  
Wound studies also show that fibroblasts and myofibroblasts can 
differentiate from circulating bone marrow cells. It is known that large 
numbers of inflammatory monocytes, the fibrocyte precursors, are 
released into the peripheral blood upon injury.
93
 These cells express the 
conserved chemokine receptor 2 (CC-chemokine receptor 2 or CD196
94
) 
in human, mice and rat.
39
 The recruitment of fibrocytes to inflammatory 
sites such as a healing wound is mediated by this receptor and its ligand 
CCL2 (also known as monocytes chemotactic protein 1, MCP1), which is  
produced by wound macrophages.
90,95
 In the wound, fibroblasts and 
myofibroblasts can differentiate from the recruited fibrocytes and 
possibly other circulating cells originating from the bone marrow.  
A burn wound study showed that nearly all cells recruited from the 
bone marrow differentiate into myofibroblasts (>95%) and that the 
remaining cells (<5%) differentiate into macrophages.
96
 In burn wounds, 
the percentage of BMD myofibroblasts increases with wound size.
97
 It is 
also suggested that the number of circulating fibrocytes is systemically 
up-regulated in burn patients.
98
 Also in granulation tissue of normal skin 
wounds, BMD fibroblasts and myofibroblasts have been detected.
31,84,86
 
More than 60% of recruited fibrocytes in skin wounds might differentiate 
into myofibroblasts, which stresses their role in wound healing.
32
 
Moreover, in fast regenerating tissues, such as the human endometrium, 
large fractions (>50%) of BMDCs were reported.
99 
 
The contribution of BMDCs to wound healing is not restricted to 
skin wounds. Also otherwise damaged tissues and even healthy tissues 
contain BMDCs. In experiments with pharmacologically damaged lung, 
kidney and stomach, colonic radiation damage, and damage by 
myocardial infarction, fractions between 15% and 64% of BMD 
myofibroblasts were detected in the wound tissues.
30,100,101
 Also in 
healthy tissues, such as skin, lung, kidney, fractions of BMD 
myofibroblasts were detected, but these were generally lower.
30
 These 
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studies show that the BMDCs and the more specific fibrocytes may be an 
important source for the myofibroblast population in wounds but large 
variations are observed in different tissues. 
 
 
1.5 Experimental study design and specific aims 
 
The background of this study is the observation that stem cells from the 
bone marrow enter the blood and are attracted to the wound, where they 
can differentiate into fibroblasts and myofibroblasts (Figure 1). The latter 
cells are responsible for wound contraction and eventually for scar 
formation. However, no data are available about the contribution of 
BMDCs to palatal wound healing. The major aim of this study is to 
unravel the contribution of circulating bone marrow-derived precursor 
cells to the myofibroblast population in palatal wounds. The hypotheses 
of the research presented in this thesis are that: 
1. BMDCs contribute to palatal wound healing 
2. Differences exist between the contribution of BMDCs to palatal 
and skin wounds 
3. Larger wounds recruit more BMDCs 
4. Myofibroblast differentiation can be modulated by modifying the 
cellular environment to intervene with wound contraction. 
 
By gaining more insight in the contribution of BMDCs to wound healing 
and the modulation of myofibroblast differentiation, possibly new 
opportunities will arise to reduce wound contraction and scar formation. 
For cleft palate patients this may lead to a better treatment outcome after 
palatal surgery. For burn patients, such new insights may contribute to 
the reduction of esthetical and functional problems.  
To study hypotheses 1-3, a rat model for palatal and skin wound 
healing was used. In short, recipient rats are lethally irradiated (Figure 2). 
To rescue them, they receive a BMT from green fluorescent protein green 
fluorescent protein (GFP)-transgenic rats, which creates chimerism in the 
animals. The chimera rats then contain GFP-labeled bone marrow in a 
non-GFP-labeled body. In this way, the bone marrow cells and their 
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offspring can be traced. The level of chimerism was analyzed in 
peripheral blood samples, and the contribution of BMDCs to both control 
tissue and wound tissue was analyzed in histological sections. To 
investigate the fourth hypothesis, an in vitro collagen gel contraction 
model was used. This model is suitable to study the effects of agents on 
contraction.
102
 The next paragraphs will give an overview of the thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Background of this study: Stem cells from the bone marrow enter the blood 
and are recruited to wounds. In the wound, the bone marrow-derived cells differentiate 
into fibroblasts, which subsequently differentiate into myofibroblasts 
 
A literature review was performed to study the functioning of stem cells 
in epithelial tissues (Chapter 2). A second literature review provides 
information on the function of MMPs and their inhibitors in oral diseases 
(Chapter 3). Subsequently, four experimental studies are presented. In 
Chapter 4 experimental wounds in the palatal mucoperiosteum of chimera 
rats are studied as a model for cleft palate surgery, using the rat model.  
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Figure 2. Bone marrow transplantation model. The recipient rat (left top) is lethally 
irradiated. Bone marrow will be collected from a green fluorescent protein (GFP) 
transgenic donor rat (right top). To rescue the recipient, GFP-labeled  bone marrow is 
injected into the recipient. This creates a chimera rat, containing GFP-labeled bone 
marrow in a non-GFP-labeled body. 
 
Two weeks after wounding, wound and control tissue are harvested to 
identify specific bone marrow-derived cell populations. Subsequently, the 
contribution of BMDCs to palatal wounds and skin wounds of the same 
size is compared. (chapter 5). The contribution of BMDCs to wounds 
with increasing size is studied to test whether wound size influences their 
recruitment (chapter 6). Hyaluronan is used in the contraction model to 
mimic part of the embryonic environment, and to study myofibroblasts 
(chapter 7). In this model for wound contraction, the expression of 
different markers, including αSMA, MMPs and their inhibitors were 
studied. Finally, all results will be discussed (chapter 8). 
 
Summarized, the specific aims of the study presented in this thesis are: 
• To review the contribution of adult stem cells to normal tissue turn-
over and wound healing in epithelial tissues (chapter 2). 
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• To review the biological functions of TIMPs, their effect on MMPs 
and their role in oral diseases, including cleft palate (chapter 3).  
• To identify the contribution of BMDCs to palatal wounds (chapter 
4). 
• To compare the contribution of BMDCs to wounded palate and skin 
(chapter 5). 
• To compare the contribution of BMDCs to skin wounds of 
increasing size (chapter 6). 
• To analyze the effect of hyaluronan on the differentiation of 
myofibroblasts in vitro (chapter 7). 
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Abstract 
 
Tissue turnover, regeneration, and repair take place throughout life. Stem 
cells are key players in these processes. The characteristics and niches of 
the stem cell populations in different tissues, and even in related tissues, 
vary extensively. In this review, stem cell differentiation and stem cell 
contribution to tissue maintenance and regeneration is compared in the 
epithelia of the skin, the cornea, the lung, and the intestine. A 
hierarchical model for adult stem cells is proposed, based on the potency 
of stem cell subpopulations in a specific tissue. The potency is defined in 
terms of the maintenance, the repair, and the regeneration of the tissue. 
The niche supplies cues to maintain the specific stem cell potency. 
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2.1 Introduction 
 
Tissue turnover, regeneration, and repair take place throughout life. Stem 
cells are important players in these processes. Their key properties are the 
potential to give rise to several other differentiated cell types and the 
ability to maintain their own population. Thus, they can fully reconstitute 
the tissue they reside in.
1,2
 However, there are differences in the potency 
of stem cells. The totipotent stem cell is the fertilized oocyte that gives 
rise to primordial germ cells and to the germ layers. It also produces the 
extra-embryonic trophoblast. Embryonic stem cells are pluripotent, which 
means that they can give rise to all cell types except the extra-embryonic 
trophoblast.
2–4
 The multipotent postnatal stem cells or adult stem cells 
differentiate only into the tissues or to the organ they reside in.
2,5
 Among 
the first well-studied adult stem cells are those that reside in the 
epidermis.
6
 
The classical definition of stem cells states that they have a high 
differentiation potential in specific conditions, but they are normally 
quiescent and slowly cycling.
7–10
 Because of the latter property, they are 
also called label-retaining cells (LRCs). After labeling a cell population 
with bromodeoxyuridine in vivo the signal fades quickly in dividing cells, 
whereas it is retained in stem cells.
11,12
 Recently, exceptions to the 
classical definition have been found, such as the rapidly dividing 
intestinal stem cells (see ‘‘Intestinal stem cells’’). In addition, the 
concept of label retention has been questioned.
13
 Stem cells are 
sometimes also referred to as side population cells, because of their flow 
cytometric characteristics after DNA staining.
14
 Furthermore, there are 
indications that stem cells can switch between a symmetric and an 
asymmetric pattern of cell division.
15
 Symmetric division yields two 
identical daughter cells, which can be either stem cells or transient 
amplifying (TA) cells. Asymmetric stem cell division gives rise to one 
new stem cell and one TA cell. In contrast to the mother stem cell, the 
TA cell differentiates and loses its potency. Finally, it becomes a 
terminally differentiated cell, which eventually dies. Early TA cells are 
sometimes referred to as progenitor cells.
2,16
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The microenvironment or niche of epithelial stem cells is generally 
located near a basement membrane, and the stem cells are part of the 
basal cell layer.
9,17,18
 Within the niche, supportive cells are present, which 
protect the stem cells from exogenous factors, and maintain the niche.
19
 
After differentiation of a stem cell into a TA cell, it migrates along the 
basement membrane while differentiation takes place.
9,16
 
The external and/or internal surfaces of many organs are covered by 
some type of epithelium. Because of the differences between the epithelia 
the corresponding tissue stem cells have various functions. This review 
focuses on adult stem cells of the four best-studied epithelial tissues: that 
of the skin, the cornea, the lung, and the intestines. These tissues will be 
briefly introduced and the functioning of their stem cells will be 
described under physiological conditions, and during tissue regeneration. 
Finally this leads to a new functional model for adult stem cells in 
epithelial tissues. 
 
 
2.2 Epidermis 
 
Mammals are covered by an epidermal layer to protect the organism 
against harmful events such as dehydration and microbial invasion. 
Figure 1A shows a blueprint of the human skin.
9
 The skin is composed of 
three structural segments: (1) the epidermis, (2) the dermis, and (3) the 
hypodermis. The epidermis is the superficial, multilayered epithelium. Its 
basal layer connects to the basement membrane, which separates the 
epidermis from the dermis. The epidermis is penetrated by hair follicles, 
which originate in the dermis.
9,20,21
 The sebaceous glands are skin 
appendages with an epithelial lining, connected to the hair follicles. They 
provide sebum produced by sebocytes, which protects the hair and the 
skin. The dermis lies just beneath the basement membrane. It is 
vascularized and innervated, and contains smooth muscles that are 
attached to the hair shafts. Finally, the deepest layer of the skin is the 
hypodermis. This layer is mainly composed of fat tissue, which insulates 
the body and stores lipids.
22
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Figure 1.(A) A transverse section of the human skin. Stem cells are found in the 
basallayer and in the bulge region. (B) The concentric layers of a hair. Adapted from 
Fuchs and Raghavan.
9
 
 
Functionally, the epidermis can be divided into epidermal 
proliferative units (EPUs). In mice, these are hexagonally shaped, the cell 
number is almost constant, and there is one central epidermal stem 
cell.
23,24
 Human EPUs are less obvious, but each also contains one 
epidermal stem cell. This stem cell gives rise to all other cells within the 
EPU.
8,12,18,20,23,25,26
 Most of the basal layer is occupied by committed TA 
cells that are migrating along the basement membrane.
16,27
 Next, they 
detach from the basal layer and migrate to the surface. Meanwhile, they 
differentiate into keratinocytes.
27
 Finally, the matured keratinocytes make 
up the squamous, cornified outer layer and are shed off. This is a cyclic 
process that takes about two weeks in humans.
9
 
The hair follicle is often referred to as a mini-organ, with a three-
dimensional structure that contains several cell populations.
28
 Multipotent 
stem cells are involved in its cyclic renewal, which makes the hair 
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follicle an interesting model for studying tissue regeneration.
28–30
 Figure 
1B shows a transverse section through the hair follicle revealing five 
concentric layers. On the outside lies the outer root sheath (ORS). Inside 
the ORS lies the inner root sheath (IRS), followed by the hair cuticle, 
cortex, and medulla, which contains the hair pigment.
9,31
 A longitudinal 
section through the hair (Figure 1A) shows that the sebaceous gland is 
attached to the hair shaft. The bulge region, which is rich in epidermal 
stem cells, is also attached to the hair shaft and connects to the lower side 
of the sebaceous gland.
9
 The dermal papilla is the deepest structure of the 
hair follicle. The dermal papilla is encapsulated by a structure, which is 
called the hair follicle matrix. This matrix is rich in TA cells. A basement 
membrane continues from the dermal papilla into the ORS to separate the 
hair follicle from the extracellular matrix (ECM) of the connective tissue 
in the dermis.
32
 Together, the dermal papilla and the hair follicle matrix 
are known as the hair bulb.
29
 
 
2.2.1 Epidermal stem cells 
The general idea is that epidermal stem cells from the bulge region can 
migrate in three directions: firstly, they can migrate into the sebaceous 
gland where they generate TA cells, which are called the unipotent 
sebocyte progenitor cells.
19,20,24
 Secondly, they can migrate upwards to 
replenish the epidermal keratinocytes, and thus contribute to epidermal 
turnover.
20
 However, the epidermis is regenerated by EPU stem cells 
under normal physiological conditions.
33
 Thirdly, they can migrate 
downwards along the ORS to the hair follicle matrix, using the ORS 
basement membrane. While migrating, they contribute to the 
(re)generation of the ORS.
8,16,34
 In the hair follicle matrix, they replenish 
the TA cell population. In turn, the TA cells from the hair follicle matrix 
migrate upwards, giving rise to the IRS and the hair itself, but not to the 
ORS.
34,35
 However, these mechanisms are questioned, based on studies 
on the mouse tail epidermis, which show that committed 
progenitors are present with both stem cell and TA cell properties.
36,37
 An 
alternative model with a ‘‘committed progenitor’’ cell is proposed that is 
self-maintaining, but already committed, and can switch between either 
reproducing itself or differentiating. 
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EPU stem cells are less potent than those in the bulge region, as they 
contribute only to the epidermis, but not to the inner hair follicle.
8,20
 
However, there is one study that suggests that these stem cells are also 
able to renew sebocytes.
38
 Bulge region stem cells, however, are able to 
generate at least three different precursors: the multipotent matrix TA 
cells, the unipotent sebocyte progenitors, and the unipotent keratinocyte 
precursors.
20,39
 Table 1A summarizes the properties of epidermal stem 
cells and their niches. 
 
Table 1. Epithelial stem cell niches and their potential 
 
2.2.2 Epidermal regeneration 
In response to acute injury, the stem cells from the surrounding bulge 
regions are activated. They leave the bulge region, migrate, and 
contribute to the epidermal repopulation.
12,33
 In mice, surrounding EPU 
stem cells are activated upon wounding, and it is likely that this also 
happens in humans.
8
 In addition, bone marrow-derived cells (BMDCs) 
contribute to epidermal regeneration, differentiating into keratinocytes.
40
 
Studies in mice show that regenerated epidermis contains BMDCs in the 
Tissue Niche Stem cell name Potential 
A) Skin Epithelial basal layer 
 
Epidermal proliferative 
unit stem cell 
Keratinocytes 
 
Bulge region 
 
 
Epidermal stem cell 
 
 
Sebaceous gland cells 
Keratinocytes 
Dermal papilla TA cells 
B) Lung Alveolar basal layer  Pneumocyte type II cell Pneumocyte type I cells 
 
Bronchioalveolar basal layer 
 
 
Bronchioalveolar stem cell 
 
 
Clara cell 
Pneumocyte type I cells 
Pneumocyte type II cells 
C) Cornea 
 
Posterior limbus 
 
Limbal stem cell 
 
Epithelial keratinocytes 
Endothelium? 
 
Cornea 
 
Oligopotent corneal stem 
cells 
Corneal keratinocytes 
Conjunctival goblet cells 
 
Stroma 
 
 
Corneal stromal stem cell 
 
 
In vitro: Keratocytes 
In vitro: circulating fibrocyte-like cells 
 Endothelial layer Endothelial stem cells Still unclear 
D) Intestines 
 
Cryptic epithelial basement 
membrane 
 
 
Intestinal (+4) stem cell 
 
 
 
Goblet cells 
Enterocytes 
Enteroendocrine cells 
Paneth cells 
 
Cryptic epithelial basement 
membrane 
 
 
Crypt base columnar 
(CBC) cells 
 
 
Goblet cells 
Enterocytes 
Enteroendocrine cells 
Paneth cells 
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hair follicle, the sebaceous glands, and the epidermis.
41
 BMDCs are able 
to migrate to the bulge region of hair follicles and the (interfollicular) 
epidermis, and their engraftment is significantly up-regulated in wounded 
epidermis.
42
 In addition, it is suggested that BMDCs show stem celllike 
properties after engrafting in the bulge region and EPU, which means that 
the BMDCs can replenish epidermal stem cell populations.
42
 
Hair follicles also regenerate after wounding, at least in mice. 
Neogenesis is more complete in young animals with large wounds than in 
small wounds.
43
 Stem cells from the bulge regions outside the wound, but 
also not yet characterized other populations contribute to the regeneration 
of the hair follicles. The newly formed hair follicles produce new, but 
unpigmentated hair.
43
 Whether this process is exactly similar in humans 
remains to be studied. 
In summary, the epidermis contains two stem cell populations, the 
EPU stem cells in the basal layer, and the stem cells in the bulge region 
of the hair follicle. The EPU stem cells contribute only to epidermal 
turnover and regeneration, whereas the bulge region stem cells also 
contribute to hair follicle and sebaceous gland turnover. Upon injury, 
stem cells from the bone marrow (BMDCs) are also recruited. Together, 
these stem cell populations are able to regenerate the epidermis during 
turnover and after injury. 
 
 
2.3 Lung epithelium 
 
The lung is the part of the respiratory tract that is responsible for gas 
exchange, and it consists of different segments. Figure 2 shows the 
airways of the lung. Air enters the lung through the trachea, which splits 
into the two primary bronchi. Then it splits into smaller bronchi, the 
distal bronchioles, and finally into the alveolar ducts, which end in the 
alveoli. The alveoli are surrounded by a capillary network where the 
actual gas exchange takes place. Three types of epithelium are identified 
within the lung. Generally, the bronchi contain a double-layered 
columnar pseudostratified epithelium with mucus-producing goblet cells, 
ciliated cells, and brush cells on top of the basal cells (Figure 2A). The 
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epithelia of the smaller bronchi and bronchioles are single-layered, 
containing ciliated cells, neuroendocrine cells, and Clara cells (Figure 
2B).
44–46
 Clara cells are also called ‘‘nonciliated bronchiolar secretory 
cells’’ and seem to play a detoxifying role. In addition, they can 
regenerate the ciliated cell population.
47,48
 Finally, the alveolar 
epithelium (Figure 2C) contains thin alveolar type I cells, or type I 
pneumocytes, which overlie the capillaries and are responsible for the 
actual gas exchange. The spherical alveolar type II cells, or type II 
pneumocytes, lie in between the type I pneumocytes, and perform 
functions such as ion transport in the alveolus and repair.
17,49,50
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. The airways of the lung. Each compartment has its typical epithelium (A–C). 
The bronchioalveolar stem cells are located in the terminal bronchioles (B) and the 
pneumocyte type II cells (C) in the alveolar epithelium. Adapted from West et al. (Eur 
Respir J 2007;29:11–7). 
 
2.3.1 Lung stem cells and lung regeneration 
The alveolar type II pneumocyte is able to replenish itself, and to give 
rise to type I pneumocytes and hence is considered as a stem cell.
51
 Type 
II pneumocyte subpopulations have been identified, but it is still unclear 
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whether these are functionally different.
17
 Animal studies show that 
BMDCs can engraft in lung epithelium during normal turnover,
52
 and 
possibly contribute to the regeneration of damaged alveoli.
53
 In humans, 
donor BMDCs were detected in the recipient lung after bone marrow 
transplantation.
54
 These data suggest a role for BMDCs in turnover and 
regeneration of lung epithelium.  
The bronchioalveolar stem cell (BASC) resides in the basal layer of 
the bronchioalveolar duct junction. These cells express both bronchiolar 
and alveolar markers, and are able to differentiate into the bronchiolar 
Clara cells, and into alveolar type I and type II pneumocytes.
45,55,56
 It is 
not clear whether the BASC-derived type II pneumocytes are able to 
function as stem cells for type I pneumocytes.
57
 
In the trachea and bronchi no specific stem cell populations or 
niches are currently known.
58,59
 However, side population cells, which 
are detected from cell suspensions by flow cytometry, are found in 
suspensions from all compartments in the mouse lung. These cells have 
both mesenchymal and epithelial potential in vitro and may be stem cells 
for lung epithelia.
60,61
 Nevertheless, their exact location and function in 
vivo still remain to be elucidated.
62
 
In summary, most studies on lung regeneration focus on he 
regeneration of Clara cells and pneumocytes.
50,56-58
 Studies into stem cell-
mediated regeneration of other areas of the lung are limited.
58-62
 It 
appears that lung stem cells are attached to the basement membrane, 
similar to those in other tissues. BASCs are able to regenerate the 
pneumocytes in the alveoli, and it is suggested that BMDCs engraft in 
lung epithelium and regenerate alveolar cells. Table 1B summarizes the 
properties of lung epithelial stem cells and their niches. 
 
 
2.4 Corneal epithelium 
 
The cornea is the tissue that covers the pupil, the iris, and the anterior 
chamber of the eye. Figure 3 shows the blueprint of the eye and the 
cornea. The cornea contains three cell layers, which are separated by two 
membranes.
63
 The outer epithelial layer is a thin stratified, squamous, 
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nonkeratinized cell layer that easily regenerates.
64,65
 Next, the acellular 
Bowman membrane is a thin but tough condensed layer of collagen.
66
 It 
is present in all primates, and chickens, but absent in rodents, rabbits, 
carnivores, and many other species.
63,67
 The stromal cell layer is attached 
to the Bowman membrane, and it is mainly composed of collagen type I, 
and a low number of keratocytes. Keratocytes are stromal fibroblasts in 
the corneal stroma,
68
 which maintain the transparent collagen matrix.
69
 
Connected to the stroma lies a thick basement membrane, known as the 
Descemet membrane.
63
 This membrane is produced by the deepest, 
endothelial, single cell layer. These cells are responsible for gas and 
nutrients exchange for the whole cornea. The complete cornea is fully 
transparent and nonvascularized. The edge of the cornea is connected to 
the surrounding sclera. The transition area is known as the limbus.
7 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The eye and the cornea. Corneal stem cells reside in the limbus, and in the 
basal layer of the corneal epithelium. 
 
2.4.1 Corneal stem cells 
The first stem cell population of the cornea lies in the posterior limbus. 
These cells are called the limbal stem cells and they are able to 
regenerate the corneal keratinocytes.
70,71
 The committed TA cells migrate 
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inwards along the Bowman membrane to the center of the cornea. After 
detachment from the Bowman membrane, they migrate to the anterior 
side of the eye and differentiate into stratified squamous cells. Finally, 
desquamation takes place.
71
 It is suggested that the corneal TA cells do 
not start to differentiate before they are detached from the corneal 
basement membrane, which resembles epidermal TA cells.
27,72
 This 
theory is underpinned by the detection of an early marker for 
differentiation of TA cells to keratinocytes in the basal layer of the 
cornea, but not in the superficial epithelium.
73
 The second stem cell 
population, referred to as the oligopotent corneal stem cells, has been 
discovered very recently in the squamous corneal epithelium of mice.
74
 
This study also showed that the cornea of different mammals, including 
humans, contains keratinocytes with clonogenic potential in vitro. The 
third stem cell population is found in the stroma, in which about 4% of 
the cells are referred to as keratocyte progenitors, corneal stromal stem 
cells, or BMDCs.
69,75-77
 This means that it is not clear whether these cells 
are real stem cells, or early TA cells. They possess markers for both 
progenitor cells and for hematopoietic cells from the monocytic lineage. 
They differentiate into cells with a fibroblastic morphology in vitro, 
resembling circulating fibrocytes.
75,78
 Isolated stromal stem cells are able 
to differentiate into keratocytelike cells in vitro,
76
 but it is not known 
whether they also do so in vivo. Finally, endothelial stem cells may be 
present in the deepest corneal endothelial layer. These stem cells have 
been isolated, but their exact nature is still unclear.
77,79
 
 
2.4.2 Corneal regeneration 
During normal turnover, the oligopotent corneal stem cells mainly 
contribute to the renewal of the cornea.
74
 BMDCs replenish the 
macrophages in the stroma and they seem to differentiate into the 
Langerhans cells of the corneal epithelial layer.
80,81
 Damage to the 
epithelial layer of the cornea often causes disruption of the Bowman 
membrane, which leads to an epithelial–stromal interaction. This may 
cause keratocytes to proliferate, and they differentiate into 
myofibroblasts and leave a scar that causes stromal haze.
63,82
 The 
epithelial keratinocytes are regenerated by the limbal stem cells that are 
Chapter 2 
 44 
recruited to the wound site.
83
 Both the limbal stem cells and the 
oligopotent corneal stem cells are able to regenerate the conjunctiva in 
mice after damage.
74
 The adjacent conjunctival epithelium is renewed 
from ‘‘bottom to top’’ as any stratified epithelium.64 Thus, both limbal 
and oligopotent corneal stem cells are able to regenerate the cornea. 
However, the limbal stem cells seem to be the main contributors for 
regeneration after severe damage.
74
 The direct application of human 
BMDCs to damaged corneal epithelium in the rat highly improved the 
regeneration and transparency of the cornea.
84
 One recent study shows 
that rabbit BMDCs can differentiate into corneal epithelial-like cells in 
vitro and in vivo.
85
 
It is suggested that keratocyte progenitors contribute to repair of the 
stromal layer,
75,86
 but it is unknown whether they can also differentiate 
into keratinocytes. 
Damage to the deepest corneal endothelial layer can result in severe 
loss of sight. The endothelial cells are able to restore the Descemet 
membrane, but they lose their regenerative capacity with age.
63,87
 
Nevertheless, it is suggested that stem cells or TA cells from the posterior 
limbus migrate to the wounded endothelium. However, it is not clear 
whether these cells are able to repair the damage,
70,79
 which questions 
their stem cell properties. 
In summary, corneal TA cells from the limbus move along the 
basement membrane to the center of the cornea. After detachment, they 
migrate to the anterior side, and they start to differentiate to form a thin 
stratified squamous epithelium. Evidence is accumulating that corneal 
stem cells are also present in other areas, but it is still unclear whether 
they contribute to epithelial regeneration. BMDCs are found in the 
normal and the damaged corneal stroma and epithelium as macrophages 
and keratocytes, but they do not seem to differentiate into keratinocytes. 
Table 1C summarizes the properties of corneal epithelial stem cells and 
their niches.  
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2.5 Intestinal epithelium 
 
The intestines are constituted of the small and large intestine. The small 
intestine is attached to the stomach, and can be divided into the 
duodenum, the jejunum, and the ileum. From there the large intestine or 
colon continues and ends in the rectum. The epithelial surface of the 
small intestine is increased by protrusions, the villi, for maximal nutrient 
absorption. In the cavities or crypts occur the cell replenishment and the 
secretion of antimicrobials. Crypts are also present in the colon, but the 
villi are not. The epithelium of the small intestine contains four 
differentiated cell types. About 90% of the villi cells are enterocytes, 
which are the absorptive cells. The other three cell types are all secretory 
cells. The Goblet cells produce a protective mucus, the enteroendocrine 
cells secrete hormones, and the Paneth cells secrete antimicrobial 
peptides.
88,89
 The Paneth cells are typically found at the bottom of the 
crypts, but the majority of the crypt cells are TA cells.
88,89
 The epithelium 
has a high turnover rate of about 5 days in humans.
90
 In contrast to the 
small intestine, the colon has no villi nor Paneth cells, and the crypts are 
larger.
88
 The main function of the colon is the uptake of water and water-
soluble vitamins.
91,92
 Directly under the epithelial basement membrane, a 
syncytium of myofibroblasts is present, which connects to the fibroblasts 
in the lamina propria.
93–95
 These myofibroblasts are known as the 
pericryptal myofibroblasts.
94,96
 
 
2.5.1 Intestinal stem cells 
Figure 4 shows the stem cell populations in the small intestine. Until 
recently, only the small-intestinal stem cells were identified. Based on 
their clonogenic properties, and the LRC technique, the ‘‘+4’’ theory has 
been developed. According to this theory stem cells are found directly 
above the Paneth cells on position 4, counted from the crypt bottom.
88
 
From there, the TA cells move up and differentiate into Goblet cells, 
enterocytes, and enteroendocrine cells, or they move down to become 
Paneth cells. 
More recently, a new slender cell type has been rediscovered in the 
small intestine, located in between the Paneth cells.
97
 These cells are 
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called the crypt base columnar (CBC) cells and were considered as 
intestinal stemcells.
98–101
 The rapidly cycling CBC cells are positive for 
the ‘‘leucinerich repeat-containing G protein-coupled receptor’’ 5 
(LGR5). This receptor is abundantly expressed around birth, but in the 
adult it is restricted to rare, scattered cells in different organs.
102
 These 
LGR5+ cells are able to maintain the villi of the small intestine and the 
crypts of the small and large intestine.
102
 Prominin 1 seems to be another 
specific marker for the cells that are LGR5+.
103
 Cells that are positive for 
Bmi1 are found at the +4 position.
104
 It is speculated that these cells are 
the quiescent form of the rapidly dividing LGR5+ cells, although others 
suggest the existence of two intestinal stem cell populations.
88,104,105
 
Furthermore, transplanted BMDCs engraft and differentiate into the 
intestinal epithelium.
52
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The intestinal crypt. Two stem cell populations may exist next to each other 
in the intestinal crypts: the +4 label-retaining cells and the crypt base columnar cells. 
Adapted from Scoville et al.
88
 and from Andoh et al.
94
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2.5.2 Intestinal regeneration  
Intestinal damage by irradiation leads to the destruction of intestinal stem 
cells and severe mucosal damage occurs.
106,107
 After such damage, 
BMDCs are recruited to the small and large intestines. They contribute to 
the regeneration of the pericryptal myofibroblasts and to the cells in the 
crypts and the villi of the small intestine. 
96,106,108
 The BMDCs can also 
contribute to neovasculogenesis in the intestines.
109
 Damage caused by 
bowel diseases, such as Crohn’s disease and ulcerative colitis, leads to 
the loss of epithelial cells and the degradation of the ECM.
107
 BMDCs 
can differentiate into these epithelial cells in rats, and thus contribute to 
the regeneration after inflammation.
110
 Currently, no data are available on 
the function of the local +4 intestinal stem cells and CBCs during 
regeneration. 
In summary, intestinal epithelium has a high turnover rate because 
the epithelial cells are continuously shed into the gut lumen. There are 
two stem cell populations, which both have stem cell properties, and are 
able to regenerate the intestinal epithelium. It is debated whether these 
populations coexist, or whether there is only one true intestinal stem cell 
population. Both populations are located at the basement membrane, 
along which the TA cells migrate. In case of chronic disease or severe 
damage BMDCs are recruited, which contribute to the regeneration of 
myofibroblasts, blood vessels, and epithelial cells. Table 1D summarizes 
the properties of intestinal epithelial stem cells and their niches.  
 
 
2.6 Discussion 
 
Each type of epithelium has its specific mechanism for regeneration from 
local stem cells. The different stem cell populations cooperatively 
regenerate all terminally differentiated cell types within the tissue. In 
addition to the local stem cells, BMDCs may also contribute to 
regeneration of the epithelia, at least in skin, lung, and intestine.
41,42,52,53
 
Furthermore, stem cells with BMDC characteristics are found in the 
corneal stroma and in the epidermal bulge region. This suggests that 
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BMDCs have the capacity to replenish local stem cell populations.
42,69,75-
77
 
All epithelia function as a protective border between the 
environment and the organism. These tissues are exposed to stress-
inducing factors, such as dehydration, antigens and pathogens, UV 
radiation, mechanical damage, and air pollution. However, the tissue 
region determines the degree of exposure to these factors: deeper regions 
are generally better protected from external factors. These regions might 
have their specific stem cell population such as the more superficial EPU 
stem cells vs. the deeper bulge stem cells. Another example is the corneal 
stem cells vs. the limbal stem cells. In the lungs, the BASCs are in a 
betterprotected region, just outside the alveoli where gas exchange takes 
place. As an exception, the intestinal +4 stem cells and the CBCs are 
located close to each other. However, the +4 intestinal stem cells are 
quiescent, which better protects them against genetic damage than the 
more rapidly dividing CBCs.
88
 The stem cells in the less protected 
regions of a tissue are generally less potent, as summarized in Table 1. 
 
Table 2. Epithelial stem cell populations can be classified by their performance 
BMDC, bone marrow-derived cell; BASC, bronchioalveolar stem cell. 
 
From this point of view, stem cells can be separated in two classes: a 
class of stem cells that maintains the integrity of the outer layer of the 
epithelium and another that is responsible for repair (Table 2). The 
former ‘‘maintenance’’ stem cells are less potent, but are rapidly 
available. The latter ‘‘repair’’ stem cells are better protected, and can  
differentiate into all tissue cell types. However, this requires more time as 
they are generally located further away from the epithelium, or need more 
time to replicate as in the intestines.
88
 The specific properties of the niche 
seem to restrict the maintenance stem cells, because under experimental  
conditions they can differentiate into other cell types.
111,112
 
Stem cell class 
 
Skin Cornea Lung Intestines 
Maintenance Epidermal stem cell Oligopotent corneal stem cells Alveolar stem cells Basal crypt stem cell 
Repair Bulge stem cells Limbal stem cells BASCs Intestinal +4 stem cells 
Rescue BMDCs BMDCs (?) BMDCs BMDCs 
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The repair stem cells might function as a backup for the maintenance 
stem cells, since they are able to regenerate at least the same cell type(s). 
The BMDCs might function as a second backup. In case of extensive 
injury, they can generate all cell types of the epithelium, as they are more 
potent than the local stem cells. However, it will take more time to recruit 
BMDCs from the circulation to the wound. There seems to be a positive 
correlation between the level of recruitment of BMDCs and the wound 
size.
42,113
 It has already been proposed that BMDCs might function as a 
backup in case of extensive injury.
42
 We call these cells the ‘‘rescue’’ 
stem cells. In Figure 5, a hierarchical model is presented for this backup 
system of stem cell populations. There are indications that BMDCs can 
also contribute to the regeneration of other tissues, such as muscle, 
cartilage, and bone.
114,115
 A similar model may therefore be applicable to 
the stem cells in other tissues. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Epithelial stem cells are classified by their function in the backup system.The 
maintenance stem cells are quickly regenerating the epithelium during normal turnover. 
The repair stem cells can regenerate more cell types after injury. The rescue stem cells 
are the bone marrow-derived stem cells, and are able to regenerate all tissue cell types 
after extensive damage and they might replenish local stem cell populations. 
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Abstract 
 
Several families of enzymes are responsible for the degradation of 
extracellular matrix (ECM) proteins during the remodeling of tissues. An 
important family of such enzymes is that of the matrix metalloproteinases 
(MMPs). To control MMP-mediated ECM breakdown, tissue inhibitors of 
metalloproteinases (TIMPs) are able to inhibit MMP activity. A disturbed 
balance of MMPs and TIMPs is found in various pathologic conditions, 
such as cancer, rheumatoid arthritis and periodontitis. The role of MMPs 
in pathology has been extensively described in literature. The main focus 
of this review lies on the biological functions of TIMPs and their 
occurrence in disease, especially in the head and neck area. Firstly, their 
biological functions will be discussed and secondly their role in diseases 
like oral cancers and periodontitis, and in the development of cleft palate. 
Finally, the diagnostic and therapeutical opportunities of TIMPs will be 
evaluated. 
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3.1 Introduction 
 
Proteins in the extracellular matrix (ECM) such as collagen are 
responsible for the coherence of connective tissues. Tissue remodeling 
during embryonic development, growth, or disease processes, requires the 
degradation of these proteins to allow changes in shape, cell migration, or 
tissue resorption. Matrix metalloproteinases are known to play an 
important role in these processes. However, other enzymes such as 
cathepsins, the plasminogen activator/plasmin system, and neutrophil 
elastase have recently gained more attention as ECM degrading 
proteins.
1,2
 Matrix metalloproteinases (MMPs) are able to degrade most 
proteins of the ECM. MMPs are counteracted by the tissue inhibitors of 
metalloproteinases (TIMPs), which inhibit MMP activity and thereby 
restrict ECM breakdown. The balance between MMPs and TIMPs plays 
an important role in maintaining the integrity of healthy tissues. A 
disturbed balance of MMPs and TIMPs is found in various pathologic 
conditions including rheumatoid arthritis, cancer, and periodontitis .
3,4
 In 
rheumatoid arthritis and malignant tumors the imbalance is generally in 
favor of MMPs and leads to cartilage destruction, or is associated with 
metastasis. Abundant information is available on the role of MMPs in 
health and disease, but information on TIMPs is limited, especially with 
respect to their role in oral diseases.  
The first TIMP was described in 1975 as a protein in culture medium 
of human fibroblasts and in human serum, which was able to inhibit 
collagenase activity.
5,6
 The molecular weight of this protein was later 
shown to be 28.5 kDa.
7
 Since then, three new TIMPs have been 
discovered in different species, and have been designated TIMP-2, -3, 
and -4 respectively.
8-12
 The molecular weight of TIMP proteins varies 
between species. 
All four currently known TIMPs are very well conserved, since they 
have been identified in humans, other vertebrates, insects, and even in 
Caenorhabditis elegans, a nematode worm that is commonly used as a 
model organism for genetic and cell biological research.
4,13-14
 
The main goal of this review is to discuss the biological functions of 
TIMPs. Firstly, the occurrence and biological functions of TIMPs in the 
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human body will be discussed. Next, their role in pathology will be 
reviewed with the emphasis on oral cancer, periodontitis, and cleft palate. 
Finally, the diagnostic and therapeutic opportunities of TIMPs will be 
evaluated. 
 
 
3.2 Time expression 
 
The genes that encode human TIMP-1 to -4 are mapped to the X-
chromosome Xp11.3 - Xp11.23, chromosome 17q25, chromosome 
22q12.1-q13.2, and chromosome 3p25 respectively.
15-18
 The size of the 
TIMP-1 mRNA transcript is 0.9 kb. For TIMP-2, two transcripts have 
been described of 1.0 kb and 3.5 kb respectively. The major TIMP-3 
mRNA transcript is 5.0 kb, but two minor transcripts of 2.4 and 2.6 kb 
have also been found. Finally, the single transcript of TIMP-4 is 1.4 kb.
3 
 
Table 1. Information on the gene location and type of expression of human TIMPs as  
 found in the NCBI PubMed gene database (www: gene bank TIMP-1, -2, -3,  
 and -4 gene information (September 2005) and in the literature:  
* Gomez et al., 1997, ** Lambert et al., 2004. Although different mRNA sizes have been  
described, only one protein product is known for each TIMP. TIMP-3 is found in both an 
unglycosylated (-g) and a glycosylated (+g) form. (MW: molecular weight). 
 
TIMP-1 and TIMP-3 expression is inducible, whereas TIMP-2 
expression is largely constitutive (www: TIMP-1, -2, and -3 gene 
information, Table 1). In contrast to the other TIMPs, TIMP-4 mRNA 
expression is highly regulated and restricted to neural tissue, fetal testes 
and Sertoli cells or ovaries, and cardiac, breast, and skeletal muscle 
tissues in mice and this is partly confirmed for humans.
4,19
 This 
restriction might be due to specific binding sites for transcription factors 
Gene GeneID Chromosome & gene 
location 
mRNA * 
(kb) 
MW ** 
(kDa) 
Expression 
TIMP-1 7076 Xp11.3-p11.23 0.9 28.5 Inducible 
TIMP-2 7077 17q25 1.0 
3.5 
21 Constitutive 
TIMP-3 7078 22q12.3 5.0 
2.4 
2.6 
21 (-g) 
27 (+g) 
Inducible 
TIMP-4 7079 3p25 1.4 22 Highly regulated and 
restricted 
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in the TIMP-4 gene.
19
 A distinguishing feature of TIMP-3 is its ability to 
bind tightly to the ECM.
20,21
 Figure 1 shows the primary protein 
structures of the TIMPs. Their amino acid sequences show about 40% 
homology.
4
 The tertiary structures of TIMP-1 and -2 have been resolved 
by X-ray diffraction and NMR studies.
22,23
 By their homology with these 
TIMPs, the tertiary structures of TIMP-3 and -4 have been suggested to 
be very similar (reviewed by Douglas
24
). All currently known TIMP 
proteins contain six loops and have a junction between the N- and C-
terminal domains. TIMPs are produced in many tissues, although not 
every tissue expresses all four TIMPs.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The primary protein structure of TIMPs. In each TIMP, 6 pairs of cysteines 
are linked to each other to form 6 disulfide bridges. The arrows indicate the junctions 
between the N- and the Cterminal domains of the proteins. The conserved VIRAK 
sequence is indicated in yellow. Reprinted from Critical Reviews in 
Oncology/Hematology, 49, Lambert E, Dassé E, Haye B, Petitfrère E, TIMPs as 
multifacial proteins, 187-198, Copyright (2004), with permission from Elsevier. 
 
TIMPs in Oral Disease 
 65 
In general, most mesenchymal and epidermal cells are able to produce 
TIMPs.
25
 TIMP-1, -2, and -3 are also produced by white blood cells.
26,27
 
TIMPs can be co-expressed with MMPs, but some studies show a 
reciprocal regulation of their expression, which may depend on 
endogenously expressed (growth) factors and cytokines.
3
 In summary, the 
balance between MMPs and TIMPs is variable, both in physiological 
processes such as growth and development, and in pathological 
conditions such as cancer and periodontitis.
4,28-30
 
 
3.2.1 Mutations of TIMPs 
Some polymorphisms and haplotypes of TIMP genes are associated with 
disease. A polymorphism of TIMP-1 is associated with asthma in 
Australian women but not men.
31
 TIMP-3 haplotype variants are found in 
patients suffering from idiopathic pulmonary fibrosis, and it is also 
suggested that some TIMP-3 haplotypes are involved in pigeon breeders’ 
disease, a chronic lung disorder.
32
 Moreover, specific mutations in the 
TIMP-3 gene cause the autosomal dominant disorder dystrophy, a disease 
that leads to degeneration of the macula and finally to blindness .
33,34
 The 
effects of the TIMP mutations in these diseases seem to be quite 
different. In Sorsby's fundus dystrophy, the mutant TIMP-3 proteins were 
found in high levels as active dimers. It is suggested that these mutated 
proteins are less susceptible to degradation. Hence, due to their increased 
levels, ECM degradation will be reduced and the Bruch’s membrane in 
the eye will thicken, which leads to the disease phenotype.
35
 On the other 
hand, in pigeon breeders’ disease, the mutations lead to an altered 
immune response and even to a reduced number of lymphocytes in the 
blood (Hill et al., 2004). Thus, TIMP-3 has multiple targets and acts 
through multiple pathways. 
 
3.2.2 TIMPs in body fluids 
TIMPs and MMPs can be produced by many different cell types and are 
also found in all body fluids, such as saliva, gingival crevicular fluid 
(GCF), serum and urine.
36-39
 MMP and TIMP levels change during 
physiological and pathological processes. Correlations between 
rheumatoid arthritis and different forms of cancer, and the levels of 
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MMPs and TIMPs are found in urine and serum. The MMP-9 / TIMP-1 
ratio in urine is thought to predict the risk of bladder cancer, whereas the 
TIMP-2 levels in urine from patients with urothelial carcinomas is 
significantly decreased.
38,40
 In the serum of patients with hepatocellular 
carcinoma and rheumatoid arthritis, TIMP-2 levels are significantly 
increased, whereas the serum TIMP-2 levels in patients with gastric 
cancer and cancer of the uterus are significantly decreased.
36 
This shows 
that MMPs and TIMPs occur throughout the entire body, including all 
body fluids. An imbalance between MMPs and TIMPs might be 
associated with disease. In general, the relevance of systemic levels of 
enzymes and inhibitors can be questioned since the local balance of  these 
proteins eventually determines matrix degradation. 
 
 
3.3 Biological functions of TIMPs 
 
The number of known biological functions of TIMPs has been expanding 
rapidly over the last decades. These findings indicate that TIMPs are 
multifunctional proteins and not just mere MMP inhibitors. In addition, it 
is becoming more evident that MMPs also have several additional 
biological functions. It is even questioned whether ECM breakdown 
should be considered as their primary function.
41
 
 
3.3.1 MMP inhibition  
The first known biological function of TIMPs, which led to their 
discovery, is the inhibition of collagenases. At the present, 25 MMPs are 
identified, numbered consecutively from 1 to 28 but MMP-4, -5 and -6 
are missing. The MMPs can be divided into subgroups according to their 
primary substrates.
42
 
In the ECM, TIMPs form non-covalent 1:1 stoichiometric complexes 
with MMPs. Almost all MMPs can be inhibited by all four TIMPs, 
although differences in binding affinity are known.
43
 The so-called 
membrane type (MT-) MMPs form a distinct group as they are bound to 
the cell membrane and are hardly inhibited by TIMP-1.
44,45
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All TIMPs contain the NH2-terminal domain and the conserved 
VIRAK amino acid consensus sequence, and both are suggested to be 
essential for MMP binding and inhibition.
3,4,46
 However, the analysis of 
the tertiary structure of TIMP-2 by NMR measurements shows that the 
VIRAK sequence is sterically unable to be involved in binding 
interactions.
22
 X-ray crystallographic studies have been performed to 
analyze TIMP-1•MMP-3 and TIMP-2•MT1-MMP complexes.23,47 These 
studies show that the TIMP-1 and -2 molecules have a wedge-like shape 
that fits into the active site cleft of an MMP, just like a substrate 
molecule would do.
48
 The conserved cysteine in the N-terminal domain, 
at least in TIMP-1, will subsequently chelate the active-zinc site and 
expel the water molecule, thereby inactivating the MMP protein.
23
 The X-
ray structures of TIMP-3 and -4 and their complexes with MMPs have 
not yet been described.
49
 Besides MMP inhibition, many other biological 
functions of TIMPs have been discovered. Some of these might be 
explained by the inhibition of MMP activity, but most of the alternative 
functions seem to be MMP-independent. 
 
3.3.2 MMP activation 
In contrast to the inhibition of MMPs by TIMPs, some studies clearly 
show that TIMP-2 is also involved in the activation of pro-MMP-2. 
Figure 2 summarizes these activation steps in a simplified way. The N-
terminal region of TIMP-2 firstly binds to the active site of the 
membrane-bound MT1-MMP (MMP-14). The hemopexin-like domain of 
the secreted pro-MMP-2 subsequently binds to the C-terminal region of 
the complexed TIMP-2.
50
 Then the bound pro-MMP-2 is activated by 
MT1-MMP in the pro-MMP-2•TIMP-2•MT1-MMP complex or by 
uncomplexed MT1-MMP.
50-52
 A similar pro-MMP-2 activation is known 
to occur in complexes of TIMP-3 and MT3-MMP, but not in those of 
TIMP-3 and MT1-MMP. TIMP-4 is unable to activate pro-MMP-2 in a 
ternary complex with either MT1- or MT3-MMP.
50
 Theoretical 
calculations show that a half-molar ratio of TIMP-2 to MT1-MMP is 
optimal for activation of pro-MMP-2.
53
 This mechanism stimulates cell 
migration and processes such as tumor metastasis and invasion.  
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Figure 2. Schematic representation of pro-MMP-2 activation by MT1-MMP and 
TIMP-1. MT1-MMP is bound at the cell surface (A). TIMP-1 binds to MT1-MMP (B). 
Pro-MMP-2 binds to this complex, and becomes activated. Uncomplexed MT1-MMPs may 
be recruited and aid to the activation of pro-MMP-2 (C). Subsequently, the complex 
dissociates (D). The binding sites for the formation of this complex are found in the N-
terminal and C-terminal domains of TIMP-2, the hemopexin-like domain of pro-MMP-2, 
and the active site of MT1-MMP as described in the text. 
 
3.3.3 Mitogenic effects 
TIMP-1 and TIMP-2 have been identified as potent growth factors for a 
wide range of cells.
54,55
 TIMP-1 can bind to breast cancer cells through 
an 80-kDa transmembrane protein in vitro and induce a dose-dependent 
mitogenic effect.
56
 These findings led to new studies on the use of TIMP-
1 as a marker for primary breast cancer.
57,58
 TIMP-1, but not TIMP-2 and 
-3, has also been detected in the nuclei of gingival fibroblasts where its 
level depends on the cell cycle. This was also found in other fibroblasts, 
suggesting that this is a more general phenomenon.
59
 There is need for 
additional research to explain how TIMP-1 is transported to the nucleus. 
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In other cell types, such as aortic smooth muscle cells and 
keratinocytes, TIMP-1 also has a mitogenic effect.
60,61
 The mitogenic 
signal might be transduced through tyrosine-phosphorylation, Ras 
effector, ERK2, and MAPK pathways.
56,61,62
 Most of these intracellular 
effects of TIMP-1 are also found after TIMP-2 stimulation,
62
 but very 
little is known about the actual TIMP receptors. A few putative receptors 
for TIMP-1 have been found, which might mediate the mitogenic 
effects.
60,63
 These receptors, including the 80-kDa transmembrane 
protein, have not yet been fully characterized.
4
 Moreover, these receptor 
studies have all been performed in vitro but their function in vivo is 
completely unknown. On the other hand, the presence of TIMP-1 in the 
nuclei of fibroblasts in vitro strongly suggests the existence of a non-
degrading transport mechanism, which might include a specific TIMP 
receptor.  
TIMP-2 also stimulates the proliferation of a wide range of other 
cells such as dental pulp fibroblast-like cells and gingival fibroblasts, but 
also leucocytes and epithelial cells.
54
 Most of these cells are TIMP-2 
producers themselves, suggesting an autocrine mechanism. In contrast to 
their mitogenic effects, TIMPs can also inhibit cell growth. The 
overexpression of TIMP-2 inhibits tumor growth, metastasis, and 
invasion in vivo.
64
 The latter two effects can be explained by the 
inhibition of matrix degradation by MMPs.
65
 TIMP-2 is also able to 
inhibit angiogenesis in vivo, probably by an MMP-independent 
mechanism. This might be the cause of the inhibition of tumor growth. 
Moreover, angiogenic responses to the vascular endothelial growth factor 
and fibroblast growth factor 2 are also inhibited by TIMP-2 in an MMP-
independent way.
66
 In vitro, TIMP-2, but not TIMP-1, inhibits the 
proliferation of human microvascular endothelial cells.
67
 This might 
explain the inhibition of angiogenesis by TIMP-2 in vivo. 
 
3.3.4 Apoptosis 
TIMPs seem to play a role in the regulation of apoptosis. In epithelial 
breast cells and in B-lymphocytes apoptosis is reduced by TIMP-1, but 
not by TIMP-2.
68-70
 Alternatively, TIMP-2 inhibits apoptosis in 
melanoma cell lines.
71
 It has been suggested that an increased expression 
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of TIMP-3 stimulates apoptosis in retinas affected by simplex retinitis 
pigmentosa, an autosomal dominant mutation that disrupts the retina.
72-74
 
In addition, TIMP-3 may also have indirect pro-apoptotic effects by 
protection of tumor necrosis factor (TNF)-α receptors on human colon 
carcinoma cells from degradation by MMPs. Consequently, these cells 
are more sensitive to apoptosis induction by TNF-α.75 The overexpression 
of human TIMP-4 in rat vascular smooth muscle cells and in transformed, 
but not wild type, cardiac fibroblasts also induces apoptosis.
76,77
 The 
mechanism behind this process remains to be elucidated. These data show 
that TIMP-1 and TIMP-2 seem to have anti-apoptotic effects, whereas 
TIMP-3 and TIMP-4 seem to be pro-apoptotic. Furthermore the direct or 
indirect effects of TIMPs on apoptosis are cell-type specific.  
 
3.3.5 Immunological interactions 
In the immune system, TIMP-1 is primarily produced by B cells, whereas 
TIMP-2 expression is restricted to T cells.
26
 Other lymphocytes such as 
mononuclear phagocytes, neutrophils and dendritic cells are also able to 
produce TIMPs and MMPs.
30,78,79
 Neutrophils are also able to store pro-
MMP-8 and -9, and release them upon stimulation.
80
 Dendritic cells 
patrol the body by migrating through the extracellular matrix, and sample 
the local 'antigenic' environment. They are able to produce, store, and 
secrete MMP-1, -2, -3,-9, and TIMP-1, -2, and -3. The balance between 
MMPs and TIMPs determines the migratory capacity of these cells .
79,81
 
MMPs are able to cleave all four known human monocyte 
chemoattractant proteins (MCPs). Upon cleavage, the MCPs are 
inactivated and may even function as receptor antagonists.
82
 
Many cytokines (CKs) are produced by the immune system and are 
involved in cell signaling. Some CKs are able to interact with the 
transcription of MMP and TIMP genes or to alter their expression. This 
makes the effects of CKs on MMPs and TIMPs very complex. Depending 
on the cell type, the same CK can either stimulate or inhibit MMP or 
TIMP expression. Some important effects of specific CKs on MMP and 
TIMP expression are discussed below. These CKs also play a role in 
some of the pathologies we will discuss later. 
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In general, TGF-β downregulates MMP expression and upregulates 
TIMP expression.
83,84
 However, the expression of several MMPs in 
fibroblasts and keratinocytes in vitro, is stimulated by TGF-βs.85-88 The 
expression of TIMP-2 in vivo seems to be unaffected by TGF-β in dermal 
fibroblasts, but IL-13 and TGF-β synergistically increase TIMP-3 
expression in airway fibroblasts.
89-91
 IL-10 inhibits MMP-9 expression in 
vitro but induces TIMP-1 expression.
78
 On the other hand, IL-10 is able 
to inhibit the expression of other CKs and thus may counteract its own 
effects on MMP and TIMP expression.
84,88,92,93
 TNF-α stimulates the 
expression of several MMPs and thus contributes to tissue degradation in 
inflammatory conditions.
88
 Thus, in general, changes in CK expression 
may affect the MMP / TIMP balance in a cell-type dependent manner. 
 
3.3.6 Inhibition of other metalloproteinases 
TIMPs are also able to inhibit other metalloproteinases. The 
transmembrane proteins known as “a disintegrin and metalloproteinase” 
(ADAMs) are widely expressed in mammalian tissues. As an exception, 
ADAMs with trombospondin repeats (ADAM-TS) are soluble factors that 
do not contain a transmembrane domain. Members of this family may be 
involved in a range of cellular processes such as fertilization, 
myogenesis, neurogenesis and angiogenesis. All ADAMs have a 
metalloproteinase-like domain, but some lack the zinc-binding catalytic 
consensus sequence HEXXH and therefore lack proteolytic activity. This 
last group of proteins are expressed in specific tissues and have 
specialized functions (reviewed by Handsley and Edwards
94
), such as cell 
adhesion in the testes.
95
 TIMPs are able to inhibit both the ADAM and 
ADAM-TS proteins.
94
 There is no evidence up to now that TIMPs are 
able to inhibit aspartic, serine, and cysteine proteinases (reviewed by 
Uitto et al.
1
).  
 
3.3.7 Indirect systemic effects of TIMPs  
Besides the direct effects on a (peri)cellular level, TIMPs are also 
indirectly involved in the regulation of blood pressure through their 
effects on MMPs (reviewed by Overall
41
). Blood pressure can be 
increased by MMP-2 through cleaving big endothelin-1 to the active 
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protein endothelin-1, a potent vasoconstrictor.
96
 MMP-2, but not MMP-9, 
is also able to control blood pressure by cleaving the vasodilator peptide 
adreno-medullin.
97
 Available TIMPs are able to inhibit MMP activity and 
thereby also control their indirect systemic effects.  
Taken together, these studies show that TIMPs have a broad range of 
biological functions extending far outside their ability to inhibit 
metalloproteinases. Just like TIMPs, MMPs have other biological effects 
besides ECM breakdown. To our knowledge, no biological TIMP 
inhibitors have been described up to now, although MMPs might be 
considered as such. 
 
 
3.4 TIMPs in oral disease 
 
A disturbed balance between MMPs and TIMPs might contribute to the 
disease process in degenerative diseases. Similar patterns of MMP and 
TIMP expression can be found in different diseases involving matrix 
degradation. In some cases, the occurrence of MMPs and TIMPs in body 
fluids such as saliva, GCF, or serum provide addition information about 
the progression of the disease. 
 
3.4.1 Periodontitis  
Periodontitis is an infection that results from the interactions of many 
bacteria. Chronic periodontitis has been defined by the American 
Academy of Periodontology as “an infectious disease resulting in 
inflammation within the supporting tissues of the teeth, progressive 
attachment and bone loss … characterized by pocket formation and / or 
recession of the gingiva. The inflammatory reactions over time lead to 
tissue destruction within the periodontium” .98 Bacteria that are implicated 
in periodontitis are mainly anaerobic, Gram negative organisms, and they 
carry lipopolysaccharide (LPS) in their outer membrane. They are also 
referred to as putative periodontal pathogens.
99
 
In healthy periodontal tissue, TIMP levels are generally higher than 
in inflamed periodontal tissue, in which MMP levels exceed TIMP levels. 
The more severe the inflammation is, the higher the concentrations of 
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active MMPs.
100
 In GCF and in gingiva from patients, MMP-1, -2, -3, and 
-9 are significantly increased whereas TIMP-1 and -2 are significantly 
decreased, compared to samples from healthy controls.
101
 Tissue 
destruction might be reduced by restoring this balance.  
A range of cell types produce interleukins such as IL-6 during 
inflammation. The level of this CK is also increased during 
periodontitis.
102
 In turn, IL-6 will increase MMP-1 and -9, and TIMP-1 
expression. In addition, stimulated neutrophils will release stored pro-
MMP-8 and -9, which are activated by bacterial proteases.
80
 Also other 
pro-MMPs present in the tissue are activated by bacterial proteases. LPS-
stimulated macrophages will express TNF-α and MMPs. Subsequently, 
TNF-α will also increase MMP expression by other cell types. The 
TIMP-1 expression is not affected by bacterial proteases.
84,103
 
Furthermore, fibroblasts in the inflamed periodontal tissue will also 
become activated and start to produce latent metalloproteinases, 
plasminogen activator, and TIMPs. Plasminogen activator activates 
plasmin, which in turn activates metalloproteinases.
100
 All these 
processes will contribute to the destruction of the diseased tissue. 
Although some studies show increased TIMP levels in periodontitis, 
these levels are probably insufficient to inhibit all MMPs.
104
 Thus, 
bacterial inflammation will lead to a cascade of expression and activation 
of MMPs by different cell types, resulting in degradation of the ECM. 
Apoptotic neutrophils are able to interact with LPS-activated monocytes 
through cell-cell contact. Subsequently, the monocytes will mainly 
express IL-10 and TGF-β instead of the proinflammotary cytokines.105 
TGF-β seems to reduce inflammatory progression in periodontal 
diseases.
87
 One of the many effects of this cytokine is the upregulation of 
TIMP expression and the downregulation of certain MMPs.
83,87
 In 
contrast, TGF-β also induces the synthesis of MMP-2, but the overall 
result is an overexpression of TIMPs relative to MMPs.
41
 
The amount of TIMPs and MMPs in GCF also changes during 
periodontitis. In chronic periodontitis, MMP-1, -8, and -9, and TIMP-1 
levels are elevated.
37
 In saliva, TIMP-1 and MMP-1 levels are not 
increased.
37
 Taken together, the tissue and bone destruction in 
periodontitis is the consequence of a relative overexpression of MMPs in 
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relation to TIMPs. The inhibition of MMP expression or activity, or an 
increased TIMP expression, might reduce tissue destruction in 
periodontitis. 
 
3.4.2 Tumors 
In general, different tumors show varying patterns of MMP and TIMP 
expression. In serum of cancer patients, both MMP and TIMP levels are 
increased. If the MMP / TIMP ratio is in favor of MMPs, the prognosis 
for the patient seems to be poor.
106
 However, there is no clear correlation 
between the serum level of MMPs and TIMPs, and the metastatic 
potential of the tumor. Possibly, the serum levels of MMPs and TIMPs do 
not reflect the local tissue levels, which eventually contribute to the 
metastatic potential. Nevertheless, overexpression of TIMP-1 and -2 in 
tissues generally decreases tumor growth and metastasis, whereas 
downregulation increases the invasiveness.
4
 In the head and neck region, 
different types of tumors have been described, but relatively little is 
known about their MMP and TIMP expression.  
 
3.4.3 Oral squamous cell carcinoma  
In general, several MMPs and TIMPs are expressed in squamous cell 
carcinoma (SCC) of different organs, such as the skin, airways, the 
uterine cervix, the vulva, the esophagus and the mouth. SCC of the skin 
is a very common malignant tumor. In contrast to oral SCC, no TIMP 
expression is found in skin SCC.
30,53
 In oral SCC, the correlation of MMP 
and TIMP expression with clinical features is still not fully understood.
107
 
In addition, the expression of MMP-1, -2 and -9 is increased in oral SCC, 
and pro-MMP-2 levels are strongly increased after lymph node 
metastasis.
108,109
 The expression of MMP-2, MT1-MMP and TIMP-2 
correlate with local recurrence of tongue SCC.
53
 It is even suggested that 
MMP-2 can be used as a predictive marker for metastasis.
110
 Moreover, 
the correlation between the levels of MMP-1, MMP-9, and TIMP-1, and 
on the other hand the size of the tumor is significant, but no association is 
found between these markers and the histological grade.
111
 This shows 
that the levels of MMPs increase during oral SCC progression and 
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invasion, and that TIMP-1 and -2 levels are correlated with tumor-growth 
and recurrence. 
The prognosis of SCC seems to depend on the cellular origin of 
MMPs. In one cell-type, MMP expression may lead to increased invasion 
and metastasis, whereas in another the same MMP may lead to the 
inhibition of vascularization of the tumor and thus limit its growth.
30
 
 
3.4.4 Salivary gland tumors  
Salivary gland tumors are rare neoplasms of the head and neck region. In 
healthy salivary glands, MMP-2 and -9, and TIMP-1 and -2 seem to be 
expressed mainly by duct cells, but not by acinar cells.
112,113
 On the other 
hand, acinar cells strongly express TIMP-3, whereas duct cells mostly 
have a low expression level of TIMP-3.
113
 Homogenized tumor tissue 
revealed a significant higher expression of MMP-1, -2, -13, -14 and 
TIMP-1 than non-neoplastic tissue. The expression levels of MMP-7, -8, 
-9 and TIMP-2 show no significant difference in homogenized tumor 
tissue, but in the acinar cells MMP-2 and -9 and TIMP-1 and -2 levels are 
significantly higher.
113,114
 No correlation with pathological parameters 
such as lymph node metastasis have been found.
114
 However, TIMP-1 
expression is reduced in malignant salivary gland tumor cell lines 
compared to a benign cell line,
115
 and so there is a clear difference 
between the in vitro and in vivo situation. 
These data show that in salivary gland carcinomas some MMPs 
levels are increased, and seem to exceed the TIMP levels. 
 
3.4.5 Orofacial clefts 
During embryonic craniofacial development, MMP and TIMP expression 
are highly regulated in order to control tissue remodeling. If their balance 
is disrupted, malformations such as a cleft lip and palate can occur .
86
 
Normally, the secondary palate develops from two lateral shelves in 
mammalian embryos. In the human fetus, the secondary palate is formed 
between the sixth and eighth week after implantation in the uterus 
(reviewed by Moxham
116
). After a process of elevation and elongation, 
the opposing shelves fuse in the midline,
116,117
 as schematically shown in 
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figure 3. The midline seam will finally be degraded to allow merging of 
the shelves. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Palatal fusion during embryonic development. Initially, the palatal shelves 
(ps) are positioned next to the developing tongue (A). Subsequently, the tongue descends 
and the palatal shelves rotate towards eachother (B). Finally, the palatal shelves fuse and 
the midline seam (ms) is degraded by MMPs (C). The nasal septum (ns) simultanously 
merges with the secondary palate. 
 
Mouse embryos show distinct spatio-temporal MMP and TIMP 
expression patterns during palate morphogenesis.
28
 The expression of 
TIMP-1 and -2 is enhanced in the medial mesenchyme next to the palatal 
seam. It has been shown that the palatal epithelium, nerve, endothelium, 
osteogenic cells and components of the tooth germ all express TIMP-3. 
More recent data show that TIMP-3 mRNA is restricted to the 
mesenchyme around the nasal epithelium, but is absent in the palate. The 
expression of MMP-2, -3, -9 and -13 is increased during the regression of 
the midline seam.
28,85,86
 Thus, although TIMPs seem to be expressed 
selectively, and may inhibit MMP activity, there are contradictory 
findings in the different studies. The additional biological functions of 
TIMPs might be involved in their differential expression. 
The epithelio-mesenchymal transdifferentiation is a process that 
normally occurs simultaneously with degradation of the midline seam, 
and is necessary for a complete fusion of the palatal shelves. This process 
seems to be MMP-dependent. The inactivation of MMPs by TIMP-2 or a 
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synthetic MMP inhibitor in vitro leads to a failure of fusion of mouse 
palatal shelves.
86
 Therefore, strict regulation of MMP activity is required 
for palatal fusion and a imbalance in favor of TIMP-2 might increase the 
risk of a palatal cleft. 
During palatal fusion in the mouse, not only the expression of 
MMPs and TIMPs is tightly regulated, but also the expression of TGF-
βs.116 As described earlier, TGF-βs are able to regulate MMP and TIMP 
expression. TGF-β3 expression is restricted to the medial edge epithelium 
of the palatal shelves.
86,118
 After the fusion, TGF-β1 and -2 are also 
detected in the medial edge epithelium and the mesenchymal cells, 
respectively.
116
 TGF-β3 knockout mice develop a palatal cleft. Moreover, 
palatal fusion in vitro can be restored by TGF-β3 in these mice.86 The 
expression of MMP-13 in the degrading midline seam in mice seems to 
be regulated by TGF-β3.86 This shows that MMPs and TIMPs play a 
crucial role in palatal fusion, and also that TGF-βs seem to be important 
for the regulation of this process. Further elucidation of these 
mechanisms might help to develop strategies to prevent this type of 
disorder in the future. 
 
 
3.5 Diagnostic and therapeutic opportunities 
 
In degenerative diseases, the balance between MMPs and TIMPs is often 
disturbed. Relative overactivity of MMPs leads to tissue destruction such 
as in periodontitis and rheumatoid arthritis, and facilitates the invasion of 
tumors leading to metastases.
30
 The general hypothesis for cancer is that 
an overexpression of MMP-2 relative to TIMP-1 leads to an increased 
metastasis of tumors. Metastasis is facilitated by increased ECM 
breakdown, in which MMPs play an important role. Considering that 
TIMP-1 has mitogenic properties and can protect cells from apoptosis, we 
think that a tumor-specific expression pattern of TIMP-1 might exist. 
Initially, TIMP-1 is overexpressed in relation to MMPs, which stimulates 
tumor expansion and prevents apoptosis. Subsequently, MMPs are 
overexpressed to facilitate migration and metastasis by matrix 
degradation. A similar concept has been described for the role of MMPs 
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in tumor progression.
119
 Nowadays, MMP-9 and TIMP-1 are suggested to 
be suitable as clinical prognostic markers in different forms of cancer, 
such as oral SCC, non-small cell lung carcinoma, and in primary breast 
cancer.
57,120-122
 In the development of palatal clefts, the opposite seems to 
happen. Overexpression of TIMPs impairs palatal fusion and increases 
the risk of a cleft palate. Although the exact relative levels of MMPs and 
TIMPs are not fully known in different tissues, therapeutic opportunities 
may be found in restoring this balance. Obviously, this problem can be 
tackled from the MMP side as well as from the TIMP side. For instance, 
the activity of MMP-8 and -13 can be reduced by low doses of 
doxycycline, which is already used clinically in the treatment of 
periodontitis.
123
 However, it may be more complex than suggested here. 
As in many complex biological systems, the modulation of a single 
factor may have unexpected side effects. For example, broad-range MMP 
inhibitors are unable to block metastasis in patients with advanced cancer 
(reviewed by Folgueras et al.
119
; Overall
41
). Several explanations have 
been suggested for this phenomenon. Firstly, MMPs have multiple 
biological effects such as the inhibition of angiogenesis.
124
 Secondly, the 
broad-range MMP inhibitors are not only affecting MMPs, but also other 
proteases such as ADAMs and anti-angiogenic ADAM-TSs.
119,125
 Finally, 
other matrix proteinases such as the cathepsins, which are not affected by 
TIMPs, seem to be involved in tumor metastasis as well.
2,126
 Next to this, 
several polymorphisms and haplotypes of TIMPs are known to be 
involved in specific diseases. Other polymorphisms may also contribute 
to the disease process in conditions such as cancer and inflammatory 
diseases.  
Although more research is needed to unravel all actions and 
interactions of MMPs and TIMPs, some diagnostic tools are already 
being developed. TIMP-1 might be a marker for the recurrence of non-
small cell lung carcinoma after surgery.
120
 Evidence is accumulating that 
TIMP-1 and MMP levels can be used as prognostic markers in serum of 
primary breast cancer patients.
57
 In oral SCC, MMP-9 levels in serum can 
be correlated to survival, and also TIMP-1 levels seem to have a 
prognostic value.
121,122
 In the serum of patients with other tumors such as 
hepatocellular cancer and stage IV breast cancer, the levels of MMPs and 
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TIMPs also have been shown to change.
36,106
 This may be helpful as a 
diagnostic tool in the future. However, TIMP-2 levels have already been 
shown to have only limited value as a prognostic marker in colorectal 
cancer.
106
 MMP and TIMP levels in GCF change during periodontitis. 
MMP-8 in GCF may be suitable as a marker to monitor periodontal 
health.
37
 This shows that several options are available for the diagnostic 
and therapeutic use of MMPs and TIMPs, but also that more research is 
required especially into the role of other matrix proteinases.  
 
 
3.6 Conclusion 
  
Degradation of the ECM depends on a delicate interplay between 
proteolytic enzymes and their inhibitors. Apart from MMPs, other ECM-
degrading enzymes such as cathepsins are gaining more attention in this 
field. The biological effect of a shift in MMP and / or TIMP levels 
depends on their relative balance. Overactivity of MMPs results from 
their overexpression or from reduced expression of TIMPs, and vice 
versa. This sensitive balance is continuously controlled from fertilization 
of the ovum to death. TIMPs have been found in all body fluids and 
aberrant expression levels can be associated with disease. Therefore, they 
may have a diagnostic value as disease markers. However, the complete 
spectrum of actions and interactions of MMPs and TIMPs is still not fully 
known. In recent years, several additional biological functions of MMPs 
and TIMPs have been discovered, varying from local to systemic. Among 
these are the mitogenic functions of TIMPs and their effect on apoptosis, 
but also the regulation of blood pressure by MMPs. It is likely that more 
biological functions of MMPs and TIMPs will be found in the future. If 
all currently known biological effects of MMPs and TIMPs are taken into 
account, it is already nearly impossible to predict the exact result of 
changes in their levels. For example, in cancer treatment, it is difficult to 
use MMPs and TIMPs as targets, because a clear picture of the kinetics of 
MMP and TIMP interaction is still lacking. Moreover, the shift in MMP 
and TIMP levels in serum does not necessarily reflect the local balance in 
the tissue. 
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At present, we are just starting to discover the diagnostic and 
therapeutic opportunities of MMPs and TIMPs. In periodontitis 
irreversible damage to the alveolar bone can be reduced by exogenous 
MMP inhibitors such as doxycycline. In cancer treatment, no successful 
therapy targeting MMPs or TIMPs has evolved until now. In conclusion, 
much is already known about the MMP and TIMP system, but more 
research is needed to fully exploit their possible diagnostic and 
therapeutic possibilities. 
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Abstract 
 
Objective: Myofibroblasts are responsible for contraction and scarring 
after cleft palate repair. This leads to growth disturbances in the upper 
jaw. We hypothesized that cells from the bone marrow are recruited to 
palatal wounds and differentiate into myofibroblasts.  
Methods: We transplanted bone marrow from green fluorescent 
protein-transgenic rats into lethally irradiated wild-type rats. After 
recovery, experimental wounds were made in the palatal 
mucoperiosteum, and harvested two weeks later. Green fluorescent 
protein-expressing cells were identified by immunostaining. 
Myofibroblasts, activated fibroblasts, endothelial cells, and myeloid cells 
were quantified with specific markers. 
Results: After transplantation, 89 ± 8.9% of mononuclear cells in the 
blood expressed the green fluorescent protein and about 50% of adherent 
cells in the bone marrow. Tissue obtained during initial wounding 
contained only minor numbers of GFP positive cells, like adjacent control 
tissue. Following wound healing, 8.1 ± 5.1% of all cells in the wound 
area were positive, and 5.0 ± 4.0 % of the myofibroblasts, which was 
significantly higher than in adjacent tissue. Similar percentages were 
found for activated fibroblasts and endothelial cells, but for myeloid cells 
it was considerably higher (22 ± 9%).  
Conclusions: Bone marrow-derived cells contribute to palatal wound 
healing, but are not the main source of myofibroblasts. In small wounds, 
the local precursor cells are probably sufficient to replenish the defect.  
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4.1 Introduction 
 
Wound healing consists of three partly overlapping phases; inflammation, 
tissue formation, and tissue remodeling.
1
 During tissue formation and 
remodeling, fibroblasts differentiate into myofibroblasts in response to 
mechanical tension, transforming growth factor-beta 1, and the extra 
domain-A splice variant of fibronectin.
2
 Myofibroblasts are responsible 
for wound contraction and the production of abundant extracellular 
matrix leading to a scar.
3,4 
They typically express alpha-smooth muscle 
actin (αSMA), which enables them to generate the contractile forces. The 
highest myofibroblast density in a wound is generally found around two 
weeks post-wounding.
1
 After wound closure, myofibroblasts and other 
cells disappear by apoptosis.
5
 Ultimately, a rigid scar with a low cell 
density remains, which may lead to functional and esthetic problems. 
Scar formation after cleft palate repair impairs maxillary growth.
6,7
 
Upon injury, local stem cells are activated and start to proliferate to 
regenerate the lost or damaged tissue.
8,9
 In addition, circulating bone 
marrow-derived cells (BMDCs) may be recruited.
10
 These cells include 
hematopoietic stem cells (HSC), mesenchymal stem cells (MSC), 
endothelial progenitor cells (EPC,
11
), and circulating fibrocytes. The 
latter are a distinct  mononuclear subpopulation of fibroblast and 
myofibroblast precursors with both hematopoietic and mesenchymal 
markers.
12-15
 HSCs are known to give rise to all blood cell lineages but 
possibly also to non-blood cells such as hepatocytes, endothelial cells, 
smooth muscle cells, and cardiac myocytes.
11
 MSCs are far less abundant 
precursors that can differentiate in vitro into non-hematopoietic cells like 
osteoblasts, chondrocytes, fibroblasts, astrocytes and others .
11
 BMDCs 
are also able to differentiate into several cell types in normal and 
regenerating tissues in vivo such as macrophages, satellite cells, epithelial 
cells and endothelial cells, but also myofibroblasts.
16-20
 BMDCs also have 
the capacity to differentiate into oral and craniofacial tissues but, as in 
other adult tissues, local populations of progenitor cells also seem to be 
present in the lamina propria of the oral mucosa.
21,22
 However, no studies 
are available on the contribution of BMDCs to oral mucosa wounds. 
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We hypothesized that circulating BMDCs are recruited to palatal 
wounds and differentiate into myofibroblasts. If so, this might offer new 
opportunities for anti-scarring therapy in cleft palate surgery and other 
fibrotic conditions, by preventing the recruitment of specific 
myofibroblast precursors. To investigate the recruitment of myofibroblast 
precursors originating from the bone marrow, we transplanted bone 
marrow from green fluorescent protein (GFP)-transgenic rats into wild-
type rats. Then, we investigated the contribution of BMDCs to the 
myofibroblast population after the inflammation phase in experimental 
wounds in the palate. In addition, we estimated the contribution of 
BMDCs to other cell populations. 
 
 
4.2 Materials & methods 
  
4.2.1 Animals 
Five GFP-transgenic Sprague-Dawley rats were used as donors for the 
bone marrow transplantation (BMT) (rats provided by Dr M. Okabe and 
Dr. T. Suzuki, Japan SLC, Inc., Shizuoka, Japan). Ten wild-type 
Sprague-Dawley rats (Janvier, Le Genest, France) were used as 
recipients. The rats were six weeks old at the start of the experiment and 
kept under sterile housing conditions with free access to food and water. 
The Board for Animal Experiments of the Radboud University Nijmegen 
Medical Centre has approved these experiments (RU-DEC 2005-104).  
 
4.2.2 Bone marrow transplantation 
The recipient rats received two doses of 5 Gy total body irradiation with 
an interval of 18 hours. Bone marrow from the femurs of the GFP-
transgenic donor rats was harvested by flushing with phosphate-buffered 
saline (PBS) (Invitrogen/GIBCO, San Diego, CA, USA), supplemented 
with 2% penicillin / streptomycin (Invitrogen/GIBCO, San Diego, CA, 
USA). After washing, mononuclear cells were isolated by density 
centrifugation over Lymphoprep (p = 1.077 g/m
-l
) (Axis-Shield POC AS, 
Oslo, Norway), and washed twice in 0.9% NaCl. Subsequently, 2.3x10
8
 
mononuclear cells per kg rat (0.4 ml) were injected in the tail vein, three 
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hours after the second irradiation. The weight of the rats was monitored, 
and only a temporary weight reduction was observed. Five weeks after 
the BMT, blood was drawn and mononuclear cells were analyzed for GFP 
by flow cytometry on a FACScan (Becton and Dickinson, Franklin Lake, 
NJ, USA). Blood from 15 GFP-transgenic rats and seven wild-type rats 
was analyzed for comparison. The wild-type blood contained no GFP-
positive cells. Bone marrow from four transplanted rats was put in culture 
to analyze GFP expression of mesenchymal precursors by flow 
cytometry. 
 
4.2.3 Experimental wounding 
Seven weeks after the BMT, four-mm palatal wounds were made (Fig. 1) 
in the mucoperiosteum between the third molars under anesthesia of a 
mix of fentanyl and fluanisone (Hypnorm, Vetaphrama Ltd, Leeds, UK) 
and midazolam (Dornicum, Deltaselect, Dreiech, Germany). 
Buprenorfinehydrochloride (Temgesic
®
, Schering-Plough, Brussels, 
Belgium) was used post-operatively as an analgesic. Two weeks after 
wounding, when the inflammation reaction has faded, the rats were killed 
by CO2/O2
 
inhalation. Wound and adjacent control tissue was harvested 
with a five-mm biopsy punch, and cut in two parts (figure 1). The tissue 
samples were fixed in 4% paraformaldehyde for 24 hours, and embedded 
in paraffin. 
 
4.2.4 Bone marrow cultures 
The femurs from four recipient rats were dissected, washed in 80% 
ethanol and subsequently in PBS with 4% penicillin/streptomycine and 
2% fungizone (all from GIBCO, Paisly, UK). The femurs were flushed 
with 2% penicillin/streptomycine in PBS and the marrow was 
resuspended through an injection needle. The cell suspension was then 
centrifuged at 400 g for 5 minutes, the pellet was resuspended in culture 
medium. Cells were plated in non-coated culture flasks in culture medium 
(LG-DMEM, Invitrogen, Carlsbad, California, USA) supplemented with 
penicillin/streptomycin and 10% FBS (Hyclone and cultured for nine 
days. We used FBS batches preselected for their potential to support 
Bone marrow-derived cells in palatal wound healing 
 99 
MSC expansion. The MSC were harvested by trypsinization, and 
analyzed by flow cytometry. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. The wound model. Left panel: Initially, a 4-mm ø palatal wound was created 
between the third molars and behind the third ruga (A). Two weeks later, wound (B) and 
control (C) tissue was harvested. Right panel: The biopsy was cut into two parts and 
embedded in paraffin. 
 
4.2.5 Histology and immunohistochemistry 
Five-µm sections were cut and stained with haematoxillin and eosin 
(H&E) for general tissue survey. The initial biopsy tissue from five rats 
was also processed. For immunohistochemical staining, three sections per 
sample (125 µm apart) containing both wound and control tissue, were 
mounted on Superfrost Plus slides (Menzel-Gläser, Braunschweig, 
Germany). The sections were deparaffinated, rehydrated, and incubated 
with 3% H-2O2. The sections were post-fixed with 4% formalin and 
washed in 0.75 µg/ml
-1
 glycine in PBS (PBS-G). Antigens were retrieved 
with citrate buffer (pH 6.01) at 70°C, followed by incubation in 0.075 
g/ml trypsin (Difco Laboratories, Detroit, USA) in PBS at 37°C. Then, 
the sections were pre-incubated with 10% normal donkey serum (NDS) 
(Chemicon, Temecula, USA) in PBS-G. 
All antibodies and the Vectastain ABC Standard alkaline 
phosphatase mix (ABC-AP) (Vector Laboratories, Burlingame, CA, 
USA) were diluted in 2% NDS. To detect GFP, the sections were 
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incubated overnight at 4°C with a polyclonal rabbit-anti-GFP antibody 
(1:300) (Invitrogen/Molecular Probes, Eugene, OR, USA). Subsequently, 
biotinylated donkey-anti-rabbit (1:500) (Jackson Labs, West Grove, PA, 
USA) was added. Next, the sections were treated with ABC-AP, and 
washed with TRIS-HCl (pH 8.2). The Fast Blue substrate (Sigma 
Chemical CO, St Louis, MO, USA) was freshly prepared, and applied to 
the sections. The reaction was stopped in demineralized water (Milli-Q 
pore system, Millipore SA, Molsheim, France), and the sections were 
washed in PBS and pre-incubated again for double-staining with the 
following primary mouse monoclonal antibodies: 
A)  Anti αSMA (Sigma Chemical CO), 1:1.600, 1 hour at room  
 temperature to detect myofibroblasts 
B)  Anti CD-68 (Serotec, DPC, Breda, the Netherlands), 1:100,  
 overnight at 4°C to detect macrophages 
C)  Anti heat-shock protein (HSP)-47 (Stressgen, Ann Arbor, MI,  
 USA), 1:24.000, overnight at 4°C to detect activated fibroblasts. 
D)  Anti collagen type IV (The Developmental Studies Hybridoma  
 Bank / University of Iowa, Iowa City, IA, USA), 1:300, overnight  
 at 4°C to detect blood vessels. 
The primary antibodies were omitted for negative controls, which were 
always blank. Next goat-anti-mouse-AlexaFluor-594 (1:200, one hour at 
room temperature) (Invitrogen/Molecular Probes, Eugene, OR, USA) was 
added. Finally, the sections were washed and the nuclei were stained with 
DAPI (Roche Diagnostics Nederland BV, Almere, The Netherlands). A 
1,4-Diazabicyclo[2.2.2]octane solution (DABCO, Sigma Chemical CO) 
solution in TRIS buffered glycerin was used as anti-fading agent. Slides 
were stored in the dark at 4°C. Photographs were taken on a Carl Zeiss 
Imager Z.1 system (Carl Zeiss Microimaging Gmbh, Jena, Germany). 
GFP photos were acquired under bright field conditions. The other 
stainings were photographed with fluorescent settings. The GFP images 
were inverted and merged with the fluorescent images to reveal co-
localization using ImageJ (National Institutes of Health, Bethesda, 
Maryland, USA). 
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4.2.6 Cell counting and statistics 
The fraction of GFP-positive mononuclear cells was determined by the 
FACScan in wild-type blood, GFP-transgenic blood, and recipient blood. 
In three sections of each tissue sample, αSMA-positive cells and nuclei 
were counted in the wound and control area within a frame with a width 
of 50 µm and a depth of 300 µm. GFP-positive and GFP/αSMA double-
positive cells were counted in a larger area of 200 µm wide. The 
epithelium was excluded from counting. The results were considered 
statistically significant when a paired one-tailed Student t-test returned a 
p value of less than 0.05.  
To estimate the fraction of the other bone marrow-derived cell types, 
three rats with a high number of GFP-positive cells in the wound area 
were selected. Three tissue sections were used to determine the number 
of double-positive cells. To estimate the number of GFP-positive 
endothelial cells, only the cells in the inner layer of the blood vessel 
walls were counted. No statistics was applied to these results.  
 
 
4.3 Results 
 
Nearly all mononuclear cells in the blood of the GFP-donors and the 
recipients were GFP-positive (89.0 ± 8.9% and 89.2 ± 4.5%, 
respectively), indicating a successful bone marrow transplantation (Fig. 
2a). The fraction of GFP-positive adherent cells from the cultured 
recipient bone marrow was 49 ± 6.6% (Fig. 2b). 
All wounds were closed at two weeks post-wounding. General 
histology of the samples is shown in figure 3A. The tissue consists of a 
multilayered keratinized epithelium overlying the lamina propria. The 
wound area shows a much higher cell density than the adjacent control 
tissue. The presence of a ruga further marks the control area.  
Figure 3B shows the immunohistochemical stainings for each 
marker. In the wound area of the samples, much more GFP-positive cells 
were present than in the control area (first panel). Abundant αSMA-
positive were present in the wound area (second panel), but only few of 
them were GFP-positive. The adjacent control tissue only showed αSMA-
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positive cells in the blood vessels. Relatively more GFP-positive cells 
were also CD68-positive in the wound area compared to the control (third 
panel). Only few double-positive cells were found with the HSP-47 and 
collagen IV staining (fourth and fifth panel).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. A: Flow cytometry of blood mononuclear cells five weeks after BMT. 
Recipients and transgenic donors respectively. 89% of the mononuclear blood cells of the 
recipients and donors was GFP-positive. B: Flow cytometry graph of a representative 
bone marrow culture from a recipient rat. On average 49 ± 6.6% of the cultured cells 
were GFP-postive (n = 4). M1 represents the GFP-positive cells, M2 the GFP-negative 
cells, and M3 the cell culture debris. 
 
The percentage of GFP-positive cells (Fig. 4A) was significantly 
higher in the wound area (8.1 ± 5.1%) than in the control area (0.7 ± 
0.8%, p = 0.0025) and the initial biopsy (1.0 ± 0.4%). In the wound area 
46 ± 24% of all cells were myofibroblasts, but only 4.6 ± 3.0% of them 
were GFP-positive (Fig. 4B). In the control area, nearly no 
myofibroblasts were detected (0.3 ± 0.8%) and none of them were GFP-
positive. The fraction of GFP-positive myofibroblasts was significantly 
higher in the wound area (p = 0.007). 
Figure 4C shows the percentages of the other cell types. In the 
wound area, 14 ± 5.6% of all cells were CD68-positive and 21 ± 8.2% of 
these were GFP-positive. The control area contained 7.5 ± 5.7% CD68-
positive cells, of which 9.1 ± 6.9% were GFP-positive.  
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Figure 3. Histology and immunohistochemistry of palatal wounds. A: H&E staining. 
The wound area shows a higher cell density than the control area. B: Staining with DAPI 
(blue, nuclei), and antibodies against GFP (green), and cell type markers (red). The first 
merged picture shows the GFP distribution in the wound and control area. The next 
merged pictures show GFP co-localization with: αSMA, CD-68, HSP-47, and with GFP-
positive cells at the inner side of blood vessels stained by collagen type IV. The latter cells 
were considered as endothelial cells. Arrows indicate the GFP-positive cells with the co-
localized cell type marker in the wound area. The yellow arrows in the control area 
indicate double-positive cells. 
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In the wound area, 57 ± 13% of all cells were HSP47-positive cells, and 
7.3 ± 3.8% of them were also GFP-positive. In the control area, 35 ± 12% 
of all cells were HSP47-positive, and 1.9 ± 2.0% of them were also GFP-
positive. Only 2 ± 2% of the endothelial cells in the wound area were 
GFP-positive. In the control area, no GFP-positive endothelial cells were 
detected. Finally, very few GFP-positive cells were detected in the 
epithelium of both control and wound areas (Fig. 3B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The fractions of stained cells in the tissue obtained from experimental  
wounding, control tissue and the wounds A: GFP-positive cells. B: Myofibroblasts (left) 
and GFP-positive myofibroblasts (right). C: GFP-positive macrophages (CD-68), 
activated fibroblasts (HSP-47), and endothelial-like cells (Coll IV). The asterisk indicates 
a statistically significant difference (p<0.05). 
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4.4 Discussion 
 
The aim of our study was to investigate whether circulating BMDCs 
contribute to palatal wound healing. The bone marrow transplantation 
was very efficient as about 90% of the mononuclear cells in the blood 
were GFP-positive, which was similar to the percentage in the donor 
animals. In the remaining cells the transgene is apparently silenced .
23
 In 
contrast, only about 50% of the cultured adherent cells from the bone 
marrow was GFP-positive, which shows that the engraftment of 
mesenchymal precursors was less efficient. This is also a common 
observation in human bone marrow transplantation.
24,25
 
We showed that a small percentage (8.1%) of all cells in the wounds 
was bone marrow-derived. Studies in wounded skin show that  up to 37% 
of the cells originates from the bone marrow.
26,27
 Both studies in skin 
used larger wound sizes, and it has been suggested that this could be an 
important factor for the recruitment of BMDCs.
28,29
 In patients with large 
burn wounds the number of circulating BMDCs is up-regulated and 
correlates with wound size.
30,31
 The number of bone marrow-derived cells 
recruited to burn wounds also increases with wound size.
27
 This suggests 
that the limited wound size in our model restricts the contribution of 
BMDCs to palatal wounds. In small wounds, the available local stem 
cells might be sufficient to replenish the wound. As mesenchymal 
precursors are engrafted less efficiently, the actual contribution of 
precursors from this population might be higher in this type of studies.  
We also found a small percentage (4.6 %) of bone marrow-derived 
myofibroblasts in the wound tissue. This population largely overlaps with 
the HSP47-positive population, which contains both activated fibroblasts 
and myofibroblasts.
32
 In other wounded or chemically damaged tissues, 
the number of bone marrow-derived myofibroblasts is generally higher 
(4-67 %).
15,17,28
 (Myo)fibroblasts originate from mesenchymal precursors 
but they can also differentiate from circulating fibrocytes, which have 
both mesenchymal and hematopoietic properties.
14,15
 In burn wounds, a 
positive correlation was also found between wound size and the number 
of circulating fibrocytes,
30
 and their subsequent recruitment to the 
wound.
33
 In small and relatively quickly healing palatal wounds,
34
 only a 
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low fraction of bone marrow-derived myofibroblasts might therefore be 
found.  
By contrast, a higher fraction of macrophages and other myeloid 
cells was derived from the bone marrow. Macrophages differentiate from 
circulating monocytes.
35
 A high percentage of the blood mononuclear 
cells in the recipient rats was derived from donor bone marrow. In 
addition, macrophage recruitment may be promoted by other BMDCs in 
the wound.
36
 However, the majority of myeloid cells in our study was not 
donor-derived and thus originates from local tissue precursors. 
Only few epithelial cells were bone marrow-derived, both in the 
wound area and the adjacent tissue. In studies on skin, the percentage of 
bone marrow-derived epithelial cells ranges from 0.0001% to 11%.
28,37,38
 
However, these studies do not show a positive correlation between wound 
size and the number of bone marrow-derived epithelial cells. These and 
our data therefore strongly suggest that the palatal wounds re-
epithelialize mainly from the surrounding local stem cells.  
In conclusion, only a small fraction of the myofibroblast population 
in palatal wound healing is derived from circulating BMDCs. The 
recruitment of BMDCs is probably limited by the small wound size. The 
vast majority of wound myofibroblasts in this model may be derived from 
local fibroblasts invading from the adjacent tissue. 
 
 
4.5 Acknowledgements 
 
The monoclonal Collagen type IV antibody developed by Dr. H. 
Furthmayr was obtained from the Developmental Studies Hybridoma 
Bank developed under the auspices of the NICHD and maintained by The 
University of Iowa, Department of Biology, Iowa City, IA 52242. This 
study was funded by the Radboud University Nijmegen Medical Centre. 
 
 
 
 
 
Bone marrow-derived cells in palatal wound healing 
 107 
4.6 References 
 
1. Singer AJ and Clark RAF (1999). Cutaneous Wound Healing. N Engl J Med 
341:738-46. 
2. Gabbiani G (2003). The myofibroblast in wound healing and fibrocontractive 
diseases. J Pathol 200:500-3. 
3. Powell DW, Mifflin RC, Valentich JD, Crowe SE, Saada JI and West AB 
(1999). Myofibroblasts. I. Paracrine cells important in health and disease. Am J 
Physiol Cell Physiol 277:C1-19. 
4. van Beurden HE, Von den Hoff JW, Torensma R, Maltha JC and Kuijpers-
Jagtman AM (2005). Myofibroblasts in palatal wound healing: prospects for the 
reduction of wound contraction after cleft palate repair. J Dent Res 84:871-80. 
5. Desmoulière A, Badid C, Bochaton-Piallat ML and Gabbiani G (1997). 
Apoptosis during wound healing, fibrocontractive diseases and vascular wall 
injury. Int J Biochem Cell Biol 29:19-30. 
6. Berkowitz S (1977). Cleft lip and palate research: an updated state of the art. 
Section III. Orofacial growth and dentistry. Cleft Palate J 14:288-301. 
7. Ross RB (1987). Treatment variables affecting facial growth in complete 
unilateral cleft lip and palate. Cleft Palate J 24: 5-77. 
8. Ghazizadeh S and Taichman LB (2001). Multiple classes of stem cells in 
cutaneous epithelium: a lineage analysis of adult mouse skin. EMBO J  
20:1215-22. 
9. Li A, Pouliot N, Redvers R and Kaur P (2004). Extensive tissue-regenerative 
capacity of neonatal human keratinocyte stem cells and their progeny. J Clin 
Invest 113: 390-400. 
10. Wang Y, Johnsen HE, Mortensen S, Bindslev L, Sejersten Ripa R, Haack-
Sorensen M, Jorgensen E, Fang W and Kastrup J (2006). Changes in circulating 
mesenchymal stem cells, stem cell homing factor, and vascular growth factors 
in patients with acute ST elevation myocardial infarction treated with primary 
percutaneous coronary intervention. Heart 92:768-74. 
11. Wu Y, Wang J, Scott PG and Tredget EE (2007). Bone marrow-derived stem 
cells in wound healing: a review. Wound Repair Regen 15: S18-S26. 
12. Abe R, Donnelly SC, Peng T, Bucala R and Metz CN (2001). Peripheral blood 
fibrocytes: differentiation pathway and migration to wound sites. J Immunol. 
166:7556-62. 
13. Bucala R (2007). Fibrocytes: New Insights into Tissue Repair and Systemic 
Fibroses. World Scientific Publishing Co Ltd, pp. 1-18. 
Chapter 4 
 108 
14. Bucala R, Spiegel LA, Chesney J, Hogan M and Cerami A (1994). Circulating 
fibrocytes define a new leukocyte subpopulation that mediates tissue repair. 
Mol Med 1:71-81. 
15. Mori L, Bellini A, Stacey MA, Schmidt M and Mattoli S (2005). Fibrocytes 
contribute to the myofibroblast population in wounded skin and originate from 
the bone marrow. Exp Cell Res 304:81-90. 
16. Badiavas EV, Abedi M, Butmarc J, Falanga V and Quesenberry P (2003). 
Participation of bone marrow derived cells in cutaneous wound healing. J Cell 
Physiol 196:245-50. 
17. Direkze NC, Forbes SJ, Brittan M, Hunt T, Jeffery R, Preston SL, Poulsom R, 
Hodivala-Dilke K, Alison MR and Wright NA (2003). Multiple organ 
engraftment by bone-marrow-derived myofibroblasts and fibroblasts in bone-
marrow-transplanted mice. Stem Cells 21:514-20. 
18. Dreyfus PA, Chretien F, Chazaud B, Kirova Y, Caramelle P, Garcia L, Butler-
Browne G and Gherardi RK (2004). Adult bone marrow-derived stem cells in 
muscle connective tissue and satellite cell niches. Am J Pathol 164:773-9. 
19. Krause DS, Theise ND, Collector MI, Henegariu O, Hwang S, Gardner R, 
Neutzel S and Sharkis SJ (2001). Multi-organ, multi-lineage engraftment by a 
single bone marrow-derived stem cell. Cell 105:369-77. 
20. Taylor HS (2004). Endometrial cells derived from donor stem cells in bone 
marrow transplant recipients. JAMA 292:81-5. 
21. Maria OM, Khosravi R, Mezey E and Tran SD (2007). Cells from bone marrow 
that evolve into oral tissues and their clinical applications. Oral Dis 13:11-6. 
22. Stephens P and Genever P (2007). Non-epithelial oral mucosal progenitor cell 
populations. Oral Dis 13:1-10. 
23. Torensma R and Figdor CG (2004). Differentiating stem cells mask their 
origins. Stem Cells 22: 250-2. 
24. Bartsch K, Al-Ali H, Reinhardt A, Franke C, Hudecek M, Kamprad M, 
Tschiedel S, Cross M, Niederwieser D and Gentilini C (2009). Mesenchymal 
stem cells remain host-derived independent of the source of the stem-cell graft 
and conditioning regimen used. Transplantation 87:217-21. 
25. Rieger K, Marinets O, Fietz T, Korper S, Sommer D, Mucke C, Reufi B, Blau 
WI, Thiel E and Knauf WU (2005). Mesenchymal stem cells remain of host 
origin even a long time after allogeneic peripheral blood stem cell or bone 
marrow transplantation. Exp Hematol 33:605-11. 
Bone marrow-derived cells in palatal wound healing 
 109 
26. Fathke C, Wilson L, Hutter J, Kapoor V, Smith A, Hocking A and Isik F 
(2004). Contribution of bone marrow-derived cells to skin: collagen deposition 
and wound repair. Stem Cells 22:812-22. 
27. Rea S, Giles NL, Webb S, Adcroft KF, Evill LM, Strickland DH, Wood FM 
and Fear MW (2009). Bone marrow-derived cells in the healing burn wound--
More than just inflammation. Burns 35:356-64. 
28. Brittan M, Braun KM, Reynolds LE, Conti FJ, Reynolds AR, Poulsom R, 
Alison MR, Wright NA and Hodivala-Dilke KM (2005). Bone marrow cells 
engraft within the epidermis and proliferate in vivo with no evidence of cell 
fusion. J Pathol. 205:1-13. 
29. Verstappen J, Katsaros C, Torensma R and Von den Hoff JW (2009). A 
functional model for adult stem cells in epithelial tissues. Wound Repair Regen 
17:296-305. 
30. Mansilla E, Marín GH, Drago H, Sturla F, Salas E, Gardiner C, Bossi S, 
Lamonega R, Guzmán A, Nuñez A, Gil MA, Piccinelli G, Ibar R and Soratti C 
(2006). Bloodstream Cells Phenotypically Identical to Human Mesenchymal 
Bone Marrow Stem Cells Circulate in Large Amounts Under the Influence of 
Acute Large Skin Damage: New Evidence for Their Use in Regenerative 
Medicine. Transplant Proc 38:967-9. 
31. Yang L, Scott PG, Giuffre J, Shankowsky HA, Ghahary A and Tredget EE 
(2002). Peripheral blood fibrocytes from burn patients: identification and 
quantification of fibrocytes in adherent cells cultured from peripheral blood 
mononuclear cells. Lab Invest 82:1183-92. 
32. Kuroda K and Tajima S (2004). HSP47 is a useful marker for skin fibroblasts in 
formalin-fixed, paraffin-embedded tissue specimens. J Cutan Pathol 31:241-6. 
33. Yang L, Scott PG, Dodd C, Medina A, Jiao H, Shankowsky HA, Ghahary A 
and Tredget EE (2005). Identification of fibrocytes in postburn hypertrophic 
scar. Wound Repair Regen 13: 398-404. 
34. Von den Hoff J, Maltha J and Kuijpers-Jagtman A (2006). Palatal wound 
healing: the effects of scarring on growth. In: Berkowitz S, ed. Cleft Lip and 
Palate. Diagnosis and Management. 2nd Edition. Springer-Verlag: Berlin 
Heidelberg, pp. 301-13. 
35. Dipietro LA, Reintjes MG, Low QEH, Levi B and Gamelli RL (2001). 
Modulation of macrophage recruitment into wounds by monocyte 
chemoattractant protein-1. Wound Repair Regen 9:28-33. 
Chapter 4 
 110 
36. Chen L, Tredget EE, Wu PYG and Wu Y (2008). Paracrine Factors of 
Mesenchymal Stem Cells Recruit Macrophages and Endothelial Lineage Cells 
and Enhance Wound Healing. PLoS ONE 3: e1886. 
37. Borue X, Lee S, Grove J, Herzog EL, Harris R, Diflo T, Glusac E, Hyman K, 
Theise ND and Krause DS (2004). Bone marrow-derived cells contribute to 
epithelial engraftment during wound healing. Am.J Pathol. 165:1767-72. 
38. Fan Q, Yee CL, Ohyama M, Tock C, Zhang G, Darling TN and Vogel JC 
(2006). Bone marrow-derived keratinocytes are not detected in normal skin and 
only rarely detected in wounded skin in two different murine models. 
Experimental hematology 34:672-9. 
 Chapter 5 
 
 
 
 
 
 
Preferential recruitment of bone marrow-
derived cells to rat palatal wounds but not 
to skin wounds 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
J Verstappen 
REM van Rheden 
C Katsaros 
R Torensma 
JW Von den Hoff 
 
 
Archives of Oral Biology 2012;57:102-8 
  
  
Preferential recruitment of bone marrow-derived cells  
 113 
Abstract 
 
Objective. To investigate the contribution of bone marrow-derived cells 
to oral mucosa wounds and skin wounds. 
Background. Bone marrow-derived cells are known to contribute to 
wound healing, and are able to differentiate in many different tissue-
specific cell types. As wound healing in oral mucosa generally proceeds 
faster and with less scarring than in skin, we compared the bone marrow 
contribution in these two tissues.  
Design. Bone marrow cells from GFP-transgenic rats were 
transplanted to irradiated wild-type rats. After recovery, 4-mm wounds 
were made in the mucoperiosteum or the skin. Two weeks later, wound 
tissue with adjacent normal tissue was stained for GFP-positive cells, 
myofibroblasts (α-smooth muscle actin), activated fibroblasts (HSP47), 
and myeloid cells (CD68). 
Results. The fraction of GFP-positive cells in unwounded skin (19%) 
was larger than in unwounded mucoperiosteum (0.7%). Upon wounding, 
the fraction of GFP-positive cells in mucoperiosteum increased (8.1%), 
while it was unchanged in skin. About 7% of the myofibroblasts in both 
wounds were GFP-positive, 10% of the activated fibroblasts, and 25% of 
the myeloid cells.  
Conclusions. The results indicate that bone marrow-derived cells are 
preferentially recruited to wounded oral mucosa but not to wounded skin. 
This might be related to the larger healing potential of oral mucosa.  
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5.1 Introduction 
 
Wound healing consists of three partly overlapping phases of 
inflammation, tissue formation, and tissue remodeling.
1
 During 
inflammation, the wound is cleared from debris and bacteria by 
neutrophils and macrophages. In addition, myeloid cells are recruited to 
the wounded tissue, of which the monocytes differentiate into 
macrophages.
1,2
 Next, neo- epithelialization and the formation of 
granulation tissue take place in the tissue formation phase. Cells from the 
surrounding tissue including local stem cells are activated and invade the 
wound bed.
1,3,4
 Upon tissue damage, circulating bone marrow-derived 
cells (BMDCs) are also recruited to the wound and can differentiate into 
tissue-specific cells.
5,6
 Finally, in the remodeling phase, part of the 
fibroblasts differentiate into myofibroblasts, which can also originate 
from BMDCs.
5,7
 Myofibroblasts possess contractile properties and are 
mainly responsible for wound contraction. Those cells also deposit large 
amounts of collagen and then go into apoptosis, ultimately leaving behind 
an acellular scar.
8,9
  
The contribution of BMDCs to the myofibroblast population in 
wounds depends on the type of tissue.
7
 For skin wounds large differences 
in the involvement of BMDC’s were reported,5,7 which may be explained 
by wound size,
10,11
 but also by the availability of local stem cells. A valid 
explanation is that BMDCs are only recruited when the local stem cell 
populations are unable to resolve the tissue damage.
10,11
 Hence, BMDCs 
are sometimes referred to as “rescue stem cells”.10 
The skin and the palatal mucoperiosteum are two homologous 
tissues, which both possess a keratinized epithelium in rats.
12,13
 It is 
generally known that wounds in the oral mucosa heal faster than skin 
wounds, which might be related to the growth factors in saliva.
14-16
 
Additionally, phenotypic differences between oral and cutaneous 
fibroblasts may be involved.
17
 The stem cell niches of skin epithelium are 
located in the basal layer and in the bulge region of the hair follicle.
10,18
 
The basal layer stem cells contribute to renewal of the epidermis in 
physiological turnover and injury. The stem cells from the bulge region 
are activated upon wounding, and can contribute to epidermal renewal 
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but also to the hair bulb and the sebaceous glands.
3,19
 So far, little data 
are available on stem cells niches in the oral mucosa. Isolated small cells 
from human mucosa keratinocyte cultures are considered as oral 
keratinocyte progenitors or stem cells.
20
 These cells are able to generate a 
stratified epithelium on a suitable substrate.
20
 A large number of (neural) 
stem cell niches have been described in superficial neural endings in the 
palatal mucoperiosteum of rats and humans.
21
 Multipotent stem cells 
have recently been  identified in the human and rat lamina propria of the 
oral mucosa. These cells can differentiate into mesodermal, endodermal 
and ectodermal lineages in vitro.
22-24
 Strikingly, these stem cells can also 
differentiate into tumors consisting of two germ layer-derived cell types 
(muscle, cartilage, and neural tissue) in mice.
22
  
Little is known about the recruitment of BMDCs to oral mucosa. 
There are indications that BMDCs contribute to normal tissue turnover, 
and are able to differentiate into buccal keratinocytes.
25
 No studies are 
available on the contribution of BMDCs to the wounded 
mucoperiosteum.  
Since the wounded oral mucosa heals more rapidly than skin, we 
hypothesized that BMDCs are more efficiently recruited to 
mucoperiosteal wounds than to skin wounds. To test this hypothesis, 
bone marrow was labeled by performing a bone marrow transplantation 
(BMT) from green fluorescent protein (GFP) transgenic rats to irradiated 
wild-type animals. Subsequently, we compared the contribution of 
BMDCs to standardized full-thickness wounds in the rat mucoperiosteum 
and skin at two weeks after wounding. This time point was chosen 
because of the relevance for remodeling and scarring.  
 
 
5.2 Materials & methods 
 
5.2.1 Animals 
Fifteen GFP-transgenic Sprague-Dawley rats of six to twelve weeks old 
(provided by Dr M. Okabe and Dr. T. Suzuki, Japan SLC, Inc., Shizuoka, 
Japan) were obtained, of which eight were used as donors for the bone 
marrow transplantation (BMT). Fifteen wild-type Sprague-Dawley rats 
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(Janvier, Le Genest, France) were used as recipients. The latter rats were 
six to eight weeks old at the start of the experiment and kept under sterile 
housing conditions with free access to food and water. The Board for 
Animal Experiments of the Radboud University Nijmegen Medical 
Centre has approved these experiments (RU-DEC 2005-104 and RU-DEC 
2008-051). The palatal wounds (10 rats) and the skin wounds (5 rats) 
were made in different animals to avoid mutual interferences.  
 
5.2.2 Bone marrow transplantation 
The recipient rats received two doses of 5 Gy total body irradiation from 
an X-ray source, with an interval of 18 hours. Bone marrow from the 
femurs of the transgenic donor rats was harvested by flushing with 
phosphate-buffered saline (PBS) (Invitrogen/GIBCO, San Diego, CA, 
USA), supplemented with 2% penicillin/streptomycin 
(Invitrogen/GIBCO). Mononuclear cells were isolated by density 
centrifugation over Lymphoprep (p = 1.077 g/ml) (Axis-Shield POC AS, 
Oslo, Norway), and washed twice with 0.9% NaCl. Three hours after the 
second irradiation, 2.3-3.0•108 mononuclear cells per kg (0.4 ml) were 
injected in the tail vein of the recipients rats. The weight of the rats was 
monitored every other day. Three weeks after the BMT, one rat from the 
skin wounding group was killed based because of ongoing weight loss, 
possibly due to a sub-clinical infection. In the other rats only a temporary 
small weight reduction was observed. Five weeks after the BMT, blood 
was drawn and mononuclear cells were analyzed for GFP expression by 
flow cytometry on a FACScan (Becton and Dickinson, Franklin Lake, NJ, 
USA). Blood from 15 GFP-transgenic rats was analyzed for comparison. 
The blood from seven wild-type rats was used as a negative control to 
check the settings of the FACScan. 
 
5.2.3 Experimental wounding 
Seven weeks after the BMT, four-mm wounds were made in the palatal 
mucoperiosteum of 10 rats between the third molars under anesthesia by 
a mix of fentanyl and fluanisone (Hypnorm, Vetaphrama Ltd, Leeds, UK) 
and midazolam (Dornicum, Deltaselect, Dreiech, Germany). In four rats,  
the skin on the back was shaved and disinfected (Hibiscrub
®
, Regent 
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Medical Ltd., Manchester). Next, four-mm full thickness skin wounds 
were made under isoflurane (Pharmachemie BV, Haarlem, The 
Netherlands) anesthesia. These wounds were covered by a semipermeable 
polyurethane dressing (Tegaderm, 3M, Neuss, Germany) to create a moist 
wound environment. Subsequently, one layer of dry sterile fine-mesh 
gauze (Medicomp, Hartmann-Rico a.s., Masarykovo nám. 77, Czech 
Republic) was applied, and the rats were wrapped in elastic tape (Petflex, 
Andover, USA Salisbury, MA) to fix the bandages. About every two 
days, the elastic tape was replaced under isoflurane anesthesia. The 
polyurethane dressing was never removed during the experiment. 
Buprenorfinehydrochloride (Temgesic
®
, Schering-Plough, Brussels, 
Belgium) was used post-operatively as an analgesic. Two weeks after 
wounding, the rats were killed by CO2/O2 inhalation, and wounds with 
adjacent control tissue were harvested.  
 
5.2.4 Histology and immunohistochemistry 
The tissue samples were fixed in 4% paraformaldehyde for 24 hours and 
embedded in paraffin. Five-µm sections were used for histology and 
immunohistochemistry. For general tissue survey, sections were stained 
with hematoxylin and eosin (H&E). For immunohistochemical staining, 
three sections (125 µm apart) of each tissue sample were mounted on 
Superfrost Plus slides (Menzel-Gläser, Braunschweig, Germany). The 
sections were deparaffinated and rehydrated. Next, they were post-fixed 
with 4% formalin and washed with PBS supplemented with 0.75 µg/ml 
glycine (PBS-G). Antigens were retrieved with citrate buffer (0.01 M, pH 
6.01) at 70 °C for 10 minutes, followed by incubation in 0.075 g/ml 
trypsin (Difco Laboratories, Detroit, USA) in PBS at 37 °C for 5 minutes. 
Then, the sections were pre-incubated with 10% normal donkey serum 
(NDS) (Chemicon, Temecula, USA) in PBS-G. 
All antibodies and the Vectastain ABC Standard alkaline 
phosphatase mix (ABC-AP) (Vector Laboratories, Burlingame, CA, 
USA) were diluted in 2% NDS. To detect GFP, the sections were 
incubated overnight at 4 °C with a polyclonal rabbit-anti-GFP antibody 
(1:300) (Invitrogen/Molecular Probes, Eugene, OR, USA). Subsequently, 
biotinylated donkey-anti-rabbit (1:500) (Jackson Labs, West Grove, PA, 
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USA) was added. Next, the sections were treated with ABC-AP, and 
washed with TRIS-HCl (pH 8.2). Fast Blue substrate (Sigma Chemical 
CO, St Louis, MO, USA) was freshly prepared, and applied to the 
sections. The reaction was stopped in demineralized water (Milli-Q pore 
system, Millipore SA, Molsheim, France), and the sections were washed 
in PBS and pre-incubated again for double-staining with the following 
primary mouse monoclonal antibodies: 
A)  Anti αSMA (Sigma Chemical CO), 1:1.600, 1 hour at room  
 temperature to detect myofibroblasts. 
B)  Anti heat-shock protein (HSP)47 (Stressgen, Ann Arbor, MI, USA),  
  1:24.000, overnight at 4 °C to detect activated fibroblasts. HSP47 is  
 a chaperone protein in collagen synthesis. 
C)  Anti CD-68 (Serotec, DPC, Breda, the Netherlands), 1:100,  
 overnight at 4 °C to detect macrophages. 
Next goat-anti-mouse-AlexaFluor-594 (1:200, one hour at room 
temperature) (Invitrogen/Molecular) was added. Finally, the sections 
were washed, and the nuclei were stained with DAPI (Roche Diagnostics 
Nederland BV, Almere, The Netherlands). A 1,4-
Diazabicyclo[2.2.2]octane solution (DABCO, Sigma Chemical CO) 
solution in TRIS-buffered glycerin was used as anti-fading agent. Slides 
were stored in the dark at 4 °C. Photographs were taken on a Carl Zeiss 
Imager Z.1 system (Carl Zeiss Microimaging Gmbh, Jena, Germany). 
GFP photos were acquired under bright field conditions. The other 
sections were photographed with fluorescent settings. The GFP images 
were inverted and merged with the fluorescent images to reveal co-
localization using ImageJ (National Institutes of Health, Bethesda, 
Maryland, USA). 
 
5.2.5 Cell counting 
The fraction of GFP-positive mononuclear cells was determined in the 
blood of GFP-transgenic rats and recipient rats by flow cytometry. In 
three sections of each mucoperiosteal tissue sample, αSMA-positive cells 
and nuclei were counted in the wound and control area within a frame 
with a width of 50 μm and a depth of 300 μm. GFP-positive and 
GFP/αSMA double-positive cells were counted in a larger area of 200 μm 
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wide because they are less abundant. The epithelium was excluded. The 
fraction of the other bone marrow-derived cell types in the 
mucoperiosteum was estimated in three rats with a high fraction of GFP-
positive cells in the wound tissues. Three tissue sections were used to 
determine the number of double-positive cells as described above. 
In the tissue sections from the skin similar countings were performed 
but the selected areas had a depth of 500 µm and a width of 300-600 µm. 
Epithelial cells, cells in blood vessels, muscle cells, and hair follicle cells 
were excluded.  
 
5.2.6 Statistics 
Values are presented as the mean ± standard deviation. The flow 
cytometry data were subjected to a Mann-Whitney rank sum test 
(SigmaStat, version 3.10, Systat Software, Inc., Chicago, IL). The data 
were considered statistically different if p<0.05. The data for GFP and 
αSMA were tested with a paired two-tailed Student t-test, and a normal 
Student t-test for differences between the wound tissue in skin and in 
mucoperiosteum. The data from the adjacent tissue in skin and 
mucoperiosteum were tested similarly. If the data were not normally 
distributed, a Wilcoxon signed rank test was performed for paired data, 
and a Mann-Whitney rank sum test for independent data. The HSP47 and 
CD68 data were only tested for differences between the wound tissue and 
the adjacent tissue in skin. The data were considered statistically 
significant when p<0.025.  
 
  
5.3 Results 
 
The fraction of GFP-positive mononuclear cells in the blood of the donor 
rats and the transplanted rats was not significantly different (86 ± 2% and 
69 ± 9% respectively, figure 1). This indicates a good take of the bone 
marrow graft. The histology of the mucoperiosteum and skin is shown in 
figure 2A. Both tissues have a keratinized epithelium overlaying the 
lamina propria (mucoperiosteum) and dermis (skin). The mucoperiosteal 
epithelium contains more cell layers than the epidermis. Skin dermis also 
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contains hair follicles with the arector pili muscles and sebaceous glands. 
Underneath the dermis lies the hypodermis with fat cells. Both types of 
wounds have a high cell density. In the skin wounds, no regenerated hair 
follicles are present, and the hypodermis is lost.  
Further, figure 2 shows representative examples of the 
immunostainings. In the wounded mucoperiosteum, more GFP-positive 
cells are present than in the adjacent tissue (Figure 2B). In skin, the 
numbers in wounded and adjacent tissue are similar. Few GFP-positive 
cells were detected in the epithelia or in the hair follicles of the 
unwounded skin. In the mucoperiosteal wounds, high numbers of 
myofibroblasts were present, whereas far less were present in the skin 
wounds (Figure 2C). Only few of these were also GFP-positive. No 
myofibroblasts were detected in the adjacent tissues of the 
mucoperiosteum and the skin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. GFP-positive cells in the blood. The fraction of GFP-positive cells in the 
blood of the donor rats and the transplanted rats was determined by flow cytometry. The 
two fractions were not significantly different (p=0.121). Data are shown as mean ± sd. 
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Figure 2. Histology and immunohistochemistry. A) General histology (hematoxylin 
and eosin) of the wounds and the adjacent tissues of the mucoperiosteum and skin. (B-E) 
Immunohistochemistry. GFP-staining is shown in green and nuclei in blue. (B) Single 
staining for GFP. (C) Double staining for GFP and α SMA (red). (D) Double staining for 
GFP and HSP47 (red). (E) Double staining for GFP and CD68 (red). GFP-positive cells 
are marked with single-headed arrows (B) and double-positive cells are marked with 
double-headed arrows (C-E). 
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Activated fibroblasts (HSP47-positive cells) were present in the wounds 
and adjacent tissues of both the mucoperiosteum and the skin (Figure 
2D). Activated fibroblasts were brightly stained in the wounds, while 
they were stained less intensely in the adjacent tissues. Only few of the 
activated fibroblasts were also GFP-positive. The number of 
macrophages was similar in the wounds and the adjacent tissues of the 
mucoperiosteum and the skin (Figure 2E). A relatively large number of 
these cells were also GFP-positive. 
Figure 3 shows the quantitative data of the immunostainings. The 
total fraction of GFP-positive cells (Figure 3A) in the mucoperiosteal 
wounds (8.1 ± 5.1%) was significantly larger than in the adjacent tissue 
(0.7 ± 0.8%, p=0.025). The GFP-positive fraction in the skin wounds and 
the adjacent tissue was similar (18.7 ± 15.0 and 17.4 ± 8.0% 
respectively). The GFP+ fraction in the adjacent tissue of the skin was 
significantly larger than in the adjacent tissue of the mucoperiosteum 
(p=0.004).  
The fraction of myofibroblasts (Figure 3B) in the mucoperiosteal 
wounds (46.4 ± 23.8%) was larger than in the adjacent tissue (0.69 ± 
0.53%; p=0.002) but also larger than in the skin wounds (7.3 ± 7.1%; 
p=0.012). In contrast, the fraction of myofibroblasts in skin wounds and 
adjacent tissue was similar.  The fraction of GFP-positive myofibroblasts 
(3C) in the mucoperiosteal wounds (4.6 ± 3.0%) was larger than in the 
adjacent tissue (0 ± 0%; p=0.023), which was not the case in skin wounds 
and adjacent tissue. 
The fraction of activated fibroblasts (Figure 3D) in the skin wounds 
(78.5 ± 4.7%) was slightly larger than in the adjacent tissue (64.6 ±7.4%, 
p=0,010). The slight difference in the mucoperiosteum was not 
significant. The fraction of GFP-positive activated fibroblasts tended to 
be larger in both types of wound tissues than in the adjacent tissues 
(Figure 3E).  
The fraction of macrophages (Figure 3F) was not significantly 
different in all tissues. The mucoperiosteal adjacent tissue (7.5 ± 5.7%) 
and the skin adjacent tissue (16.1 ± 6.2%) contained similar numbers of 
macrophages. No significant differences were found in the fraction of 
GFP-positive macrophages (Figure 3G).  
Preferential recruitment of bone marrow-derived cells  
 123 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Quantification of cell populations. Data are expressed as percentage 
positive cells. (A) GFP-positive fraction of all cells. (B)  αSMA-positive fraction of all 
cells. (C) GFP-positive fraction of αSMA-positive cells. (D) HSP47-positive fraction of all 
cells. (E) GFP-positive fraction of HSP47-positive cells. (F) CD68-positive fraction of all 
cells. (G) GFP-positive fraction of CD68-positive cells. Asterisks mark a significant 
difference (p<0.025). 
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5.4 Discussion 
 
We hypothesized that more BMDCs are recruited to quickly healing 
tissues such as the oral mucosa than to more slowly healing tissues such 
as the skin. This was based on earlier data obtained from regenerating 
endometrium of the human uterus where up to 48 % of the epithelial cells 
are derived from the bone marrow.
26
 However, later it was shown in some 
mouse models that the contribution was far less.
27
 This is probably due to 
differences in the process of endometrial regeneration between humans 
and rodents. Previous studies indicate that about 14% of the cells in skin 
wounds in mice are derived from the bone marrow, and that  this is 
increased by wounding.
28
 
Our data show that about 8% of the cells in mucoperiosteal wounds 
is recruited from the bone marrow, which is about 10 times higher than in 
the normal adjacent tissue. In contrast, the recruitment of BMDCs to skin 
wounds and the adjacent normal tissue is comparable, but about twofold 
larger than in mucoperiosteal wounds. Moreover, the total population of 
BMDCs in normal skin is about 25 times larger than in normal 
mucoperiosteum. Our data indicate that, in the mucoperiosteum, BMDCs 
are preferentially recruited to the wound but not in the skin. 
Alternatively, BMDCs recruitment in skin wounds might have peaked 
earlier than two weeks after wounding as reported in a mouse 
model.
28
The longterm contribution of BMDCs, however, was similar to 
our findings. In the light of tissue remodeling and scarring, this might be 
the more relevant population.  
It further appears from our data that far less BMDCs are required for 
normal tissue maintenance in the mucoperiosteum than in the skin. In the 
mucoperiosteum, the recruitment of BMDCs is increased upon wounding, 
while these cells are already present in the skin. These differences might 
be related to the larger repair capacity of oral mucosa.
16
  
Much more myofibroblasts were present in the mucoperiosteal 
wounds than in the skin wounds. This could be related to the different 
course of wound healing in both tissues. The skin of rats is very loose 
and can contract easily. Contraction will therefore not generate a high 
tension within the wound tissue, which limits myofibroblast 
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differentiation.
29
 The mucoperiosteum, however, is tightly attached to the 
palatal bone by Sharpey’s fibers.16 Therefore, contraction will generate 
higher mechanical tension, and hence more myofibroblasts appear.
30
 
However, less than 10% of the myofibroblasts in both wound types is 
derived from BMDCs. This is similar to another study performed in 
mice.
7
 Myofibroblasts can originate from circulating fibrocytes which are 
part of the hematopoietic lineage but also have mesenchymal properties.
31
 
Activated fibroblasts were also present in both types of wounds, as 
detected by staining for HSP47, a chaperone protein in collagen 
synthesis. This population of cells probably includes the myofibroblasts, 
which are also producing large amounts of collagen. This is supported by 
double-staining for αSMA and HSP47 (data not shown). Especially in 
skin, the population of activated fibroblasts is much larger than that of 
myofibroblasts, both in the wound and in normal tissue. These cells 
might be more important in the healing of these easily contracting 
wounds than the myofibroblasts. In contrast, in mucoperiosteal wounds, 
the population of activated fibroblasts was only slightly larger than that 
of myofibroblasts. 
The largest population of BMDCs is that of CD68-positive myeloid 
cells, notably macrophages. In skin wounds, this population is about 40% 
of the total bone marrow-derived population. This is to be expected since 
bone marrow ablation followed by bone marrow grafting replaces most of 
the hematopoietic stem cells. Part of the local population of macrophages 
might already have been replaced by hematopoietic precursors in the 
recovery period after bone marrow transplantation, especially in the skin.  
In conclusion, the data indicate that a much larger population of local 
BMDCs is present in the skin than in the mucoperiosteum. The skin 
population of BMDCs seems to be able to resolve tissue damage, as no 
further BMDCs are recruited upon wounding at two weeks after 
wounding. In contrast, the small population of BMDCs in the 
mucoperiosteum is replenished with cells from the bone marrow during at 
the same time point. This might partly explain the rapid wound healing 
reported in oral mucosal wounds. Other important factors seem to be the 
growth factors present in saliva and the specific properties of oral 
fibroblasts.
16
 he major population of BMDCs in our study is that of 
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macrophages, while myofibroblasts and activated fibroblasts only 
represent smaller fractions. Further studies into the time sequence of 
recruitment, and the physiology of BMDCs might elucidate the 
preferential healing of mucosal wounds as compared to skin wounds. 
This knowledge may contribute to the development of new therapies for 
difficult healing wounds. 
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Abstract 
 
Wounded skin recruits progenitor cells, which repair the tissue defect. 
These cells are derived from stem cells in several niches in the skin. In 
addition, bone marrow-derived cells are recruited and contribute to 
wound repair. We hypothesized that larger wounds recruit more cells 
from the bone marrow. Wild type rats were lethally irradiated and 
transplanted with bone marrow cells from GFP-transgenic rats. Seven 
weeks later, 4, 10, and 20-mm wounds were created. The wound tissue 
was harvested after 14 days. The density of GFP-positive cells in the 
wounds and the adjacent tissues was determined, as well as in normal 
skin from the flank. Bone marrow-derived myofibroblasts, activated 
fibroblasts, and macrophages were also quantified. After correction for 
cell density, the recruitment of bone marrow-derived cells (23±11%) was 
found to be independent of wound size. Similar fractions of GFP-positive 
cells were also detected in non-wounded adjacent tissue (29±11%), and in 
normal skin (26 ±19%). The data indicate that bone marrow-derived cells 
are not preferentially recruited to skin wounds. Furthermore, wound size 
does not seem to affect the recruitment of bone marrow-derived cells.   
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6.1 Introduction 
 
Upon wounding, three partly overlapping phases of inflammation,  tissue 
formation, and tissue remodeling occur sequentially.
1
 During 
inflammation, monocytes of the hematopoietic lineage are recruited to the 
wound, where they differentiate into macrophages to clear the wound of 
debris.
1,2
 In the tissue formation phase, fibroblasts in the newly formed 
granulation tissue differentiate into myofibroblasts, which express alpha-
smooth muscle actin (αSMA). These cells are largely responsible for 
wound contraction and scarring during remodeling.
3,4
 Normally, around 
two weeks post-wounding the largest population of myofibroblasts is 
found, which subsequently disappears by apoptosis.
5
  
Stem cells are involved in the process of wound healing by 
generating tissue-specific cell types.
6
 Firstly, local stem cells maintain 
the tissue and restore the tissue after wounding. The best known niches of 
local skin stem cells are the epidermal basal layer and the bulge region of 
the hair follicle, which both contain stem cells that contribute to normal 
turn-over and wound repair.
7
 Very recently, a new skin stem cell 
population, located just above the bulge region, was reported to 
contribute to all lineages of skin during repair of full thickness wounds in 
mice.
8
 Secondly, mesenchymal stem cells with myogenic, osteogenic, 
chondrogenic, and adipogenic potential were detected perivascularly in 
different human tissues, including the skin.
9,10
 Thirdly, circulating bone 
marrow-derived cells (BMDCs), including fibrocytes, are recruited to 
wounds.
11-14
 Fibrocytes are precursors with both hematopoietic and 
mesenchymal properties.
14,15
 In mice, up to 37% BMDCs are found in the 
restored dermis after wounding.12 Subsequently, these cells differentiate 
into tissue-specific cell types such as keratinocytes, fibroblasts, and 
myofibroblasts.
4,11,13,15-17
  
The number of fibrocytes in peripheral blood increases after large 
burn wounds.
18,19
 In addition, the fraction of recruited bone marrow-
derived myofibroblasts in burn wounds depends on wound size.
16
 Bone 
marrow-derived myofibroblasts have also been found in other full-
thickness skin wounds in fractions ranging from 0% up to 60%.
12,13,15
 
Major differences between these studies are the method of bone marrow 
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labeling, the period of wound healing, the wound size (5-15 mm
2
) and the 
number of wounds per animal, the species, and the analytical methods. 
The highest fraction of bone-marrow derived myofibroblasts (60%) was 
detected by flow cytometry in five-mm wounds in mice between four and 
seven days post-injury.
15
 In non-wounded skin, a fraction of 14% 
BMDCs was reported in mice,
12
 indicating that these cells also contribute 
to normal tissue turn-over. 
BMDCs were also detected in other wounded and non-wounded 
tissues, such as the lung and the kidney.
13
 Endometria of women that 
received a transplantation with male bone marrow contain up to 50% 
BMDCs.
20
 Based on the literature, we hypothesized that the recruitment 
of BMDCs correlates with wound size in full-thickness wounds of the 
skin. In small wounds, local progenitors might be sufficient for tissue 
repair, whereas in larger wounds additional bone marrow-derived 
progenitors are recruited. 
The aim of this study is to test whether the contribution of BMDCs 
in healing skin wounds increases with wound size. Therefore, bone 
marrow cells were isolated from transgenic green fluorescent protein 
(GFP) rats, and transplanted to lethally irradiated wild-type rats. Next, 
circular full-thickness skin wounds of 4, 10, or 20 mm were made on the 
back. Two weeks post-wounding, tissue samples of the wounds with 
adjacent skin were harvested for histological and immunohistochemical 
evaluation.   
 
 
6.2 Materials & methods 
 
6.2.1 Animals 
Seven GFP-transgenic Sprague-Dawley rats between five and twelve 
weeks old were used as donors for the bone marrow transplantation 
(BMT) (provided by Dr M. Okabe and Dr. T. Suzuki, Japan SLC, Inc., 
Shizuoka, Japan). Nineteen wild-type Sprague-Dawley rats of six weeks 
old (Janvier, Le Genest, France) were used as recipients at the start of the 
experiment and kept under sterile housing conditions with free access to 
food and water. The Board for Animal Experiments of the Radboud 
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University Nijmegen Medical Centre approved these experiments (RU-
DEC 2008-051).  
 
6.2.2 Bone marrow transplantation 
The recipient rats received two doses of 5 Gy total body irradiation with 
an interval of 18 hours.  
The femurs of the GFP-transgenic rats were used to collect GFP-
positive donor bone marrow by flushing the femurs with phosphate-
buffered saline (PBS) (Invitrogen/GIBCO, San Diego, CA, USA), 
supplemented with 2% penicillin / streptomycin (Invitrogen/GIBCO, San 
Diego, CA, USA). After washing, mononuclear cells were isolated by 
density centrifugation over Lymphoprep (p=1.077 g/ml) (Axis-Shield 
POC AS, Oslo, Norway), and washed twice in 0.9% NaCl. Subsequently, 
3x10
8
 mononuclear cells per kg rat (0.4 ml) were injected in the tail vein, 
three hours after the second irradiation. Five weeks after the BMT, blood 
was drawn and mononuclear cells were analyzed for GFP by flow 
cytometry on a FACScan (Becton and Dickinson, Franklin Lake, NJ, 
USA). Blood cells from fifteen GFP-transgenic rats and seven wild-type 
rats were analyzed for comparison. During recovery from the bone 
marrow transplantation, six rats died. 
 
6.2.3 Experimental wounding 
Seven weeks after the BMT, the back was shaved and disinfected 
(Hibiscrub
®
, Regent Medical Ltd., Manchester) before the standardized 
full thickness circular skin wounds were made under isoflurane 
(Pharmachemie BV, Haarlem, The Netherlands) anesthesia. The 13 rats 
were subdivided into three groups for four-mm (diameter) wounds (n=4), 
10-mm wounds (n=5), and 20 mm-wounds (n=4), and each rat received 
one wound. The first two wound sizes were created with surgical biopsy 
punches, the 20-mm wound was created by drawing a circle on the back, 
which was cut out. As an analgesic, buprenorfinehydrochloride 
(Temgesic
®
, Schering-Plough, Brussels, Belgium) was applied one hour 
pre-operatively and two consecutive days post-operatively. 
The wounds were covered by a semipermeable polyurethane 
dressing (Tegaderm , 3M, Neuss, Germany) to create a moist wound 
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environment. Subsequently, one layer of dry fine-mesh gauze 
(Medicomp, Hartmann-Rico a.s., Masarykovo nám. 77, Czech Republic) 
was applied, and the rats were wrapped up in elastic tape (Petflex, 
Andover, USA Salisbury, MA). On days 1, 2, 5, 7, 9, and 12 the 
wrapping and gauze were removed under isoflurane anesthesia, and 
digital images (Lumix DMC-FZ8, Panasonic, Osaka, Japan) were taken 
to monitor wound closure. On day 14, the rats were killed by CO2/O2 
inhalation, and a photograph was taken of the wounds. Subsequently, the 
wounds with their adjacent tissue were harvested, and a reference sample 
of normal skin from the flank. The tissue samples were routinely fixed in 
4% paraformaldehyde for 24 hours. To avoid epithelial tissue damage, 
the semipermeable polyurethane dressing remained in place during 
fixation. After fixation, the dressings were detached and the tissues were 
subsequently embedded in paraffin. The wound contraction was 
calculated from the images, using ImageJ (National Institutes of Health, 
Bethesda, Maryland, USA). 
 
6.2.4 Histology and immunohistochemistry 
Six-µm sections were cut and stained with hematoxylin and eosin for 
general tissue survey. Tissue was considered as adjacent to the wound 
between 0.5 and 1 cm away from the wound edge. In addition, the normal 
skin samples were processed. For immunohistochemical staining, three 
consecutive sections through the center of the wound (150 µm apart) 
were taken per sample containing both wound and adjacent tissue, and 
mounted on Superfrost Plus slides (Menzel-Gläser, Braunschweig, 
Germany). The sections were routinely deparaffinated, post-fixed with 
4% formalin and washed in 0.75 µg/ml glycine in PBS (PBS-G). 
Antigens were retrieved with citrate buffer (0.01 M, pH 6.01) at 70°C, 
followed by incubation in 0.075 g/ml trypsin (Difco Laboratories, 
Detroit, USA) in PBS at 37°C. Then, the sections were pre-incubated 
with 10% normal donkey serum (NDS) (Chemicon, Temecula, USA) in 
PBS-G. 
All antibodies and the Vectastain ABC Standard alkaline 
phosphatase mix (ABC-AP) (Vector Laboratories, Burlingame, CA, 
USA) were diluted in 2% NDS. To detect GFP, the sections were 
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incubated overnight at 4°C with a polyclonal rabbit-anti-GFP antibody 
(1:300) (Invitrogen/Molecular Probes, Eugene, OR, USA). Subsequently, 
biotinylated donkey-anti-rabbit (1:500) (Jackson Labs, West Grove, PA, 
USA) was added. Next, the sections were treated with ABC-AP, and 
washed with TRIS-HCl (pH 8.2). The Fast Blue substrate (Sigma 
Chemical CO, St Louis, MO, USA) was freshly prepared, and applied to 
the sections. The reaction was stopped in demineralized water (Milli-Q 
pore system, Millipore SA, Molsheim, France), and the sections were 
washed in PBS and pre-incubated again for double-staining with the 
following primary mouse monoclonal antibodies: 
A) Anti αSMA (Sigma Chemical CO), 1:1.600, 1 hour at room  
 temperature to detect myofibroblasts 
B) Anti heat-shock protein (HSP) 47 (Stressgen, Ann Arbor, MI,  
 USA), 1:24.000, overnight at 4°C to detect activated fibroblasts. 
C) Anti CD68 (Serotec, DPC, Breda, the Netherlands), 1:100,  
 overnight at 4 °C to detect macrophages. 
The sections of the wounds with the adjacent tissues were stained for 
either αSMA, HSP47, or CD68, resulting in three double-stained sections 
for each marker. 
Next goat-anti-mouse-AlexaFluor-594 (1:200, one hour at room 
temperature) (Invitrogen/Molecular Probes, Eugene, OR, USA) was 
added. Finally, the sections were washed and the nuclei were stained with 
DAPI (Roche Diagnostics Nederland BV, Almere, The Netherlands). A 
1,4-Diazabicyclo[2.2.2]octane solution (DABCO, Sigma Chemical CO) 
solution in TRIS buffered glycerin was used as anti-fading agent. Slides 
were stored in the dark at 4°C. Photographs were taken on a Carl Zeiss 
Imager Z.1 system (Carl Zeiss Microimaging GmbH, Jena, Germany). 
GFP photos were acquired under bright field conditions. The other 
stainings were photographed with fluorescent settings. The GFP images 
were inverted and merged with the fluorescent images to reveal co-
localization using ImageJ. 
 
6.2.5 Data acquisition and statistics 
The fraction of GFP-positive mononuclear cells in the GFP-transgenic 
blood and the blood of the transplanted rats was determined by flow 
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cytometry. The data were considered statistically different if p<0.05 after 
applying a t-test. 
The areas of the wounds were measured from the digital 
macroscopic pictures, by tracing the wound edge in ImageJ. These data 
were subjected to a two way ANOVA (SigmaStat, version 3.10, Systat 
Software, Inc., Chicago, IL), and considered significantly different if 
p<0.05. Subsequently, a Holm-Sidak post-hoc test was applied 
(SigmaStat). 
Nuclei, GFP-positive, cell type marker-positive, and double-positive 
cells (3 sections per marker) were counted in the center of the wound 
areas in squares of 300 µm wide and 500 µm deep under the epithelium. 
In the adjacent tissues and the flanks, cells were counted in larger areas 
of 500 µm deep and 600 µm wide. The epithelia and the hair follicles 
were excluded. The results were normalized by calculating the cell 
density per mm
2
.These data were tested with a two-way ANOVA and 
were considered significantly different if p<0.05 (SigmaStat). As post-
hoc test, a Holm-Sidak method was applied (SigmaStat). The results are 
shown as mean ± SD.  
 
  
6.3 Results 
 
Six rats died during recovery from the bone marrow transplantation after 
a period of weight loss and reduced activity. In the peripheral blood, 43 ± 
27% mononuclear cells from the transplanted rats were GFP-positive, 
which was significantly less than in the GFP-transgenic rats (89% ± 9%; 
p= <0,001).  
Figure 1A shows macroscopic photographs of the wounds. Minor 
bleedings were observed only after creating the 20-mm wounds. The 
four-mm wounds contracted quickly and the wound beds were 
macroscopically closed after 12 days (figure 1B). The 10-mm wounds 
were also closed after 12 days, but the seemed to be delayed from day 2 
to day 5.  
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Figure 1. Wound closure. A) Fresh wounds and the closed wounds after 14 days. The 
wounds were made with a biopsy punch (4 and 10 mm) or with a scalpel (20 mm). The 
arrows in the lower panel indicate the position of the wound beds. B) Wound closure, as 
determined by analysis of photographs taken every one to three days. Asterisks indicate a 
significant difference with the 20 mm wounds; § indicates a significant difference with the 
10 mm wounds (p<0.05). The symbols show the mean value +/- SD. 
Bone marrow-derived cells in skin wounds 
 139 
The 20-mm wounds closed significantly slower than the smaller wounds, 
and they were not completely closed at the end of the experiment (14 
days). However, later on microscopic level, the histological sections 
showed that all wounds were re-epithelialized. 
Figure 2A illustrates the general histology of the tissues. The 
histology of the adjacent tissues was similar to normal skin of the flank, 
containing an epidermis and a dermis with hair follicles. All wounds were 
completely re-epithelialized. The granulation tissue contained newly 
formed blood vessels, but no regenerated hair follicles were detected. 
Figure 2B shows the distribution of GFP-positive cells. In general, these 
cells were evenly distributed over the tissues, but their density was higher 
in the wounds. Higher concentrations of GFP-positive cells were detected 
around some larger blood vessels (not shown). The cell density (figure 
2C) was significantly higher in the wounds than in the adjacent tissues 
(p<0.001 for all wound sizes). Also, the cell density in the 20-mm 
wounds was significantly higher (26±0.4x10
2
 cells/mm
2
) than in the 10-
mm wounds (21±2.2x10
2
 cells/mm
2
; p=0.006) and the 4-mm wounds 
(21±2x10
2
 cells/mm
2
; p=0.005). The density of GFP-positive cells was 
significantly higher in the 20-mm wound tissue (7±4x10
2
 cells/mm
2
) than 
in the adjacent tissue (3±0.6x10
2
 cells/mm
2
; p=0.005). More importantly, 
the density of GFP-positive cells in the 20-mm wound was about twice as 
high than in the 4-mm wound (4±2x10
2
 cells/mm
2
; p=0.015). However, 
after correction for cell density, the fraction of GFP-positive cells was 
similar in the wounds (23±11%), the adjacent tissues (29±11%), and the 
flanks (26 ± 19%). Therefore, the following stainings were only 
performed on the wound and adjacent tissues. 
Figure 3 shows the (αSMA+) myofibroblasts. In the adjacent areas, 
the muscles around the blood vessels stained positive for αSMA, but 
there were nearly no myofibroblasts detected. Almost no myofibroblasts 
were detected in the 4-mm wounds (1±1•102 cells/mm2), but there were 
significantly more in the 10-mm wounds (8±0.9•102 cells/mm2; p<0.001) 
and the 20-mm wounds (15±4•102; p<0.001). The 20-mm wounds also 
contained more myofibroblasts than the 10 mm-wounds (p<0.001). The 
myofibroblast density in the 10-mm wounds and in the 20-mm wounds 
was significantly higher than in the adjacent tissues (p<0.001).  
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Figure 2. Histology and GFP-staining. A) 6-μm tissue sections containing wound and 
adjacent tissue, and normal tissue from the flanks were stained with hematoxylin and 
eosin. B) The distribution of GFP-positive cells was evaluated by DAPI staining combined 
with an anti-GFP antibody staining. C) From these images the cell densities were 
determined. Asterisks indicate a significant difference (p<0.05). 1) Epidermis. 2) 
Granulation tissue. 3) Hair follicle. 4) Dermis. 
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Figure 3. Myofibroblast density. Tissue sections containing wound and adjacent tissue 
were stained with anti-GFP (green) and anti-αSMA (red) antibodies. The nuclei were 
stained with DAPI (blue). Asterisks indicate a significant difference (p<0.05). 
 
Figure 4 shows the (HSP47+) activated fibroblasts. The cells in the 
adjacent tissues were rather spherical, whereas the cells in the wounds 
were more slender and spindle-shaped. The density of activated 
fibroblasts was always higher in the wounds than in the adjacent tissues 
(p<0.001). In the 10-mm wounds, significantly less (11±2x10
2
 cells/mm
2
) 
activated fibroblasts were present than in the 4-mm wounds (15±4x10
2
 
cells/mm
2
; p=0.005) and in the 20-mm wounds (18±3x10
2
 cells/mm
2
; 
p<0.001). The density of the GFP-positive activated fibroblasts was 
similar in all wounds. However, the density of the GFP-positive activated 
fibroblasts was always higher in the wounds than in the adjacent tissues 
(p=0.009, p=0.012, and p=0.001, respectively for 4-mm, 10-mm, and 20-
mm). 
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Figure 4. Activated fibroblast density. Tissue sections containing wound and adjacent 
tissue were stained with anti-GFP (green) and anti-HSP47 (red) antibodies. The nuclei 
were stained with DAPI (blue). Asterisks indicate a significant difference (p<0.05). 
 
Figure 5 shows the (CD68+) macrophage staining. These cells were 
round, and they seemed to accumulate around large blood vessels in some 
sections. In the 20-mm wounds significantly more macrophages (6±4x10
2
 
cells/mm
2
) were present than in the 10-mm wounds (3±1x10
2
 cells/mm
2
; 
p=0.010) and the 4-mm wounds (4±0.8x10
2
). Less macrophages were 
present in the 20-mm adjacent tissues (2±0.3x10
2
 cells/mm
2
; p=0.005) 
than in the 20-mm wounds. The density of GFP-positive macrophages 
was higher in the 20-mm wounds (3±3x10
2
 cells/mm
2
), than in the 10-
mm wounds (0.9±0.3x10
2
 cells/mm
2
; p=0.007), the 4-mm wounds 
(0.1±0.7x10
2
 cells/mm
2
; p=0.022). Also, more GFP-positive macrophages 
were detected in the 20-mm wounds than in the adjacent tissues 
(1±0.8x10
2
 cells/mm
2
; p=0.017). In general, no significant differences 
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were found between the adjacent tissues for any of the cell types, 
including the GFP-positive and GFP-double positive cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Macrophage density. Tissue sections containing wound and adjacent tissue 
were stained with anti-GFP (green) and anti-CD68 (red) antibodies. The nuclei were 
stained with DAPI (blue). Asterisks indicate a significant difference (p<0.05). 
 
 
6.4 Discussion 
 
We hypothesized that the recruitment of BMDCs in wounds increases 
with wound size. After the bone marrow transplantation, the rats showed 
approximately 50% chimerism. Apparently, part of the autologous bone 
marrow survived irradiation. However, the level of chimerism was high 
enough to determine the contribution of BMDC to wound healing. The 
fraction of labeled peripheral blood mononuclear cells did not correlate 
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with the fraction of labeled cells in the wound or adjacent tissues (not 
shown). Thus, the amount of labeled BMDCs in the blood seems not to 
affect the recruitment in the tissues. In fact, a single BMDC has been 
shown to be able to engraft to multiple organs in multiple lineages in 
mice.
21
  
Although more GFP-labeled cells were found in the wounds than in 
the adjacent tissues and the flanks, the total cell density in the wounds 
was also higher. After correction for cell density, the fraction of BMDCs 
in both tissues was similar. Our data show that BMDCs contribute 
similarly (about 25%) to wounds of all sizes, the adjacent tissues, and the 
normal skin of the flanks. Other studies on skin wounds showed that that 
up to 37% of the cells originates from the bone marrow.
12,16
  
In patients with large burn wounds, the number of circulating 
BMDCs is up-regulated and correlates with wound size.
18,19
 In addition, 
more BMDCs were detected within larger burn wounds.
16
 These studies, 
combined with the high percentage of BMDCs found in fast regenerating 
tissues like the endometrium,
20
 led to our hypothesis. Since we found 
similar levels of BMDCs in all wounds and adjacent tissues, BMDCs are 
apparently not preferentially recruited to the wounds. The lack of specific 
recruitment to the wounds in our study can be explained by assuming that 
larger wounds repair at the same pace as smaller wounds. It only takes 
more time for the larger wounds. Alternatively, the recently discovered 
pool of highly potent (LGR6-positive) stem cells might be able to 
repopulate the wounds completely, whereas the BMDCs only contribute 
to normal tissue turnover.
8
 The physiology of burn wounds (see above) 
might thus be different from excisional wounds in this respect.  
We showed an increasing density of myofibroblasts and bone 
marrow-derived myofibroblasts in larger wounds. Since the 4-mm 
wounds were fully closed at 14 days, wound contraction had probably 
already stopped. After wound contraction, myofibroblasts disappear by 
apoptosis.
1,5
 This is also reflected by our data on activated fibroblasts 
which probably also include collagen-producing myofibroblasts.
22
 The 
largest difference between the density of myofibroblasts and activated 
fibroblasts was found in the 4-mm wounds. Thus, the myofibroblasts had 
already disappeared, but the activated fibroblasts were still remodeling 
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the tissue. In contrast, in the 20-mm wounds, myofibroblasts were still 
actively contracting the tissue. The 20-mm wounds also showed the 
largest macrophage density, including the bone marrow-derived 
macrophage subpopulation. This suggests that the larger wounds require 
more time to progress from the earlier stage of inflammation to 
contraction and remodeling. This is also supported by the lag in closure 
of the 10 and 20-mm wounds. Thus, the stage of wound healing appears 
to be different at the end of the experiment in the wounds of different 
sizes, which might have influenced the results. Further studies on 
multiple time points during wound healing might clarify this.  
The total cell density at 14 days increases with wound size, which 
could also be a consequence of the different wound healing stage. 
Similarly, the BMDC density increases with wound size. Moreover, the 
densities of the GFP-positive subpopulations of the different cell types 
correspond with the trend of the total populations. Apparently, the 
recruited BMDCs differentiate into the cell-types that are required for 
wound repair. Furthermore, it appears that BMDCs are not preferentially 
recruited to the wounds as compared to non-wounded tissues. Another 
study also showed a substantial fraction of 14% BMDCs in non-wounded 
skin, and 18% BMDCs at 28 days post-wounding.
12
 The presence of 
specialized BMDCs in healthy tissues such as the skin is also confirmed 
by other studies.
13,21
 
In conclusion, wound size does not seem to affect the recruitment 
rate of BMDCs to skin wounds. Also, BMDCs are not preferentially 
recruited to wounds, but similarly to non-wounded skin. In the latter, they 
contribute to normal tissue turn-over and homeostasis.  Apparently, local 
stem cell populations in the skin such as the LGR6-positive cells, are 
sufficient to repair the tissue damage. 
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Abstract 
 
Hyaluronan (HA) is an extracellular matrix component putatively 
involved in scarless wound healing in fetuses. Wound contraction is also 
limited in fetal wounds. Postnatal, myofibroblasts are mainly responsible 
for wound contraction and scarring. Therefore, we hypothesized that HA 
reduces contraction. This was studied in a collagen gel contraction model 
seeded with palatal mucoperiosteal fibroblasts. At the end of the 
observation period, the gels were analyzed by histology, 
immunohistochemistry, gene expression, MMP-zymography, and DNA 
quantification. HA delayed contraction and decreased the amounts of the 
inactive form of matrix metalloproteinase (MMP) 2. No significant 
differences were detected for the active forms of MMPs or for their 
inhibitors, the tissue inhibitors of metalloproteinases (TIMPs). On 
histological and mRNA level, no myofibroblasts were detected in any of 
the gels. The reduction of wound contraction might be caused by the 
formation of a pericellular coat of HA.   
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7.1 Introduction 
 
Fetal wounds regenerate without wound contraction and scarring,
1,2
 for 
which several possible mechanisms have been identified. One of the 
factors that seems to play a role is the extracellular matrix (ECM) 
component hyaluronan (HA), which is a high molecular weight non-
sulfated glycosaminoglycan consisting of linear polysaccharides of 
glucuronic acid and N-acetylglucosamine.
3,4
 In general, HA synthesis is 
up-regulated in fetal and postnatal wound healing. It creates a hydrated 
extracellular matrix (ECM) which facilitates cell motility and 
proliferation.
5-8
 HA is more abundantly and longer expressed by 
fibroblasts in fetal wounds than in postnatal wounds,
1,8,9
 which has been 
associated with scarless wound healing.
9
 
Postnatal wound healing involves wound contraction and scarring, 
which is mainly caused by myofibroblasts. Scarring of the skin can lead 
to esthetic problems and reduced joint mobility, but, after cleft palate 
surgery, also to growth disturbances of the upper jaw. Myofibroblasts 
differentiate from wound fibroblasts in response to mechanical tension 
and TGF-ß1, and they typically express alpha-smooth muscle actin 
(αSMA), which gives them contractile properties .10 These cells are 
present for up to several weeks in postnatal wounds, whereas they are 
only present for a few days in fetal wounds.
11,12
 This might contribute to 
scarless healing in fetuses. In addition, fetal myofibroblasts express about 
50% less soluble collagen in response to TGF-ß1 than postnatal 
myofibroblasts.
13
 
Another factor is the difference in the ratio of matrix 
metalloproteinase (MMP) to tissue inhibitors of metalloproteinase 
(TIMP) in fetal and postnatal wounds. MMPs are ECM degrading 
enzymes that are inhibited by TIMPs.
14
 In fetal wounds, the MMP levels 
are relatively high, resulting in increased ECM degradation and cell 
migration.
15
 HA is known to increase the expression of MMPs in 
fibroblasts.
16-18
 
Similar to fetal wounds, oral wounds are in a wet environment which 
is rich in growth factors
19-21
 and generally show reduced scar formation.
22
 
This might be caused by HA in saliva and in the oral mucosa, which 
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contains about twice as much HA as the skin.
23
 In contrast to buccal 
wounds, however, palatal wounds do show scarring.
12
 
An established in vitro model to study the contractile properties of 
fibroblasts are collagen gels.
24-28
 HA reduces the contraction of collagen 
gels by dermal fibroblasts, while proliferation and migration were 
stimulated.
15,16,18
 In contrast, other studies show enhanced gel contraction 
or no effect at all.
25,27
 The effect of HA on collagen gel contraction by 
palatal fibroblasts has not been studied.  
In this study, we hypothesized that HA reduces collagen gel 
contraction, myofibroblast differentiation and collagen production, and 
the MMP: TIMP ratio.  
Therefore, gel contraction and cell proliferation were determined, 
and the mRNA expression of MMPs and TIMPs, TGF-ß1, collagen, and 
decorin were studied. The amounts of MMP and TIMP proteins were 
studied by zymography.
29
 
 
  
7.2 Materials & methods 
 
7.2.1 Cells 
A palatal mucoperiosteal tissue biopsy of a child (about two years old) 
was obtained with parental consent according to the guidelines of the 
local ethical committee. Fibroblasts were cultured from the biopsy and 
stored in liquid nitrogen. For the experiments, palatal fibroblasts (passage 
5) were cultured in a 75 cm
2
 culture flask for 3 days until 90% 
confluence. The culture medium consisted of Dulbecco’s modified 
Eagle’s medium (DMEM, GIBCO, Paisley, UK) supplemented with 10% 
fetal calf serum (FCS, GIBCO) and 2% penicillin and streptomycin 
(GIBCO) at 37°C in an atmosphere of 5% CO2 and 95% humidity.  
 
7.2.2 Gel preparation 
A 24 wells culture plate was coated with 1% bovine serum albumin in 
PBS for 75 minutes. The gel suspension was prepared on ice to prevent 
gelation, and finally contained 1.2 mg/ml rat-tail collagen type I (Serva 
Electrophoresis, Heidelberg, Germany), 10% (v/v) minimal essential 
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medium (10x; GIBCO), 0.1 M 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES; GIBCO), 27 mM NaHCO3 
(GIBCO), 20 mM NaOH and 1•105 cells/ml. The suspension was split in 
three, and PBS and/or HA (Hyaluronic acid sodium from rooster comb, 
Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands) in PBS was 
added to obtain control (0 mg/ml HA), 0.5 mg/ml HA (HA 0.5), and 1.6 
mg/ml HA (HA 1.6) gel suspensions. Eight 1 ml volumes of each 
suspension were pipetted into the coated wells and placed in the 
incubator for one hour until gelation. Subsequently 1 ml of DMEM 
supplemented with 0.5% FCS (Invitrogen/GIBCO), 1x Insulin-
Transferrin-Selenium (ITS, Invitrogen/GIBCO), and 2% penicillin and 
streptomycin (Invitrogen/GIBCO) was added. 
 
7.2.3 Gel contraction 
The gels were incubated for 19 hours. Standardized scans (Epson 
Perfection 4490 Photo; Epson Europe B.V., Amsterdam, The 
Netherlands) were made of the culture plates at 1, 4, 9.5 and 19 hours. 
From these images, the contraction percentage was determined with 
ImageJ (National Institutes of Health (NIH), Bethesda, Maryland, USA).  
3.4 DNA assay 
Three gels of each condition were digested with papaine 1 µg/ml in a 
buffer (pH=6.0) of NaCl, NaAc L-cysteine and 
ethylenediaminetetraacetic acid (EDTA) at 60 °C O/N. The total amount 
of DNA was determined with the fluorescent PicoGreen dsDNA 
Quantitation kit (Molecular Probes, Inc., Eugene, OR, USA) in each gel. 
As a standard, bacteriophage lambda DNA was used. The fluorescent 
signal was measure in an FL600 Microplate Fluorescence Reader (Bio-
Tek Instruments, Inc., Winooski, VT, USA) at excitation 485 nm and 
emission 520 nm. 
 
7.2.4 Histology and immunohistochemistry 
After the experiment, one gel of each condition was fixed in 2% 
paraformaldehyde for 30 minutes, washed in PBS, dehydrated in ethanol 
and processed for embedding in paraffin.  Paraffin sections (10 µm) were 
mounted on Superfrost Plus slides (Menzel-Gläser, Braunschweig, 
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Germany) and deparaffinated in xylol. Next, the sections were stained by 
a Weigert - azokarmin/aninilin blue method. Briefly, nuclei were stained 
by a two-component Weigert nuclei staining and cellular components by 
an azokarmin-solution. Subsequently, the sections were stained for 
collagen with an aninilin blue-Orange G-Acetic acid solution and sealed 
in DPX (BDH Chemicals, Victoria, Australia). 
To detect myofibroblasts, the sections were stained for αSMA. 
Firstly, the sections were deparaffinated, rehydrated, and incubated with 
3% H2O2 to destroy endogenous peroxidase. Next, the sections were post-
fixed with 4% formalin and washed in 0.75 µg/ml glycine in PBS (PBS-
G). Antigens were retrieved with citrate buffer (pH 6.01) at 70 °C, 
followed by incubation in 0.075 g/ml trypsin (Difco Laboratories, 
Detroit, USA) in PBS at 37°C. The sections were pre-incubated with 10% 
normal donkey serum (NDS) (Chemicon, Temecula, USA) in PBS-G and 
then incubated overnight with an anti-αSMA antibody (Sigma Chemical 
CO, St Louis, MO, USA) in 2% NDS. Next, the sections were washed in 
PBS-G and a biotinylated donkey-anti-mouse antibody (1:500; Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA, USA) was added 
for 1 hour.  
Vectastain ABC Standard mix (ABC; Vector Laboratories, 
Burlingame, CA, USA) was diluted in PBS-G and applied for one hour to 
bind to the biotinylated secondary antibody. The sections were stained 
with 3,3’-di-amino-benzidine tetrahydrochloride (DAB; Sigma) and 
sealed in DPX. Digital microscopic pictures were taken on a Carl Zeiss 
Imager Z.1 system (Carl Zeiss Microimaging GmBH, Jena, Germany). 
 
7.2.5 Quantitative PCR 
To measure the mRNA expression level of αSMA, TGF-ß1, MMPs and 
TIMPs, decorin and collagen type I, quantitative real time (q)PCR was 
performed. Four gels of each condition were incubated in Trizol 
(Invitrogen) with chloroform and the samples were vortexed and 
centrifuged at 4°C at 10.000 rpm for 20 minutes. The aqueous 
supernatant was removed, 70% ethanol was added to the pellets (1:1), and 
the samples were again vortexed. Next, the RNeasy minikit (Qiagen, 
Venlo, The Netherlands) was used according to the manufacturers’ 
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“Animal cells spin” manual. The amount of RNA was quantified by 
measuring the absorption at 260 and 280 nm. Samples were stored at -
80°C. 
For the reverse-transcriptase (RT) reaction, about 0.5 µg RNA was 
used. The samples were incubated with 1 µl of deoxyribonucleotide 
triphosphates containing 10 mM of each deoxyribonucleotide (dATP, 
dCTP, dGTP and dTTP) and 1 µl of 0.5 µg/µl of random primers 
(Promega, Madison, WI, USA) at 65°C for 5 minutes. The samples were 
subsequently put on ice and 4 µl SuperScript
TM
 II reverse transcriptase 
buffer [SuperScript
TM
 II RT, 5x firststrand buffer (250 mM Tris–HCl, pH 
8.3, 375 mM KCl, 15 mM MgCl 2 )] and 2 µl of 0.1 M dithiothreitol 
(GIBCO) were added. Next, the samples were heated for 2 minutes at 
25°C. Subsequently, the samples were incubated with 200 U of 
SuperScript
TM
 II reverse transcriptase for 10 minutes at 25°C. The RT 
reaction was performed at 42°C for 50 min and was stopped by heating 
the samples to 70°C for 15 min. The obtained cDNA samples were stored 
at -20°C. 
Five µl cDNA was diluted 1:40 in demineralized water (Millipore) 
and added to the quantitative PCR reaction mix, containing 12.5 µl 
SYBR
®
 Green Supermix (BioRad, Hercules, CA, USA), 4.5 µl 
demineralized water (Millipore), and 3 µl of a forward (2,5 µM) and 
reverse primer (2,5 µM) mix. The primer sequences are shown in Table 1. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as a 
reference gene. The amount of mRNA was calculated as the difference 
between the threshold cycles (Ct) of the gene of interest minus the C t of 
GAPDH, resulting in a ΔCt. Cycles above 35 were not included. The fold 
change in gene expression was expressed as 2
-ΔCt
 and plotted on a log
2
 
scale. 
 
7.2.6 Zymography 
To analyze the amount of MMP2 and -9 in the culture media at the end of 
the experiment, a 10% polyacrylamide gel with 10% (v/v) sodium 
dodecyl sulphate and 1 mg/ml gelatin was used. A marker was included 
to determine the molecular weight of the samples, and recombinant 
human pro-MMP2 and -9 (Oncogene, CN Biosciences, San Diego, CA, 
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USA) were used as a reference sample. The amount of MMP2 and -9 in 
the culture medium with 0.5% FCS was also analyzed. 
The MMP inhibitors TIMP1 and TIMP2 in the culture media were 
analyzed by reverse zymography. This technique is similar to gelatin 
zymography as described above. A 15% polyacrylamide gel with 10% 
(v/v) sodium dodecyl sulphate and 0.8 mg/ml gelatin was used, now 
supplemented with 10% (v/v) conditioned medium from baby hamster 
kidney cells (BHK-21; ATCC, Rockville, MD, USA), which is rich in 
MMP2. The gelatin in the gel will be degraded by the introduced MMP2, 
unless TIMPs are present. Recombinant human MMP1 and -2 
(Oncogene) were used as references. The culture medium with FCS was 
not included, since earlier studies (data not shown) repeatedly showed 
that TIMPs are not present in FCS. 
All samples were diluted in sample buffer (1:1) before loading the 
gels. Next, electrophoreses was performed and the gels were washed in 
2.5% Triton X-100 (Sigma-Aldrich, GmbH, Steinheim, Germany). 
Subsequently, the gels were incubated in activation buffer (50 mM Tris–
HCl (pH 7.8), 5 mM CaCl2, and 0.1% Triton X-100) at 37°C for 18 hours 
to activate the MMPs. Next, the gels were stained in Coomassie Brilliant 
Blue R250 (2.5 g/l; Imperial Chemical Industries PLC, London, UK) in 
an aqueous solution of 10% acetic acid and 40% methanol for 45 
minutes. The gels were destained in an aqueous solution of 10% acetic 
acid and 40% methanol. 
The gels were scanned using an Epson Perfection 4490 Photo flatbed 
scanner at 600 dots per inch as grey scale TIF images, and ImageJ (NIH) 
was used to analyze the band intensity, expressed as mean density x 
pixels
2
. To compare bands on different gels, the MMP2 or the TIMP2 
band intensity from the reference samples on each gel was set to 1 and all 
other bands were calculated accordingly. Subsequently, the background 
levels detected in control medium were subtracted. The band intensities 
were expressed per ng DNA. The medium of three gels per condition was 
tested separately. 
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7.2.7 Statistics 
The contraction data were tested with a two-way ANOVA (time x 
condition) (SigmaStat, version 3.10, Systat Software, Inc., Chicago, IL). 
A Holm-Sidak post-hoc test was used. The qPCR, DNA quantification 
and zymography data were tested with a one-way ANOVA (SigmaStat). 
The data were considered significant when p < 0.05. 
 
 
7.3 Results 
 
7.3.1  Collagen gel contraction and DNA content 
The contraction started immediately in all gels (Figure 1). However, the 
control and 0.5 mg/ml HA-containing gels were significantly more 
contracted than the 1.6 mg/ml HA-containing gels after 4 and 19 hours 
(p<0.05). After 9.5 hours, more contraction was measured in the control 
gels compared to both the 0.5 mg/ml and the 1.6 mg/ml HA-containing 
gels (p<0.05). The contraction of all gels significantly increased over 
time (p<0.05), except for the control between 9.5 and 19 hours.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Gel contraction. An asterisk indicates a significant difference (p < 0.05) 
between the experimental gels and the controls. Less contraction was measured in the 1.6 
mg/ml HA-containing gels after one hour. 
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Figure 2. DNA content. The amount of DNA was measured in three gels per condition 
at the end of the experiment. No significant differences were found between the different 
conditions. 
 
The DNA content (Figure 2) was not significantly different after culture 
(control: 603 ± 52, HA 0.5: 620 ± 27, and HA 1.6: 646 ± 43 ng DNA; p = 
0,487). 
 
7.3.2 Histology and immunohistochemistry 
The histological sections (Figure 3) show a lower collagen density in the 
gels with 1.6 mg/ml HA. No αSMA-positive cells were detected in any of 
the sections (not shown).  
 
 
 
 
 
 
 
 
 
Figure 3. Representative histological sections. The contraction gels were stained with 
Weigert - azokarmin/aninilin blue. The control (A) and HA 0.5 (B) containing gels have a 
higher collagen density than the HA 1.6 (C) collagen gels. 
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7.3.3 mRNA expression 
The fold change in the mRNA expression of MMP1, -2 and 3, and TIMP1 
and -2 is shown in Figure 4A. The MMP9 mRNA expression was too low 
to determine (>35 cycli). No significant differences were found for MMP 
and TIMP mRNA expression.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. mRNA expression. A: The effect of hyaluronan on the mRNA expression of 
matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs). B: 
the effect of hyaluronan on the expression of alpha-smooth muscle actin (αSMA), collagen 
type 1 (Col-1A1), decorin, and transforming growth factor-beta 1 (TGFß1). The fold 
change in gene expression is expressed as 2
-ΔCt
 on a log
2
 scale. ΔCt was calculated 
relative to the GAPDH control. Pooled cDNA from four gels per condition was tested in 
triplo. 
 
Figure 4B shows the fold change in the mRNA expression of αSMA, 
collagen type 1, decorin and TGFß1. Also for these markers, no 
significant differences were found. 
 
7.3.4 Zymography 
Typically, gelatin zymography (Figure 5A-C) revealed only pro-MMP2, 
but no MMP2 complexes or active MMP2. The pro-MMP2 amount was 
significantly less with 1.6 ng/ml HA (1348 ± 101, expressed as mean 
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density x pixels
2
/ng DNA), compared with the control (2055 ± 22; 
p<0.001) and with 0.5 ng/ml HA (1871 ± 130; p<0.001). In addition, pro-
MMP2 was also significantly less with 0.5 ng/ml compared with the 
control (p = 0.006) (Figure 5B). The MMP9 amount (Figure 5C) was very 
low in all conditions.  The TIMP amount did not reveal significant 
differences between any of the conditions (Figure 5D-F).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Zymography of the culture medium. The quantification of MMPs-2 and -9 
(A-C), and their inhibitors TIMPs-1 and -2 (D-F) (n = 3).  Figure A shows a 
representative gelatin zymogram. No active or complexed MMP2 was detected in the 
samples. Figures B and C show the quantification of pro-MMP2 and pro-MMP9, 
respectively, expressed as mean density of the bands x pixels2/ng DNA, relative to the 
reference MMP2 sample (rMMP-2 ref). The pro-MMP2 amount was significantly different 
in each condition (p < 0.01). Figure D shows a representative reverse zymogram, and 
figures E and F show the quantification of TIMP1 and TIMP2 relative to the reference 
TIMP2 sample (TIMP2 ref). 
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7.4 Discussion 
 
The aim of this study was to investigate the effect of HA on palatal 
fibroblasts in a collagen gel contraction model. Therefore, an established 
collagen contraction gel model was used.
24,28
 HA was shown to reduce 
gel contraction. This is consistent with studies on bovine skin fibroblasts 
and adult human skin fibroblasts in collagen gels and fibrillar collagen 
matrices.
26,27
 However, others found no effect of HA on collagen gel 
contraction by human foreskin fibroblasts.
25
 In their study, a collagen 
fibrillar matrix was used and the fibroblasts were placed on top of the 
collagen matrix. Others even found an increase in collagen gel 
contraction by HA with adventitial fibroblasts from cynomolgus monkey 
aorta.
30
 The differences between these studies might be due to the 
preparation of the collagen gels/matrices, and the origin of the 
fibroblasts. 
Myofibroblasts were not detected in this study, neither by 
immunostaining nor by expression of αSMA mRNA. Possibly, the 
mechanical tension in the free floating gels is too low for myofibroblast 
differentiation. Fibroblasts apply traction to the collagen, which will 
rigidify the matrix.
31
 Subsequently, the mechanical tension increases, 
which will stimulate myofibroblast differentiation.
10
 Others have shown 
that αSMA expression in cultured palatal fibroblasts stimulated by TGF-
ß1 only increases after 24 hours of stimulation.
32
 Dermal fibroblasts in 
collagen gels show a similar delayed response.
33
 This indicates that our 
culture period (19.5 hours) was too short for myofibroblast  
differentiation.  
Several studies show that MMP inhibition reduces collagen gel 
contraction.
34,35
 Our study did not show changes in MMPs and TIMPs 
except for a decrease in pro-MMP2.  
Elevated HA and MMP in fetal wounds seem to be associated with 
limited contraction and scar formation.
1,2,8,9,15
 Our study showed that HA 
in a collagen gel model containing postnatal palatal fibroblasts reduces 
contraction. However, no differences in the amounts of active MMPs 
could be detected. Therefore, other mechanisms may underlie the 
reduction of collagen gel contraction by HA. Others showed that HA 
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forms a pericellular coat around the cells that may have a shielding 
effect.
23,25-27,36
 This may reduce the ability of cells to connect to the 
ECM.
23,37
 To connect to the ECM, the HA coat needs to removed. This 
might be achieved by HA receptors such as CD44, which can actively 
push the HA coat away.
38
 HA can also be degraded by hyaluronidases 
produced by fibroblasts.
38,39
 This mechanism is most likely to play a role 
in the degradation of HA by the fibroblasts in the contraction gels. Upon 
degradation, the fibroblasts can connect to the ECM by ß1integrins, 
especially the α2-ß1.40,41 
In conclusion, the contraction of collagen gels by postnatal palatal 
fibroblasts is reduced by HA. This is probably not mediated by delayed 
myofibroblast differentiation or a shifts in MMP: TIMP ratio. We suggest 
that the fibroblasts are shielded from collagen binding by a pericellular 
HA coat. 
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Wound healing involves multiple stadia in which many different cell 
types are involved.
1
 In general, wounds contract and scar tissue 
eventually replaces the damaged tissue. The scar may impair the growth 
of the upper jaw after cleft palate surgery or impair the mobility of joints 
covered by large scars, which may cause complications later in life.
2-4
 
Although several techniques exist to reduce scar-related problems,
4,5
 the 
prevention of scarring is still a major objective of research. The most 
important cell for wound contraction and scar formation is the 
myofibroblast.
6-8
 These cells differentiate from fibroblasts under specific 
conditions, including mechanical tension and the presence of 
transforming growth factor ß1 (TGFß1), ED-A fibronectin, and platelet-
derived growth factor (PDGF).
8-10
 It is still unclear whether 
myofibroblasts can differentiate directly from precursor cells, or that an 
intermediate cell type is involved.
10,11
 One precursor cell type for 
fibroblasts and myofibroblasts are circulating bone marrow-derived cells 
(BMDCs).
12-17
 In tissues with a high turnover like the female 
endometrium, up to 50% of the cells originate from the bone marrow.
18
 
However, the reported fractions of bone marrow-derived myofibroblasts 
in wounds range from 0% up to 60%.
12,13,16
 The large range is partly 
explained by the inaccurate quantification of BMDCs in the wounds. It 
has been reported that the contribution of BMDCs to unwounded tissues 
of different types (brain, spleen, small intestine, skin, lung, kidney, aorta 
and heart) was highest in skin.
12
 Others showed higher numbers of bone 
marrow-derived myofibroblasts in wounded skin and wounded lung, 
compared with their unwounded counterparts, whereas similar amounts 
were detected in wounded and unwounded kidney.
13
 However, this study 
presents no data on the total amount of recruited BMDCs nor on other 
bone marrow-derived cell types. It has also been shown that the progeny 
of a single labeled BMDC can engraft into multiple tissues in several 
months.
19
 A limitation of this study is that only (cytokeratin-positive) 
epithelial cells were characterized.  
Our hypothesis was based on data from quickly regenerating tissue 
like the endometrium, and the capability of BMDCs to differentiate into 
myofibroblasts.
13,16
 The hypothesis was that BMDCs are recruited to 
wounds where they differentiate into myofibroblasts (figure 1).  
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Figure 1. The hypotheses of this thesis. Chapters 4-6: Bone marrow-derived cells enter 
the blood and are recruited to the wound, where they differentiate into myofibroblasts. If 
this is true, the recruitment can be targeted to reduce the myofibroblast population. 
Chapter 7: The differentiation of myofibroblasts can be decreased by changing ECM 
composition to reduce contraction and scarring. 
 
We therefore investigated the contribution of BMDCs in the healing 
of the palatal mucoperiosteum and the skin. The total population of 
recruited BMDCs and the bone marrow-derived subpopulations of 
myofibroblasts, activated fibroblasts, and macrophages were quantified in 
wounds in the palatal mucoperiosteum, in skin wounds and in unwounded 
tissues. The results are described in chapters 4-6. If our hypothesis would 
be true, it is interesting to intervene with either BMDC recruitment or 
differentiation to reduce myofibroblast populations, and thereby diminish 
contraction and scarring. The modulation of myofibroblast differentiation 
was investigated in chapter 7 using hyaluronan in a collagen gel 
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contraction model. Thus, both ways of intervention ultimately aim to 
reduce wound contraction and scarring to diminish the adverse effects of 
wound healing. 
 
 
8.1 Study design and results 
 
To quantify the recruitment of BMDCs and their subsequent 
differentiation, the bone marrow had to be labeled prior to wounding. An 
often used model consists of chimeric rats with green fluorescent protein 
(GFP)-labeled bone marrow created by means of bone marrow 
transplantation (BMT).
20,21
 GFP is an autofluorescent protein derived 
from the jellyfish Aequorea victoria.
22,23
 In general, all nucleated cells of 
GFP-transgenic rats express the soluble GFP under the control of a 
chicken beta-actin promoter and cytomegalovirus enhancer.
24
 Therefore, 
the cells derived from GFP-positive bone marrow in chimeric rats should 
be easily detectable.  
Irradiation possibly compromises wound healing,
25-27
 and therefore 
we searched for an alternative model using labeled BMDCs. During 
pregnancy, transplacental passage of fetal cells, including bone marrow-
derived progenitor cells, occurs frequently in mice and men and can lead 
to micro-chimerism.
14,28,29
 In mothers, who had previously given birth to 
a son, male cells are detectable in both the blood and in wounds up to 27 
years post-partum.
30
 Thus, as an alternative for a BMT, we conducted a 
pilot study on a pregnancy model (not shown in this thesis). Female wild-
type rats were mated with male GFP-transgenic rats. Analysis of the 
blood of the mother rats after delivery revealed only very low fractions 
(0.076 ± 0.04%) of GFP-positive cells. Neither in wounded nor in 
unwounded palatal mucoperiosteum of the mother rats, GFP-positive 
fractions were identified. Therefore, we decided to use the established 
BMT model as described above. Nevertheless, our studies (chapters 4-6) 
showed that the wound closure rate was not influenced by the irradiation; 
non-irradiated full-thickness wounds in the palatal mucoperiosteum and 
in the skin of rats are also closed in about 10-14 days post-wounding.
31-33
 
In our model, GFP was not as easily detectable as we had assumed. In 
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cryosections, the soluble GFP was rapidly lost during staining. Therefore, 
we used paraffin sections in which the GFP was thoroughly fixed. 
However, autofluorescence is a well known problem in 
paraformaldehyde-fixed, paraffin-embedded sections.
34
 Therefore, we 
applied an antibody staining against GFP to detect the bone marrow-
derived cells.  
Oral tissues generally heal quickly.
35
 We hypothesized that quickly 
healing tissues recruit high numbers of BMDCs, as was demonstrated for 
the endometrium.
18
 Therefore, we studied the recruitment of BMDCs and 
their differentiation into myofibroblasts in experimental palatal 
mucoperiosteal wounds in rats (chapter 4). This is an established model 
for palatal mucoperiosteal wound healing.
7,36
 The BMT resulted in 
fractions of up to about 90% of GFP-positive circulating mononuclear 
cells at five weeks after transplantation (chapters 4-6). Both in the 
wounds and in the unwounded tissues considerable numbers of BMDCs 
were detected, up to about 30% of the cells (chapters 4-6).  
Contrary to our expectation, only a small contribution (about 8% of 
all cells) of BMDCs to palatal mucoperiosteal wounds was found 
(chapter 4). Also low fractions of bone marrow-derived myofibroblasts 
were detected by antibodies against alpha-smooth muscle actin (αSMA). 
αSMA is typically expressed by myofibroblasts and is a key part of their 
contractile system.
6
 We also demonstrated a small population of bone 
marrow-derived activated fibroblasts in palatal wounds, as detected by 
antibodies against heat-shock protein (HSP)47.
37
 This marker is a 
collagen-specific chaperone protein involved in processing of 
procollagens, and thus includes fibroblasts and myofibroblasts.
38,39
 
Cluster of differentiation (CD)68 is mainly expressed by macrophages, 
which differentiate from circulating monocytes.
40,41
 We showed that 
about 25% of all macrophages in the wounds originate from BMDCs.  
In contrast to other studies,
12,42,43
 no BMDCs were detected in the 
epithelia of the closed wounds (chapters 4-6). We then examined whether 
GFP was expressed by epithelial cells of the GFP-transgenic rats (not 
shown in this thesis). This was not the case in the epithelia of the skin 
and the small intestine. Apparently, the expression of GFP is silenced in 
epithelial cells of our transgenic rats. In general, it is debated whether 
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BMDCs are a substantial source for epithelial tissues.
44-46
 Currently, it 
seems more likely that local stem cells regenerate epithelial tissues.
44,45
 
The epithelium of the small intestine can be regenerated by local stem 
cells expressing leucine-rich repeat-containing G protein-coupled 
receptor (LGR) 5.
44
 Similarly, LGR6-expressing cells regenerate the 
epidermis of wounded skin and also the sebaceous glands, and they form 
new functional hair follicles.
45
 However, up to now no data have been 
published on the presence of LGR-positive cells in the palate. Possibly, 
the neural crest-related stem cells, which are abundantly present in the 
palate, might act as progenitors for fibroblasts and myofibroblasts.
47,48
  
We subsequently investigated whether the recruitment of BMDCs is 
tissue-specific by characterizing and quantifying BMDCs in palatal and 
skin wounds of the same size (chapter 5). We demonstrated higher 
fractions of BMDCs in skin wounds, compared to palatal wounds 
(chapter 5). However, no significant differences were found in the total 
BMDC fraction in wounded and unwounded skin. This is in accordance 
with results of others.
12
 In our study, also no significant differences were 
found in differentiated BMDCs in wounded and in unwounded skin, 
including the myofibroblasts. Moreover, in both wounded 
mucoperiosteum and skin, the bone marrow-derived myofibroblast 
fraction was less than 10%. We conclude that the recruitment of BMDCs 
to the palatal mucoperiosteum is higher than to skin, although the total 
fraction is small. In addition, BMDCs are similarly recruited to healthy 
and wounded skin.  
Several previous studies suggested that an increase of wound size 
also increases the recruitment of BMDCs.
43,49,50
 We investigated this 
(chapter 6), by creating single wounds in chimeric rats, which were 
divided over three groups with increasing wound sizes (4 mm
2
, 10 mm
2
 
and 20 mm
2
). This study demonstrated that the fraction of BMDCs is not 
dependent of wound size. Moreover, the BMDCs were not preferentially 
recruited to wounds of any size. Differences were detected in the 
numbers of bone marrow-derived myofibroblasts. However, this could be 
attributed to differences in the stage of wound healing, since the smaller 
wounds were fully closed at the end of the experiment, while the largest 
wounds were still open. Two of the studies which suggest that an 
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increased wound size also increased BMDC recruitment were conducted 
on burn wounds.
49,50
 These wounds are known to heal differently 
compared to excisional wounds as created in our study.
51,52
 Burn wounds 
contract and reepithelialize slower than excisional wounds, and contain 
less fibroblasts and newly synthesized collagen in the dermis.
51,52
 Also, a 
reduced expression of matrix metalloproteinases (MMPs) and an 
increased expression of tissue inhibitors of metalloproteinase (TIMP)-1 
was reported for burn wounds.
51
 A high expression of MMPs correlates 
with facilitated cell migration and possibly with faster contraction.
53-56
 
These differences in healing mechanisms may explain the faster healing 
of excisional wounds, and also the differences in recruitment of BMDCs. 
Another study that suggested an increased number of BMDCs in larger 
wounds focused on the epidermis.
43
 We could not compare these results 
with our studies since GFP is not expressed by epithelial cells in our rat 
model (see above).  
Summarizing, our in vivo studies demonstrated that BMDCs are not 
a substantial source for myofibroblasts during wound healing. Possibly, 
local stem cells such as the LGR-positive and the neural crest-related 
stem cells populations are the main source of myofibroblasts during 
wound healing.  
A second way to reduce the number of myofibroblasts is to modify 
the local extracellular matrix. This was tested in an in vitro study (chapter 
7). Hyaluronan might be involved in scarless fetal wound healing, which 
also shows reduced contraction.
57-59
 Both phenomena can be explained by 
the highly reduced numbers of myofibroblasts in fetal wounds.
60
 In 
chapter 7 it was attempted to reduce myofibroblast differentiation by 
adding hyaluronan to a collagen gel contraction model. This established 
model
61,62 
is a three-dimensional system which allows cells to interact 
with an extracellular matrix and with each other. In addition, factors can 
easily be tested for their effect on cellular behavior such as the 
contraction rate, histological changes, cell proliferation, and protein- and 
gene expression.
55,62
 Our results show that hyaluronan reduces the 
contraction of collagen gels. In general, reduced amounts of MMPs 
reduce gel contraction.
54-56
 Studies by others are inconclusive about the 
effects of hyaluronan on the amount of active MMPs.
63-65
 Our study 
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shows no significant changes in the amounts of active MMP2 and -9, 
however, a decrease in the inactive form of MMP2 was found. We did 
not detect myofibroblasts in the collagen gels, which could be attributed 
to brief culture time and the absence of mechanical tension.
66-68
 
Therefore, we suggest another mechanism to explain the reduced gel 
contraction; hyaluronan shields the fibroblasts and impairs their ability to 
interact with other cells and the extracellular matrix.
69
  
 
 
8.2 Conclusions and future research 
 
Our hypothesis was that wounds recruit BMDCs and subsequently 
differentiate into myofibroblasts, which are responsible for contraction 
and scarring. We showed that BMDCs are contributing both to normal 
tissue turnover and to wound healing. Moreover, the recruitment rate 
depends on the tissue type; in the palate about a ten-fold increase in the 
BMDC fraction of all cells was detected after wounding, whereas in skin 
wounds no difference was found between wounded and unwounded 
tissue. However, the total fraction of BMDCs and the total fraction of 
bone marrow-derived myofibroblasts and activated fibroblasts were 
generally small. Therefore, we conclude that BMDCs do not substantially 
contribute to the myofibroblast population in wounded palatal  
mucoperiosteum and skin (Figure 2). However, the wound healing 
process consists of several phases and involves multiple cell types.
1
 It is 
not unlikely that, in time, the contribution of BMDCs varies, which could 
be elucidated by new long-term quantification studies. Nonetheless, 
according to our results, the aim to clinically reduce wound contraction 
and scarring by reducing the recruitment of BMDCs does not appear 
feasible. 
Another approach is to study the contribution of local stem cells in 
more detail. The recently discovered LGR-positive stem cells in the 
intestines and skin, and the neural crest-related stem cells in the palate 
might be precursors for fibroblasts and myofibroblasts.
44,45,47,70,71
 We 
demonstrated that hyaluronan can reduce contraction in vitro. The 
shielding of fibroblasts by hyaluronan might reduce contraction and 
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myofibroblast differentiation. Another possible target to interfere with 
myofibroblast differentiation is blocking ED-A fibronectin. This protein 
is specific for adult wound healing and it is one of the key factors for 
myofibroblast differentiation.
8
 Ultimately, the reduction of the 
myofibroblast population in wounds limits wound contraction and 
scarring, which might reduce scar-related problems. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Main conclusions of this thesis. We demonstrated that only limited numbers 
of bone marrow-derived myofibroblasts are recruited to the wound. Therefore, limiting 
BMDC recruitment is not likely to reduce the myofibroblast population. The activation 
and recruitment of local stem cells in the tissue adjacent to the wound appears to be the 
most important source for the recruitment of myofibroblasts to the wound. We provided in 
vitro evidence for a reduction of contraction by hyaluronan. The exact mechanism has to 
be further elucidated. 
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Wound healing is a process to restore tissue integrity after damage or 
injury. This normally beneficial process involves wound contraction to 
reduce the wound surface. Ultimately scar tissue is formed. The main 
cells in wound contraction and scarring are the myofibroblasts. 
Myofibroblasts can be recruited from local tissues surrounding the 
wound. Also circulating bone marrow-derived cells (BMDCs) can be 
recruited to a wound and differentiate into myofibroblasts. By reducing 
the myofibroblast population in wounds and thus the formation of scar 
tissue clinical opportunities arise. This can be achieved by interfering 
with the recruitment and differentiation of myofibroblasts. Therefore, it is 
important to identify the main sources for myofibroblasts. The aims of 
our study were to investigate whether substantial numbers of 
myofibroblasts are recruited from the bone marrow in response to 
wounding, and whether myofibroblast differentiation can be modulated. 
Chapter 1 describes the background of the study and provides an 
overview of the experiments. Myofibroblasts are discussed in the context 
of wound healing with the focus on BMDCs as a potential source. 
Differences in wound healing between different tissue types, and between 
prenatal and postnatal tissues are discussed. The experimental design is 
introduced and the specific aims are summarized.  
The results of a literature review on stem cells in tissue turn-over 
and wound healing in epithelia are presented in Chapter 2. The 
characteristics of the stem cell populations and their niche in the epithelia 
of different tissues (skin, cornea, lung, and intestine) are discussed. 
Similar mechanisms were deduced regarding the contribution of stem 
cells to tissue turn-over and wound healing. A model is proposed 
identifying stem cells for local maintenance, repair, and bone marrow-
derived rescue stem cells. According to this model, BMDCs are recruited 
in response to tissue damage that exceeds the regenerative capacity of the 
local stem cells.  
In Chapter 3 matrix metalloproteinases (MMPs) and tissue 
inhibitors of metalloproteinases (TIMPs) are introduced. These enzymes 
and their inhibitors play a key role in tissue turn-over, wound healing and 
development by regulating the degradation of the extracellular matrix. 
Apart from the inhibitory effect of TIMPs on MMPs, additional 
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biological functions of these proteins are discussed. This literature study 
shows that the balance between MMPs and TIMPs is disrupted in the 
development of cleft palate, in periodontitis, and also in different  types of 
cancer. The measurement of the MMP and TIMP levels might provide 
diagnostic markers for several pathologies, and modulation of their 
balance might offer therapeutic possibilities. 
The recruitment of BMDCs to palatal wounds in vivo is investigated 
in Chapter 4.  Therefore, rats were lethally irradiated to ablate their bone 
marrow cells. Subsequent, labeled bone marrow cells were transplanted 
to create chimeric rats. This model was also used for the studies in 
Chapters 5 and 6. In the rats, experimental wounds were made on the 
palate. Fourteen days later, the wounds were analyzed for labeled 
BMDCs. Statistically significant more BMDCs are recruited to the 
wounds compared to the unwounded palate. The BMDCs differentiated 
into myofibroblasts, activated fibroblasts and macrophages. Also 
endothelial cells originating from the bone marrow were detected. 
Although significantly more labeled BMDCs and myofibroblasts were 
detected in the wounds, their numbers were not substantial. Most of the 
myofibroblasts probably originated from local precursor cells. Therefore, 
we wondered whether the tissue-type or the wound size is crucial in the 
recruitment of BMDCs. 
In Chapter 5, the contribution of BMDCs to palatal and skin wounds 
of equal size in rats is compared. Fourteen days after wounding, about a 
twelve-fold increase of BMDCs was recruited to palatal wounds 
compared to unwounded palate. In contrast, no significant changes were 
detected in the numbers of BMDCs recruited to the skin wounds, 
compared to unwounded skin. Significantly more bone marrow-derived 
myofibroblasts were only detected in palatal wounds compared to 
unwounded palate. However, the numbers of bone marrow-derived 
myofibroblasts and also activated fibroblasts were similar but not 
substantial in both palatal and skin wounds. From these results we 
concluded that BMDCs are preferentially recruited to oral wounds and 
not to skin wounds.  
To study the effect of wound size, only skin wounds were 
subsequently investigated. The maximum wound size on the palate of rats 
Summary 
 187 
is limited. In Chapter 6 we tested whether wound size plays a pivotal role 
in the recruitment of BMDCs in skin wounds. Fourteen days after 
wounding, the smaller wounds were already closed, whereas the large 
wounds still were open. The density (i.e. the number of cells per square 
mm) of BMDCs in the wounds and the adjacent tissues was determined, 
as well as in normal skin from the flank. After correction for cell density, 
the recruitment of BMDCs was found to be independent of wound size. 
Moreover, no significant differences were found by comparing the 
number of BMDCs in wounded and unwounded skin. The density of 
myofibroblasts and also of bone marrow-derived myofibroblasts 
significantly increased with wound size, which can be explained by 
different stages of wound healing; since the smaller wounds were already 
closed, wound contraction had probably already stopped. After wound 
contraction, myofibroblasts disappear by apoptosis. This study confirms 
the results in Chapter 5 in that BMDCs are not preferentially recruited to 
skin wounds. Additionally, wound size does not seem to affect the 
recruitment of BMDCs.  
In Chapter 7 an approach is described to interfere with 
myofibroblast differentiation. In a three dimensional collagen gel 
contraction model the effect of hyaluronan was investigated. Hyaluronan 
is abundantly present in fetal wounds, which heal without a scar. A 
significant reduction in contraction was measured in the gels with high 
concentrations of hyaluronan. In these gels also a lower amount of  pro-
MMP2 was found. No different amounts were detected for the active 
forms of MMPs or for TIMPs. Also no differences were detected in 
mRNA expression of MMPs and TIMPs. On histological and mRNA 
level, no myofibroblasts could be detected. Therefore, we suggest that the 
reduction of contraction is caused by the pericellular coating of 
fibroblasts by hyaluronan.  
Chapter 8 is the general discussion of the results summarized above. 
Also, the experimental design is discussed. Finally, general conclusions 
and suggestions for future research are given. 
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Wondgenezing is een proces waarbij de integriteit van weefsels hersteld 
wordt na beschadiging of verwonding. Dit proces, wat normaal een 
gunstig effect heeft, omvat onder andere wondcontractie om de 
oppervlakte van de wond te reduceren. Uiteindelijk wordt litteken 
weefsel gevormd. De voornaamste cellen voor wondcontractie en 
littekenvorming zijn de myofibroblasten. Myofibroblasten kunnen 
gerekruteerd worden uit het lokale weefsel dat de wond omgeeft. Ook de 
circulerende cellen die voortkomen uit het beenmerg, ook wel de “bone 
marrow-derived cells” (BMDCs) genoemd, kunnen worden gerekruteerd 
door een wond en differentiëren in myofibroblasten. Door de 
myofibroblasten populatie in wonden te reduceren, en dus de vorming 
van littekenweefsel, ontstaan therapeutische mogelijkheden. Dit kan 
worden bereikt door te interfereren met de rekrutering en differentiatie 
van myofibroblasten. Daarom is het belangrijk om de voornaamste 
bronnen van deze cellen te identificeren. De doelen van onze studie 
waren om te onderzoeken of substantiële aantallen van de 
myofibroblasten gerekruteerd worden uit het beenmerg, en of de 
differentiatie naar myofibroblasten  gemoduleerd kan worden.  
Hoofdstuk 1 beschrijft de achtergrond van deze studie en geeft een 
overzicht van de experimenten. Myofibroblasten worden bediscussieerd 
in de context van wondheling, met de focus op BMDCS als potentiële 
bron. Verschillen tussen wondheling in verschillende weefseltypes en 
tussen prenatale en postnatale weefsels worden besproken. De 
experimentele opzet wordt geïntroduceerd en de specifieke doelen 
worden samengevat. 
De resultaten van een literatuurreview over de rol van stamcellen bij 
de vernieuwing en de wondheling van epithelia worden gepresenteerd in 
Hoofdstuk 2. De karakteristieken van stamcelpopulaties en hun niches in 
de epithelia van verschillende weefsels (huid, cornea, long en darm) 
worden besproken. Vergelijkbare mechanismen werden afgeleid omtrent 
de contributie van stamcellen aan de reguliere vervanging en wondheling. 
Een model wordt voorgesteld waarin stamcellen functioneel 
onderverdeeld worden in cellen voor lokaal onderhoud, herstel, en uit het 
beenmerg afkomstige BMDCs, die als “reddingscellen” bij grotere 
weefselschade worden gerekruteerd. Volgens dit model worden BMDCs 
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gerekruteerd bij weefselschade die de regeneratieve capaciteit van de 
locale stamcellen overschrijdt.  
In Hoofdstuk 3 worden de „matrix metalloproteinases‟ (MMPs) en 
„tissue inhibitors of metalloproteinases‟ (TIMPs) geïntroduceerd. Deze 
enzymen en hun remmers spelen een belangrijke rol bij de vernieuwing 
van weefsels, wondheling en tijdens de ontwikkeling, doordat zij de 
afbraak van de extracellulaire matrix reguleren. Naast de remmende 
effecten van TIMPs op MMPs worden bijkomende functies van deze 
eiwitten besproken. Deze literatuur studie laat zien dat de balans tussen 
MMPs en TIMPs is verstoord in de ontwikkeling van een gespleten 
verhemelte (schisis), bij parodontitis, en ook bij verschillende soorten 
van kanker. Het meten van de MMP en TIMP niveaus zou kunnen leiden 
tot diagnostische markers voor verschillende pathologische afwijkingen. 
Daarnaast zou het wijzigen van de MMP:TIMP balans kunnen leiden tot 
nieuwe therapeutische mogelijkheden. 
De rekrutering van BMDCs naar palatinale wonden wordt 
onderzocht in vivo in Hoofdstuk 4. Hiervoor werden ratten lethaal 
bestraald om hun beenmergcellen te vernietigen. Vervolgens werden 
gelabelde beenmergcellen getransplanteerd om chimere ratten te creëren. 
Dit model is ook gebruikt in Hoofdstukken 5 en 6. In de ratten werd een 
experimentele wond in het palatum gemaakt. Veertien dagen later werden 
deze wonden geanalyseerd voor gelabelde BMDCs. Er werden statistisch 
significant meer BMDCs gerekruteerd naar de wonden, vergeleken met 
het onverwonde palatum. De BMDCs differentieerden in 
myofibroblasten, geactiveerde fibroblasten en macrofagen. Ook werden 
endotheelcellen afkomstig uit het beenmerg gedetecteerd. Hoewel 
significant meer gelabelde BMDCs en myofibroblasten werden 
gedetecteerd in de wonden, bleken deze aantallen niet substantieel groot 
te zijn. Waarschijnlijk waren de meeste myofibroblasten afkomstig uit 
lokale voorlopercellen. Hierdoor vroegen wij ons af of het weefseltype of 
de wondgrootte een cruciale rol speelt in de rekrutering van BMDCs. 
In Hoofdstuk 5 wordt de contributie van BMDCs vergeleken aan 
wonden van gelijke grootte in het palatum en in de huid van ratten. 
Veertien dagen na verwonding werd gevonden dat ongeveer een 
twaalfvoudige toename van BMDCs was gerekruteerd in de wonden, 
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vergeleken met het niet verwonde palatum. In tegenstelling hiermee 
werden in de huidwonden geen significante verschillen gevonden in de 
aantallen BMDCs, vergeleken met de niet verwonde huid. Er werden 
alleen significant meer myofibroblasten afkomstig van het beenmerg 
gedetecteerd in palatinale wonden, vergeleken met het onverwonde 
palatum. De aantallen uit het beenmerg afkomstige myofibroblasten en 
geactiveerde fibroblasten waren gelijk, maar niet substantieel groot, in 
zowel palatinale als huidwonden. Uit deze resultaten concludeerden wij 
dat BMDCs bij voorkeur door orale wonden, maar niet door huidwonden, 
gerekruteerd worden. 
Om het effect van wondgrootte te bestuderen werden vervolgens 
alleen huidwonden onderzocht. De maximale wondgrootte in het palatum 
van ratten is beperkt. In Hoofdstuk 6 onderzochten wij of wondgrootte 
een cruciale rol speelt in de rekrutering van BMDCs in huidwonden. 
Veertien dagen na verwonding waren de kleinere wonden gesloten, 
terwijl de grotere wonden nog steeds open waren. De dichtheid (i.e. het 
aantal cellen per vierkante mm) van de BMDCs in de wonden en 
aangrenzende weefsels werd bepaald, alsook in de normale huid uit de 
flank. Na correctie voor de celdichtheid bleek dat de rekrutering van 
BMDCs niet afhankelijk was van de wondgrootte. Bovendien werden 
geen significante verschillen gevonden tussen het aantal BMDCs in 
verwonde en onverwonde huid. De dichtheid van myofibroblasten en ook 
van de beenmerg afkomstige myofibroblasten nam significant toe met de 
wondgrootte. Dit kan verklaard worden door de verschillende stadia van 
wondheling. Omdat de kleinere wonden al gesloten waren was de 
wondcontractie waarschijnlijk gestopt, waarna de myofibroblasten 
verdwijnen door apoptose. Deze studie bevestigt de resultaten uit 
Hoofdstuk 5 waarin beschreven werd dat de rekrutering van BMDCs dat 
huidwonden niet beter in staat zijn om BMDCs te rekruteren dan 
palatinale wonden bij huidwonden. Daarnaast lijkt het er niet op dat de 
wondgrootte invloed heeft op de rekrutering van BMDCs.  
In Hoofdstuk 7 wordt een benadering beschreven om te interfereren 
met de differentiatie van myofibroblasten. In een driedimensionaal 
collageen gelcontractie model werd het effect van hyaluronan onderzocht. 
Hyaluronan is overvloedig aanwezig in foetale wonden die zonder 
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litteken genezen. Een significante afname in de contractie werd gemeten 
in de gellen met de hoogste hyaluronan concentratie. In deze gelen werd 
ook een lagere hoeveelheid van pro-MMP2 gevonden. Geen verschillen 
werden gevonden in de  hoeveelheid van de actieve vormen van MMPs of 
voor TIMPs. Ook werden er geen verschillen gevonden voor de expressie 
van mRNA van MMPs of TIMPs. Op histologisch en mRNA niveau 
konden geen myofibroblasten worden gedetecteerd. Daarom suggereren 
wij dat de verminderde contractie veroorzaakt wordt door pericelullaire 
afscherming van de fibroblasten door hyaluronan. 
Hoofdstuk 8 is de algemene discussie over de resultaten die 
hierboven zijn samengevat. Ook wordt de experimentele opzet 
bediscussieerd. Uiteindelijk worden algemene conclusies en suggesties 
voor toekomstig onderzoek gegeven. 
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de fijne kneepjes van het labwerk mogen leren. René, je input en hulp bij 
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Onze discussies over film en muziek doordrenkt van humor maakten het 
werken met jou altijd bijzonder aangenaam. Ook van jou vind ik het een 
eer om je als paranimf naast me hebben mogen staan. Marjon, dankzij je 
zwangerschap van Iris heb ik mijn weg naar het lab terug gevonden wat 
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samengewerkt, waar ik met plezier op terugkijk. Pia, naast jouw gevoel 
voor humor, leek voor jou het begrip “onmogelijk” voor het snijden van 
coupes niet te bestaan en was je altijd bereid om een helpende hand te 
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waar natuurlijk Arnold en Peter ook hun bijdrage aan hebben geleverd. 
 
Mijn directe collega’s bij Synthon, inclusief het “wandelgroepje”, 
bedankt voor jullie voortdurende interesse voor mijn proefschrift. 
 
Mijn vrienden waar ik altijd op kan rekenen en waarmee ik al veel 
bijzondere momenten heb meegemaakt en dat nog lang hoop te mogen 
doen, op afstand of dichtbij. In het bijzonder Annemarie, Arjan, Bert, 
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en Vincent bedankt voor jullie aanhoudende interesse in de 
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